

---

**UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
WASHINGTON, D.C. 20549**

---

**FORM 10-Q**

(Mark One)

- QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934**

For the quarterly period ended March 31, 2018

OR

- TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934**

For the transition period from \_\_\_\_\_ to \_\_\_\_\_

Commission file number 333-211719

**ASHLAND GLOBAL HOLDINGS INC.**

(a Delaware corporation)

I.R.S. No. 81-2587835

50 E. RiverCenter Boulevard

Covington, Kentucky 41011

Telephone Number (859) 815-3333

Indicate by check mark whether the Registrant: (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the Registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes  No

Indicate by check mark whether the Registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (232.405 of this chapter) during the preceding 12 months (or for such shorter period that the Registrant was required to submit and post such files). Yes  No

Indicate by check mark whether the Registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of "large accelerated filer," "accelerated filer," "smaller reporting company," and "emerging growth company" in Rule 12b-2 of the Exchange Act. (Check One):

|  |                                     |                           |                          |
|--|-------------------------------------|---------------------------|--------------------------|
| Large Accelerated Filer                        | <input checked="" type="checkbox"/> | Accelerated Filer         | <input type="checkbox"/> |
| Non-Accelerated Filer                          | <input type="checkbox"/>            | Smaller Reporting Company | <input type="checkbox"/> |
| (Do not check if a smaller reporting company.) |                                     | Emerging Growth Company   | <input type="checkbox"/> |

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

Indicate by check mark whether the Registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes  No

At March 31, 2018, there were 62,383,233 shares of Registrant's Common Stock outstanding.

---

---

**PART I - FINANCIAL INFORMATION**

**ITEM 1. FINANCIAL STATEMENTS**

**ASHLAND GLOBAL HOLDINGS INC. AND CONSOLIDATED SUBSIDIARIES  
STATEMENTS OF CONSOLIDATED COMPREHENSIVE INCOME (LOSS)**

| (In millions except per share data - unaudited)              | Three months ended |        | Six months ended |          |
|--|--------------------|--------|------------------|----------|
|  | March 31           |        | March 31         |          |
|  | 2018               | 2017   | 2018             | 2017     |
| Sales  | \$ 974             | \$ 806 | \$ 1,816         | \$ 1,510 |
| Cost of sales  | 699                | 578    | 1,312            | 1,093    |
| Gross profit   | 275                | 228    | 504              | 417      |
| Selling, general and administrative expense                  | 163                | 155    | 334              | 312      |
| Research and development expense                             | 21                 | 21     | 43               | 41       |
| Equity and other income                                      | 4                  | 1      | 6                | 4        |
| Operating income   | 95                 | 53     | 133              | 68       |
| Net interest and other financing expense                     | 29                 | 29     | 59               | 152      |
| Other net periodic benefit income                            | 1                  | —      | 1                | 3        |
| Net loss on divestitures                                     | —                  | —      | 1                | 1        |
| Income (loss) from continuing operations before income taxes | 67                 | 24     | 74               | (82)     |
| Income tax expense (benefit)                                 | 1                  | (5)    | 15               | (45)     |
| Income (loss) from continuing operations                     | 66                 | 29     | 59               | (37)     |
| Income from discontinued operations (net of income taxes)    | 7                  | 76     | 10               | 152      |
| Net income   | 73                 | 105    | 69               | 115      |
| Net income attributable to noncontrolling interest (a)       | —                  | 13     | —                | 24       |
| Net income attributable to Ashland                           | \$ 73              | \$ 92  | \$ 69            | \$ 91    |

**PER SHARE DATA**

Basic earnings per share - Note L

|   |         |         |         |           |
|---|---------|---------|---------|-----------|
| Income (loss) from continuing operations                    | \$ 1.06 | \$ 0.46 | \$ 0.94 | \$ (0.59) |
| Income from discontinued operations attributable to Ashland | 0.11    | 1.02    | 0.16    | 2.06      |
| Net income attributable to Ashland                          | \$ 1.17 | \$ 1.48 | \$ 1.10 | \$ 1.47   |

Diluted earnings per share - Note L

|   |         |         |         |           |
|---|---------|---------|---------|-----------|
| Income (loss) from continuing operations                    | \$ 1.04 | \$ 0.46 | \$ 0.93 | \$ (0.59) |
| Income from discontinued operations attributable to Ashland | 0.11    | 1.01    | 0.15    | 2.06      |
| Net income attributable to Ashland                          | \$ 1.15 | \$ 1.47 | \$ 1.08 | \$ 1.47   |

**COMPREHENSIVE INCOME (LOSS)**

|  |        |        |        |        |
|--|--------|--------|--------|--------|
| Net income   | \$ 73  | \$ 105 | \$ 69  | \$ 115 |
| Other comprehensive income (loss), net of tax                |        |        |        |        |
| Unrealized translation gain (loss)                           | 55     | 60     | 58     | (86)   |
| Pension and postretirement obligation adjustment             | —      | (2)    | —      | (4)    |
| Net change in available-for-sale securities                  | (6)    | 6      | 2      | 6      |
| Other comprehensive income (loss)                            | 49     | 64     | 60     | (84)   |
| Comprehensive income   | 122    | 169    | 129    | 31     |
| Comprehensive income attributable to noncontrolling interest | —      | 14     | —      | 24     |
| Comprehensive income attributable to Ashland                 | \$ 122 | \$ 155 | \$ 129 | \$ 7   |

(a) For the three and six months ended March 31, 2017, this represents the income attributable to the previous noncontrolling interest in Valvoline Inc., whose results are now included within discontinued operations. See Note B for more information.

SEE NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS.

**ASHLAND GLOBAL HOLDINGS INC. AND CONSOLIDATED SUBSIDIARIES**  
**CONDENSED CONSOLIDATED BALANCE SHEETS**

| (In millions - unaudited)                         | March 31<br>2018 | September 30<br>2017 |
|---|------------------|----------------------|
| <b>ASSETS</b>                                     |                  |                      |
| <b>Current assets</b>                             |                  |                      |
| Cash and cash equivalents                         | \$ 225           | \$ 566               |
| Accounts receivable (a)                           | 717              | 612                  |
| Inventories - Note F                              | 649              | 634                  |
| Other assets                                      | 122              | 91                   |
| <b>Total current assets</b>                       | <b>1,713</b>     | <b>1,903</b>         |
| <b>Noncurrent assets</b>                          |                  |                      |
| Property, plant and equipment                     |                  |                      |
| Cost  | 3,859            | 3,762                |
| Accumulated depreciation                          | 1,919            | 1,792                |
| Net property, plant and equipment                 | 1,940            | 1,970                |
| Goodwill - Note G                                 | 2,503            | 2,465                |
| Intangibles - Note G                              | 1,290            | 1,319                |
| Restricted investments - Note E                   | 303              | 302                  |
| Asbestos insurance receivable - Note K            | 203              | 209                  |
| Deferred and other income taxes                   | 28               | 28                   |
| Other assets                                      | 461              | 422                  |
| <b>Total noncurrent assets</b>                    | <b>6,728</b>     | <b>6,715</b>         |
| <b>Total assets</b>                               | <b>\$ 8,441</b>  | <b>\$ 8,618</b>      |
| <b>LIABILITIES AND EQUITY</b>                     |                  |                      |
| <b>Current liabilities</b>                        |                  |                      |
| Short-term debt - Note H                          | \$ 59            | \$ 235               |
| Trade and other payables                          | 387              | 409                  |
| Accrued expenses and other liabilities            | 266              | 324                  |
| <b>Total current liabilities</b>                  | <b>712</b>       | <b>968</b>           |
| <b>Noncurrent liabilities</b>                     |                  |                      |
| Long-term debt - Note H                           | 2,579            | 2,584                |
| Asbestos litigation reserve - Note K              | 665              | 694                  |
| Deferred and other income taxes                   | 243              | 375                  |
| Employee benefit obligations - Note J             | 190              | 191                  |
| Other liabilities                                 | 541              | 400                  |
| <b>Total noncurrent liabilities</b>               | <b>4,218</b>     | <b>4,244</b>         |
| Commitments and contingencies - Note K            |                  |                      |
| <b>Stockholders' equity</b>                       | <b>3,511</b>     | <b>3,406</b>         |
| <b>Total liabilities and stockholders' equity</b> | <b>\$ 8,441</b>  | <b>\$ 8,618</b>      |

(a) Accounts receivable includes an allowance for doubtful accounts of \$9 million at both March 31, 2018 and September 30, 2017.

SEE NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS.

**ASHLAND GLOBAL HOLDINGS INC. AND CONSOLIDATED SUBSIDIARIES**  
**STATEMENT OF CONSOLIDATED EQUITY**

| (In millions - unaudited)   | Common<br>stock | Paid-in<br>capital | Retained<br>earnings | Accumulated<br>other<br>comprehensive<br>income (loss) (a) | Total           |
|---|-----------------|--------------------|----------------------|--|-----------------|
| <b>BALANCE AT SEPTEMBER 30, 2017</b>                              | \$ 1            | \$ 931             | \$ 2,696             | \$ (222)   | \$ 3,406        |
| Total comprehensive income (loss)                                 |                 |                    |                      |  |                 |
| Net income  |                 |                    | 69                   |  | 69              |
| Other comprehensive income (loss)                                 |                 |                    |                      | 60   | 60              |
| Regular dividends, \$0.45 per common share                        |                 |                    | (28)                 |  | (28)            |
| Common shares issued under stock incentive and other plans<br>(b) |                 | 4                  |                      |  | 4               |
| <b>BALANCE AT MARCH 31, 2018</b>                                  | <u>\$ 1</u>     | <u>\$ 935</u>      | <u>\$ 2,737</u>      | <u>\$ (162)</u>  | <u>\$ 3,511</u> |

(a) At March 31, 2018 and September 30, 2017, the after-tax accumulated other comprehensive loss attributable to Ashland of \$162 million and \$222 million, respectively, was each comprised of net unrealized translation losses of \$188 million and \$246 million, respectively, net unrealized gains on available-for-sale securities of \$23 million and \$21 million, respectively, and unrecognized prior service credits as a result of certain employee benefit plan amendments of \$3 million for each period.

(b) Common shares issued were 265,821 for the six months ended March 31, 2018.

SEE NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS.

**ASHLAND GLOBAL HOLDINGS INC. AND CONSOLIDATED SUBSIDIARIES**  
**STATEMENTS OF CONDENSED CONSOLIDATED CASH FLOWS**

| (In millions - unaudited)   | Six months ended |               |
|---|------------------|---------------|
|   | March 31         |               |
|   | 2018             | 2017          |
| <b>CASH FLOWS PROVIDED (USED) BY OPERATING ACTIVITIES FROM CONTINUING OPERATIONS</b>                |                  |               |
| Net income  | \$ 69            | \$ 115        |
| Income from discontinued operations (net of income taxes)   | (10)             | (152)         |
| Adjustments to reconcile income from continuing operations to cash flows from operating activities: |                  |               |
| Depreciation and amortization   | 161              | 134           |
| Original issue discount and debt issuance costs amortization  | 4                | 97            |
| Deferred income taxes   | 4                | —             |
| Stock based compensation expense  | 13               | 9             |
| Excess tax benefit on stock based compensation  | 2                | 2             |
| Gain on early retirement of debt  | —                | (3)           |
| Realized gains and investment income on available-for-sale securities                               | (8)              | (7)           |
| Net loss on divestitures  | 1                | 1             |
| Pension contributions   | (7)              | (4)           |
| Gain on post-employment plan remeasurement  | —                | (2)           |
| Change in operating assets and liabilities (a)  | (229)            | (192)         |
| Total cash flows used by operating activities from continuing operations                            | —                | (2)           |
| <b>CASH FLOWS PROVIDED (USED) BY INVESTING ACTIVITIES FROM CONTINUING OPERATIONS</b>                |                  |               |
| Additions to property, plant and equipment  | (60)             | (73)          |
| Proceeds from disposal of property, plant and equipment   | 1                | —             |
| Purchase of operations - net of cash acquired   | (11)             | —             |
| Proceeds (uses) from sale of operations   | 1                | (1)           |
| Life insurance payments   | (37)             | —             |
| Net purchase of funds restricted for specific transactions  | (8)              | (2)           |
| Reimbursement from restricted investments   | 17               | 12            |
| Proceeds from sales of available-for-sale securities  | 17               | 19            |
| Purchase of available-for-sale securities   | (17)             | (19)          |
| Proceeds from the settlement of derivative instruments  | —                | 4             |
| Payments for the settlement of derivative instruments   | (3)              | (3)           |
| Total cash flows used by investing activities from continuing operations                            | (100)            | (63)          |
| <b>CASH FLOWS PROVIDED (USED) BY FINANCING ACTIVITIES FROM CONTINUING OPERATIONS</b>                |                  |               |
| Repayment of long-term debt   | (3)              | (254)         |
| Premium on long-term debt   | —                | (5)           |
| Repayment of short-term debt  | (181)            | (151)         |
| Debt issuance costs   | —                | (2)           |
| Cash dividends paid   | (28)             | (48)          |
| Stock based compensation employee withholding taxes paid in cash                                    | (8)              | (13)          |
| Total cash flows used by financing activities from continuing operations                            | (220)            | (473)         |
| <b>CASH PROVIDED (USED) BY CONTINUING OPERATIONS</b>  |                  |               |
| Cash provided (used) by discontinued operations   | (320)            | (538)         |
| Operating cash flows  | (24)             | 60            |
| Investing cash flows  | —                | (79)          |
| Financing cash flows  | —                | (17)          |
| Total cash used by discontinued operations  | (24)             | (36)          |
| Effect of currency exchange rate changes on cash and cash equivalents                               | 3                | (10)          |
| <b>DECREASE IN CASH AND CASH EQUIVALENTS</b>  | <b>(341)</b>     | <b>(584)</b>  |
| <b>CASH AND CASH EQUIVALENTS - BEGINNING OF PERIOD</b>  | <b>566</b>       | <b>1,017</b>  |
| Change in cash and cash equivalents held by Valvoline   | —                | 37            |
| <b>CASH AND CASH EQUIVALENTS - END OF PERIOD</b>  | <b>\$ 225</b>    | <b>\$ 470</b> |

(a) Excludes changes resulting from operations acquired or sold.

SEE NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS.

---

**ASHLAND GLOBAL HOLDINGS INC. AND CONSOLIDATED SUBSIDIARIES**  
**NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS**

---

**NOTE A – SIGNIFICANT ACCOUNTING POLICIES**

*Basis of presentation*

The accompanying unaudited Condensed Consolidated Financial Statements have been prepared in accordance with accounting principles generally accepted in the United States for interim financial reporting and Securities and Exchange Commission (SEC) regulations. In the opinion of management, all adjustments considered necessary for a fair presentation have been included. Additionally, certain prior period data, primarily related to discontinued operations, have been reclassified in the Consolidated Financial Statements and accompanying notes to conform to the current period presentation, as further described in this section. These statements omit certain information and footnote disclosures required for complete annual financial statements and, therefore, should be read in conjunction with Ashland's Annual Report on Form 10-K for the fiscal year ended September 30, 2017. Results of operations for the period ended March 31, 2018 are not necessarily indicative of the expected results for the remaining quarters in the fiscal year.

On May 12, 2017, Ashland completed the distribution of its remaining 170 million shares of common stock of Valvoline Inc. which represented approximately 83% of the total outstanding shares of Valvoline Inc.'s common stock. This separation from Valvoline represented a strategic shift in Ashland's business and qualified as a discontinued operation. Accordingly, Valvoline's operating results and cash flows for the three and six months ended March 31, 2017 have been classified as discontinued operations within the Condensed Consolidated Financial Statements. See Note B for additional information on the separation of Valvoline Inc.

Subsequent to completing the separation from Valvoline Inc., Ashland's operations are managed within the following three reportable segments: Specialty Ingredients, Composites and Intermediates and Solvents.

*Use of estimates, risks and uncertainties*

The preparation of Ashland's Condensed Consolidated Financial Statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, revenues and expenses, and the disclosures of contingent assets and liabilities. Significant items that are subject to such estimates and assumptions include, but are not limited to, long-lived assets (including goodwill and other intangible assets), income taxes and liabilities and receivables associated with asbestos litigation and environmental remediation. Although management bases its estimates on historical experience and various other assumptions that are believed to be reasonable under the circumstances, actual results could differ significantly from the estimates under different assumptions or conditions.

Ashland's results are affected by domestic and international economic, political, legislative, regulatory and legal actions. Economic conditions, such as recessionary trends, inflation, interest and monetary exchange rates, government fiscal policies and changes in the prices of certain key raw materials, can have a significant effect on operations. While Ashland maintains reserves for anticipated liabilities and carries various levels of insurance, Ashland could be affected by civil, criminal, regulatory or administrative actions, claims or proceedings relating to asbestos, environmental remediation or other matters.

*New accounting standards*

A description of new U.S. GAAP accounting standards issued or adopted during the current year is required in interim financial reporting. A detailed listing of new accounting standards relevant to Ashland is included in the Annual Report on Form 10-K for the fiscal year ended September 30, 2017. The following standards relevant to Ashland were either issued or adopted in the current period, or will become effective in a subsequent period.

In May 2014, the FASB issued accounting guidance outlining a single comprehensive five step model for entities to use in accounting for revenue arising from contracts with customers (ASC 606 Revenue from Contracts with Customers). The new guidance supersedes most current revenue recognition guidance, in an effort to converge the revenue recognition principles within U.S. GAAP. This new guidance also requires entities to disclose certain quantitative and qualitative information regarding the nature, amount, timing and

---

**ASHLAND GLOBAL HOLDINGS INC. AND CONSOLIDATED SUBSIDIARIES**  
**NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS**

---

uncertainty of qualifying revenue and cash flows arising from contracts with customers. Entities have the option of using a full retrospective or a modified retrospective approach to adopt the new guidance. Ashland has identified an implementation team that is currently evaluating the impact of the new standard on the Condensed Consolidated Financial Statements and the adoption method options available as well as the overall impact the new guidance will have on the organization. The assessment process consists of categorizing Ashland's revenue streams and reviewing the current internal accounting policies and practices to determine potential differences that would result from applying the requirements of the new standard to revenue contracts. Additional discussions and meetings with each revenue stream team have occurred to solicit input, identify potential impacts and appropriate changes to Ashland's business processes, systems and controls to support the revenue recognition and disclosure requirements under the new standard. Based on various preliminary assessments conducted to date, Ashland has identified agreements with distributors and customers that are subject to rebate and incentive programs that could contain elements of material rights and/or variable consideration. Ashland does not currently believe that these elements would result in a material change to how revenue would be recognized for these agreements. Ashland currently intends to adopt this standard using the modified retrospective approach and does not believe the impact will be material to the Condensed Consolidated Financial Statements but does expect there to be significant additional disclosures within the Notes to Condensed Consolidated Financial Statements. This guidance becomes effective for Ashland on October 1, 2018.

In February 2018, the FASB issued guidance which permits entities to reclassify tax effects stranded in accumulated other comprehensive income (AOCI) as a result of U.S. tax reform legislation to retained earnings. Additionally, this guidance requires entities to disclose whether they made an election to reclassify the tax effects and to disclose their accounting policy for releasing income tax effects from AOCI. This guidance becomes effective for Ashland on October 1, 2019. Ashland is currently evaluating the impact this guidance may have on Ashland's Condensed Consolidated Financial Statements.

In March 2017, the FASB issued accounting guidance that will change how employers who sponsor defined benefit pension and/or postretirement benefit plans present the net periodic benefit cost in the Statement of Consolidated Comprehensive Income (Loss). This guidance requires employers to present the service cost component of net periodic benefit cost in the same caption within the Statement of Consolidated Comprehensive Income (Loss) as other employee compensation costs from services rendered during the period. All other components of the net periodic benefit cost will be presented separately outside of the operating income caption. This guidance must be applied retrospectively. Ashland elected to early adopt this guidance on October 1, 2017, which resulted in a reclassification of \$3 million in income from the selling, general and administrative expense and cost of sales captions to the other net periodic benefit income caption in the Statement of Consolidated Comprehensive Income (Loss) for the six months ended March 31, 2017. The components of net periodic benefits income (costs) reclassified primarily relate to interest cost, expected return on assets, curtailments, settlements and actuarial gains and losses. Ashland did not have to adjust the classification of service cost since it previously was recorded within the caption required by the new guidance. See Note J for additional information on net periodic benefit costs.

In March 2016, the FASB issued new accounting guidance for certain aspects of share-based payments to employees. This guidance requires all excess tax benefits and tax deficiencies related to share-based payments to be recognized as income tax expense in the Statements of Consolidated Comprehensive Income (Loss) instead of additional paid-in capital, and changes the classification of excess tax benefits from a financing activity to an operating activity within the Statements of Condensed Consolidated Cash Flows. This guidance also allows entities to make an accounting policy election to either estimate the number of awards that are expected to vest or account for forfeitures when they occur. In addition, this guidance increases the amount an employer can withhold to cover income taxes on awards and still qualify for equity classification and requires that cash paid by an employer when directly withholding shares for tax-withholding purposes be classified as a financing activity within the Statements of Condensed Consolidated Cash Flows. The guidance became effective for Ashland and was adopted on October 1, 2017. The guidance specifically related to the Statements of Consolidated Comprehensive Income (Loss) was adopted prospectively while the guidance related to the Statements of Condensed Consolidated Cash

---

**ASHLAND GLOBAL HOLDINGS INC. AND CONSOLIDATED SUBSIDIARIES**  
**NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS**

---

Flows was adopted retrospectively, as required by the guidance. Additionally, Ashland made a policy election to account for forfeitures when they occur across all share-based awards. Upon adoption, the overall impact on Ashland's Condensed Consolidated Financial Statements was not significant.

**NOTE B – VALVOLINE**

**Ashland Separation of Valvoline**

On September 22, 2015, Ashland announced that the Board of Directors approved proceeding with a plan to separate Ashland into two independent, publicly traded companies comprising of the new Ashland (now known as Ashland Global Holdings Inc.) and Valvoline Inc. The initial step of the separation, the initial public offering (IPO) of Valvoline Inc., closed on September 28, 2016. As discussed further within the Final Separation section of this Note, Ashland completed the distribution of its remaining shares in Valvoline Inc. on May 12, 2017. The new Ashland is a premier global leader in providing specialty chemical solutions to customers in a wide range of consumer and industrial markets. Key markets and applications include pharmaceutical, personal care, food and beverage, architectural coatings, adhesives, automotive, construction and energy.

After completing the IPO on September 28, 2016 and before the distribution of its remaining shares on May 12, 2017, Ashland owned 170 million shares of Valvoline Inc.'s common stock which represented approximately 83% of the total outstanding shares of Valvoline Inc.'s common stock. As a result, Ashland continued to consolidate Valvoline within the Condensed Consolidated Financial Statements up until the distribution of the remaining shares. The resulting outside stockholders' interests in Valvoline Inc., which was approximately 17%, was presented separately as a noncontrolling interest within Ashland's equity in the Condensed Consolidated Balance Sheets up until the distribution of the remaining shares. The amount of consolidated net income attributable to these minority holders is presented as a separate caption on the Statements of Consolidated Comprehensive Income (Loss) for the three and six months ended March 31, 2017.

*Final Separation*

Ashland completed the distribution of its remaining 170 million shares of common stock of Valvoline Inc. as a pro rata dividend on shares of Ashland common stock outstanding at the close of business on the record date of May 5, 2017. Based on the shares of Ashland common stock outstanding as of May 5, 2017, the record date for the distribution, each share of Ashland common stock received 2.745338 shares of Valvoline common stock in the distribution. The distribution was recorded at the carrying amount of Valvoline Inc.'s net assets which was a deficit of \$187 million as of May 12, 2017, as follows:



**ASHLAND GLOBAL HOLDINGS INC. AND CONSOLIDATED SUBSIDIARIES**  
**NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS**

| (In millions)                               | May 12<br>2017 |
|---|----------------|
| <b>ASSETS</b>                               |                |
| <b>Current assets</b>                       |                |
| Cash and cash equivalents                   | \$ 179         |
| Accounts receivable, net                    | 385            |
| Inventories                                 | 153            |
| Other current assets                        | 24             |
| Total current assets                        | 741            |
| <b>Noncurrent assets</b>                    |                |
| Net property, plant and equipment           | 357            |
| Goodwill                                    | 329            |
| Equity and other unconsolidated investments | 31             |
| Deferred income taxes                       | 391            |
| Other noncurrent assets                     | 93             |
| Total noncurrent assets                     | 1,201          |
| <b>Total assets</b>                         | 1,942          |
| <b>LIABILITIES AND EQUITY</b>               |                |
| <b>Current liabilities</b>                  |                |
| Short-term debt                             | 75             |
| Current portion of long-term debt           | 16             |
| Trade and other payables                    | 353            |
| Other current liabilities                   | 34             |
| Total current liabilities                   | 478            |
| <b>Noncurrent liabilities</b>               |                |
| Long-term debt                              | 662            |
| Employee benefit obligations                | 826            |
| Other long-term liabilities                 | 163            |
| Total noncurrent liabilities                | 1,651          |
| <b>Total liabilities</b>                    | 2,129          |
| <b>Net deficit</b>                          | \$ (187)       |

A Tax Matters Agreement between Ashland and Valvoline Inc. governs the rights and obligations after the separation regarding certain income taxes and other taxes, including certain tax liabilities and benefits, attributes, returns and contests.

*Discontinued Operations Assessment*

Valvoline met the criteria to qualify as a discontinued operation and accordingly, its operating results and cash flows for the three and six months ended March 31, 2017 have been classified as discontinued operations within the Condensed Consolidated Financial Statements. See Note D for more information.

*Costs of transaction*

Ashland recognized separation costs of \$2 million and \$26 million for the three months ended March 31, 2018 and 2017, respectively, and \$8 million and \$54 million for the six months ended March 31, 2018 and 2017, respectively. Of these amounts, \$7 million and \$12 million of separation costs directly related to Valvoline and were included within the discontinued operations caption of the Statement of Consolidated Comprehensive Income (Loss) for the three and six months ended March 31, 2017, respectively. Otherwise, separation costs are recorded within the selling, general and administrative expense caption of the Statements of Consolidated Comprehensive Income (Loss).

**ASHLAND GLOBAL HOLDINGS INC. AND CONSOLIDATED SUBSIDIARIES**  
**NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS**

**NOTE C – ACQUISITIONS**

**Pharmachem**

*Background*

On May 17, 2017, Ashland completed its acquisition of the stock of Pharmachem Laboratories, Inc. (Pharmachem), a leading provider of quality ingredients to the global health and wellness industries and high-value differentiated products to fragrance and flavor houses. With annual revenues of approximately \$300 million and 14 manufacturing facilities in the United States and Mexico, New Jersey-based Pharmachem develops, manufactures and supplies custom and branded nutritional and fragrance products. Ashland has included Pharmachem within the Specialty Ingredients reportable segment.

*Purchase price allocation*

The acquisition was recorded by Ashland using the purchase method of accounting in accordance with applicable U.S. GAAP whereby the total purchase price was allocated to tangible and intangible assets and liabilities acquired based on respective fair values.

The all-cash purchase price of Pharmachem was \$680 million which included working capital adjustments of approximately \$20 million. The following table summarizes the current preliminary values of the assets acquired and liabilities assumed at the date of acquisition.

| Preliminary purchase price allocation (in millions) | At<br>May 17, 2017<br>As Adjusted |
|---|-----------------------------------|
| <b>Assets:</b>                                      |                                   |
| Accounts receivable                                 | \$ 52                             |
| Inventory   | 74                                |
| Other current assets                                | 4                                 |
| Intangible assets                                   | 330                               |
| Goodwill  | 288                               |
| Property, plant and equipment                       | 97                                |
| Other noncurrent assets                             | 20                                |
| <b>Liabilities:</b>                                 |                                   |
| Accounts payable                                    | (33)                              |
| Deferred tax - net                                  | (138)                             |
| Other noncurrent liabilities                        | (14)                              |
| Total purchase price                                | \$ 680                            |

As of March 31, 2018, the purchase price allocation for the acquisition was preliminary. Adjustments to the current fair value estimates in the above table may occur as the process conducted for various valuations and assessments, including certain tangible and intangible assets, are finalized. Goodwill was calculated as the excess of the consideration transferred over the net assets recognized and represents the estimated future economic benefits arising from other assets acquired that could not be individually identified and separately recognized. The factors contributing to the recognition of goodwill were based on strategic benefits that are expected to be realized from the acquisition. None of the goodwill is expected to be deductible for income tax purposes. During the current quarter, adjustments of \$1 million were made to goodwill and accounts payable.

*Intangible assets identified*

The purchase price allocation included \$330 million of certain definite-lived intangible assets which are being amortized over the estimated useful life in proportion to the economic benefits consumed. The determination of the useful lives is based upon various industry studies, historical acquisition experience, economic factors, and future cash flows of the combined company. In addition, Ashland reviewed certain technological trends and considered the relative stability in the current Pharmachem customer base.

**ASHLAND GLOBAL HOLDINGS INC. AND CONSOLIDATED SUBSIDIARIES**  
**NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS**

The following details the total intangible assets identified as of May 17, 2017.

| Intangible asset type (in millions) | Value         | Weighted-average<br>amortization period<br>(years) |
|-------------------------------------|---------------|--|
| Trademarks and trade names          | \$ 26         | 15   |
| Intellectual property               | 68            | 22   |
| Customer and supplier relationships | 236           | 20   |
| Total                               | <u>\$ 330</u> |  |

**Vornia Limited**

In January 2018, Ashland completed the acquisition of Vornia Limited for \$12 million, of which \$1 million will be paid in future periods. Vornia Limited's principal activity is the design, development and fabrication of customized biomaterial solutions. The purchase price allocation primarily included \$8 million of intellectual property and \$4 million of goodwill and has been included within the Specialty Ingredients reportable segment.

**NOTE D – DISCONTINUED OPERATIONS**

In previous periods, Ashland has divested certain businesses that have qualified as discontinued operations. The operating results from these divested businesses and subsequent adjustments related to ongoing assessments of certain retained liabilities and tax items have been recorded within the discontinued operations caption in the Statements of Consolidated Comprehensive Income (Loss) for all periods presented and are discussed further within this note.

As previously discussed in Notes A and B, Ashland completed the distribution of its remaining 170 million shares of common stock of Valvoline Inc. on May 12, 2017. Ashland determined that the Valvoline separation qualified as a discontinued operation, in accordance with U.S. GAAP, since it represents a strategic shift for Ashland and has a major effect on Ashland's operations and financial results. Accordingly, Valvoline's operating results and cash flows for the three and six months ended March 31, 2017 have been classified as discontinued operations within the Condensed Consolidated Financial Statements. The activity during the three and six months ended March 31, 2018 generally represents subsequent adjustments that were made in conjunction with the Tax Matters Agreement.

Ashland is subject to liabilities from claims alleging personal injury caused by exposure to asbestos. Such claims result primarily from indemnification obligations undertaken in 1990 in connection with the sale of Riley Stoker Corporation (Riley), a former subsidiary of Ashland, which qualified as a discontinued operation, and from the 2009 acquisition of Hercules LLC (formerly Hercules Incorporated), a wholly-owned subsidiary of Ashland. During the three and six months ended March 31, 2018, Ashland recorded \$3 million of income within the discontinued operations caption related to receipts from insurance carriers for asbestos-related litigation.

On July 31, 2014, Ashland completed the sale of the Ashland Water Technologies (Water Technologies) business to Clayton, Dubilier & Rice. Ashland made subsequent post-closing adjustments to the discontinued operations caption as defined by the definitive agreement during the three and six months ended March 31, 2017.

Components of amounts reflected in the Statements of Consolidated Comprehensive Income (Loss) related to discontinued operations are presented in the following table for the three and six months ended March 31, 2018 and 2017.

**ASHLAND GLOBAL HOLDINGS INC. AND CONSOLIDATED SUBSIDIARIES**  
**NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS**

| (In millions)   | Three months ended |              | Six months ended |               |
|---|--------------------|--------------|------------------|---------------|
|   | March 31           |              | March 31         |               |
|   | 2018               | 2017         | 2018             | 2017          |
| <b>Income from discontinued operations (net of tax)</b>       |                    |              |                  |               |
| Valvoline   | \$ 4               | \$ 73        | \$ 7             | \$ 149        |
| Asbestos-related litigation                                   | 3                  | —            | 3                | —             |
| Water Technologies  | —                  | 3            | —                | 3             |
| <b>Total income from discontinued operations (net of tax)</b> | <u>\$ 7</u>        | <u>\$ 76</u> | <u>\$ 10</u>     | <u>\$ 152</u> |

The following table presents a reconciliation of the historically reported captions within Ashland's Statements of Consolidated Income (Loss) for the income from discontinued operations attributable to Valvoline for the three and six months ended March 31, 2017.

| (In millions)   | Three months ended | Six months ended |
|---|--------------------|------------------|
|   | March 31, 2017     | March 31, 2017   |
| <b>Income (loss) from discontinued operations attributable to Valvoline</b> |                    |                  |
| Sales   | \$ 514             | \$ 1,003         |
| Cost of sales   | (310)              | (603)            |
| Selling, general and administrative expense                                 | (90)               | (172)            |
| Research and development expense  | (3)                | (6)              |
| Equity and other income   | 6                  | 15               |
| Pretax operating income of discontinued operations                          | 117                | 237              |
| Net interest and other financing expense                                    | (9)                | (18)             |
| Pretax income of discontinued operations                                    | 108                | 219              |
| Income tax expense  | (35)               | (70)             |
| Income from discontinued operations   | <u>\$ 73</u>       | <u>\$ 149</u>    |

**NOTE E – FAIR VALUE MEASUREMENTS**

As required by U.S. GAAP, Ashland uses applicable guidance for defining fair value, the initial recording and periodic remeasurement of certain assets and liabilities measured at fair value and related disclosures for instruments measured at fair value. Fair value accounting guidance establishes a fair value hierarchy, which prioritizes the inputs to valuation techniques used to measure fair value into three broad levels. The fair value hierarchy gives the highest priority to quoted prices in active markets for identical assets or liabilities (Level 1) and the lowest priority to unobservable inputs (Level 3). An instrument's categorization within the fair value hierarchy is based upon the lowest level of input that is significant to the instrument's fair value measurement. The three levels within the fair value hierarchy are described as follows.

Level 1 – Observable inputs such as unadjusted quoted prices in active markets for identical assets or liabilities.

Level 2 – Inputs other than quoted prices included within Level 1 that are observable for the asset or liability, either directly or indirectly. These include quoted prices for similar assets or liabilities in active markets and quoted prices for identical or similar assets or liabilities in markets that are not active.

Level 3 – Unobservable inputs for the asset or liability for which there is little, if any, market activity at the measurement date. Unobservable inputs reflect Ashland's own assumptions about what market participants would use to price the asset or liability. The inputs are developed based on the best information available in the circumstances, which might include Ashland's own financial data such as internally developed pricing models, discounted cash flow methodologies, as well as instruments for which the fair value determination requires significant management judgment.

For assets that are measured using quoted prices in active markets (Level 1), the total fair value is the published market price per unit multiplied by the number of units held without consideration of transaction costs. Assets and liabilities that are measured using significant other observable inputs (Level 2) are

**ASHLAND GLOBAL HOLDINGS INC. AND CONSOLIDATED SUBSIDIARIES**  
**NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS**

primarily valued by reference to quoted prices of similar assets or liabilities in active markets, adjusted for any terms specific to that asset or liability. For all other assets and liabilities for which unobservable inputs are used (Level 3), fair value is derived using fair value models, such as a discounted cash flow model or other standard pricing models that Ashland deems reasonable.

The following table summarizes financial instruments subject to recurring fair value measurements as of March 31, 2018.

| (In millions)                           | Carrying value | Total fair value | Quoted prices in active markets for identical assets Level 1 | Significant other observable inputs Level 2 | Significant unobservable inputs Level 3 |
|---|----------------|------------------|--|---|---|
| <b>Assets</b>                           |                |                  |  |   |   |
| Cash and cash equivalents               | \$ 225         | \$ 225           | \$ 225   | \$ —  | \$ —                                    |
| Restricted investments (a)              | 333            | 333              | 333  | —   | —                                       |
| Deferred compensation investments (b)   | 160            | 160              | —  | 160   | —                                       |
| Investment of captive insurance company | 4              | 4                | 4  | —   | —                                       |
| Foreign currency derivatives            | 4              | 4                | —  | 4   | —                                       |
| Total assets at fair value              | <u>\$ 726</u>  | <u>\$ 726</u>    | <u>\$ 562</u>  | <u>\$ 164</u>                               | <u>\$ —</u>                             |
| <b>Liabilities</b>                      |                |                  |  |   |   |
| Foreign currency derivatives            | \$ 21          | \$ 21            | \$ —   | \$ 21                                       | \$ —                                    |

(a) Included in restricted investments is \$30 million classified in the other current assets caption on the Condensed Consolidated Balance Sheets.

(b) Included in other noncurrent assets in the Condensed Consolidated Balance Sheets.

The following table summarizes financial asset instruments subject to recurring fair value measurements as of September 30, 2017.

| (In millions)                           | Carrying value  | Total fair value | Quoted prices in active markets for identical assets Level 1 | Significant other observable inputs Level 2 | Significant unobservable inputs Level 3 |
|---|-----------------|------------------|--|---|---|
| <b>Assets</b>                           |                 |                  |  |   |   |
| Cash and cash equivalents               | \$ 566          | \$ 566           | \$ 566   | \$ —  | \$ —                                    |
| Restricted investments (a)              | 332             | 332              | 332  | —   | —                                       |
| Deferred compensation investments (b)   | 158             | 158              | —  | 158   | —                                       |
| Investment of captive insurance company | 3               | 3                | 3  | —   | —                                       |
| Foreign currency derivatives            | 2               | 2                | —  | 2   | —                                       |
| Total assets at fair value              | <u>\$ 1,061</u> | <u>\$ 1,061</u>  | <u>\$ 901</u>  | <u>\$ 160</u>                               | <u>\$ —</u>                             |
| <b>Liabilities</b>                      |                 |                  |  |   |   |
| Foreign currency derivatives            | \$ 36           | \$ 36            | \$ —   | \$ 36                                       | \$ —                                    |

(a) Included in restricted investments is \$30 million classified in the other current assets caption on the Condensed Consolidated Balance Sheets.

(b) Included in other noncurrent assets in the Condensed Consolidated Balance Sheets.

*Restricted investments*

During 2015, Ashland and Hercules entered into a comprehensive settlement agreement related to certain insurance coverage for asbestos bodily injury claims with Underwriters at Lloyd's, certain London Companies and Chartis (AIG) member companies, along with National Indemnity Company and Resolute Management, Inc., under which Ashland and Hercules received a total of \$398 million (the January 2015 asbestos insurance settlement). Ashland placed \$335 million of the settlement funds from the January 2015

**ASHLAND GLOBAL HOLDINGS INC. AND CONSOLIDATED SUBSIDIARIES**  
**NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS**

asbestos insurance settlement into a renewable annual trust restricted for the purpose of paying ongoing and future litigation defense and claim settlement costs incurred in conjunction with asbestos claims. These funds were classified primarily as noncurrent restricted investment assets, with \$30 million classified within other current assets, in the Condensed Consolidated Balance Sheets as of March 31, 2018 and September 30, 2017, respectively.

During 2015, Ashland diversified the restricted investments received from the January 2015 asbestos insurance settlement into primarily equity and corporate bond mutual funds that are designated as available-for-sale securities, classified as Level 1 measurements within the fair value hierarchy. Available-for-sale securities are reported at fair value with unrealized gains and losses, net of related deferred income taxes, included in the stockholders' equity section of the Condensed Consolidated Balance Sheets as a component of accumulated other comprehensive income (AOCI). Investment income and realized gains and losses on the available-for-sale securities are reported in the net interest and other financing expense caption in the Statements of Consolidated Comprehensive Income (Loss). The following table provides a summary of the available-for-sale securities portfolio as of March 31, 2018 and September 30, 2017:

| (In millions)                        |    | March 31<br>2018 |    | September 30<br>2017 |
|--------------------------------------|----|------------------|----|----------------------|
| Original cost                        | \$ | 335              | \$ | 335                  |
| Accumulated adjustments, net         |    | (38)             |    | (24)                 |
| Adjusted cost, beginning of year (a) |    | 297              |    | 311                  |
| Investment income (b)                |    | 4                |    | 9                    |
| Net unrealized gain                  |    | 37               |    | 35                   |
| Realized gains                       |    | 4                |    | 2                    |
| Settlement funds                     |    | 8                |    | 2                    |
| Disbursements                        |    | (17)             |    | (27)                 |
| Fair value                           | \$ | <u>333</u>       | \$ | <u>332</u>           |

(a) The accumulated adjustments include investment income, realized gains, disbursements and settlements recorded in previous periods.

(b) Investment income for the demand deposit includes interest income as well as dividend income transferred from the equity and corporate bond mutual funds.

The following table presents gross unrealized gains and losses for the restricted investment available-for-sale securities as of March 31, 2018 and September 30, 2017:

| (In millions)                   | Adjusted Cost | Gross<br>Unrealized Gain | Gross<br>Unrealized Loss | Fair Value    |
|---------------------------------|---------------|--------------------------|--------------------------|---------------|
| <b>As of March 31, 2018</b>     |               |                          |                          |               |
| Demand deposit                  | \$ 22         | \$ —                     | \$ —                     | \$ 22         |
| Equity mutual fund              | 154           | 40                       | —                        | 194           |
| Corporate bond mutual fund      | 120           | —                        | (3)                      | 117           |
| Fair value                      | <u>\$ 296</u> | <u>\$ 40</u>             | <u>\$ (3)</u>            | <u>\$ 333</u> |
| <b>As of September 30, 2017</b> |               |                          |                          |               |
| Demand deposit                  | \$ 9          | \$ —                     | \$ —                     | \$ 9          |
| Equity mutual fund              | 168           | 34                       | —                        | 202           |
| Corporate bond mutual fund      | 120           | 1                        | —                        | 121           |
| Fair value                      | <u>\$ 297</u> | <u>\$ 35</u>             | <u>\$ —</u>              | <u>\$ 332</u> |

The unrealized gains and losses as of March 31, 2018 and September 30, 2017 were recognized within AOCI. Ashland invests in highly-rated investment grade mutual funds. No other-than-temporary impairment was recognized in AOCI during the three and six months ended March 31, 2018 and 2017.

The following table presents the investment income, realized gains and disbursements related to the investments within the portfolio for the three and six months ended March 31, 2018 and 2017.

**ASHLAND GLOBAL HOLDINGS INC. AND CONSOLIDATED SUBSIDIARIES**  
**NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS**

| (In millions)     | Three months ended |      | Six months ended |      |
|-------------------|--------------------|------|------------------|------|
|                   | March 31           |      | March 31         |      |
|                   | 2018               | 2017 | 2018             | 2017 |
| Investment income | \$ 2               | \$ 2 | \$ 4             | \$ 5 |
| Realized gains    | 3                  | 2    | 4                | 2    |
| Disbursements     | (12)               | (12) | (17)             | (12) |

*Deferred compensation investments*

Deferred compensation investments consist of Level 2 measurements within the fair value hierarchy which are comprised primarily of a guaranteed interest fund, a common stock index fund and an intermediate government bond fund. Gains and losses related to deferred compensation investments are immediately recognized within the Statements of Consolidated Comprehensive Income (Loss).

**Foreign currency derivatives**

Ashland conducts business in a variety of foreign currencies. Accordingly, Ashland regularly uses foreign currency derivative instruments to manage exposure on certain transactions denominated in foreign currencies to curtail potential earnings volatility effects on certain assets and liabilities, including short-term inter-company loans, denominated in currencies other than Ashland's functional currency of an entity. These derivative contracts generally require exchange of one foreign currency for another at a fixed rate at a future date and generally have maturities of less than twelve months. All contracts are valued at fair value with net changes in fair value recorded within the selling, general and administrative expense caption. The impacts of these contracts were largely offset by gains and losses resulting from the impact of changes in exchange rates on transactions denominated in non-functional currencies. The following table summarizes the net gains and losses recognized during the three and six months ended March 31, 2018 and 2017 within the Statements of Consolidated Comprehensive Income (Loss).

| (In millions)                              | Three months ended |      | Six months ended |      |
|--|--------------------|------|------------------|------|
|  | March 31           |      | March 31         |      |
|  | 2018               | 2017 | 2018             | 2017 |
| Foreign currency derivative gains (losses) | \$ (16)            | \$ 8 | \$ (27)          | \$ — |

The following table summarizes the fair values of the outstanding foreign currency derivatives as of March 31, 2018 and September 30, 2017 included in accounts receivable and accrued expenses and other liabilities of the Condensed Consolidated Balance Sheets.

| (In millions)                           | March 31 |       | September 30 |  |
|---|----------|-------|--------------|--|
|   | 2018     |       | 2017         |  |
| Foreign currency derivative assets      | \$ 4     | \$ 2  |              |  |
| Notional contract values                | 302      | 79    |              |  |
| Foreign currency derivative liabilities | \$ 21    | \$ 36 |              |  |
| Notional contract values                | 958      | 1,601 |              |  |

**Other financial instruments**

At March 31, 2018 and September 30, 2017, Ashland's long-term debt (including the current portion and excluding debt issuance cost discounts) had a carrying value of \$2,613 million and \$2,615 million, respectively, compared to a fair value of \$2,710 million and \$2,768 million, respectively. The fair values of long-term debt are based on quoted market prices or, if market prices are not available, the present values of the underlying cash flows discounted at Ashland's incremental borrowing rates, which are deemed to be Level 2 measurements within the fair value hierarchy.

**ASHLAND GLOBAL HOLDINGS INC. AND CONSOLIDATED SUBSIDIARIES**  
**NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS**

**NOTE F – INVENTORIES**

Inventories are carried at the lower of cost or net realizable value. Inventories are primarily stated at cost using the weighted-average cost method. In addition, certain inventories are valued at cost using the last-in, first-out (LIFO) method.

The following table summarizes Ashland’s inventories as of the reported Condensed Consolidated Balance Sheet dates.

| (In millions)                               | March 31, 2018 |               | September 30, 2017 |               |
|---|----------------|---------------|--------------------|---------------|
| Finished products                           | \$             | 404           | \$                 | 390           |
| Raw materials, supplies and work in process |                | 248           |                    | 245           |
| LIFO carrying values                        |                | (3)           |                    | (1)           |
|   |                | <u>\$ 649</u> |                    | <u>\$ 634</u> |

**NOTE G – GOODWILL AND OTHER INTANGIBLES**

*Goodwill*

Ashland reviews goodwill and indefinite-lived intangible assets for impairment annually or when events and circumstances indicate an impairment may have occurred. This annual assessment is performed as of July 1 and consists of Ashland determining each reporting unit’s current fair value compared to its current carrying value. For its July 1, 2017 assessment, Ashland determined that its reporting units for the allocation of goodwill are its three reportable segments: Specialty Ingredients, Composites and Intermediates and Solvents. At that time, Ashland determined no additional impairment existed.

The following is a progression of goodwill by reportable segment for the six months ended March 31, 2018.

| (In millions)                 | Specialty<br>Ingredients |                 | Composites |               | Intermediates<br>and Solvents (a) |             | Total |                 |
|-------------------------------|--------------------------|-----------------|------------|---------------|-----------------------------------|-------------|-------|-----------------|
| Balance at September 30, 2017 | \$                       | 2,315           | \$         | 150           | \$                                | —           | \$    | 2,465           |
| Acquisitions (b)              |                          | 4               |            | —             |                                   | —           |       | 4               |
| Currency translation          |                          | 33              |            | 1             |                                   | —           |       | 34              |
| Balance at March 31, 2018     |                          | <u>\$ 2,352</u> |            | <u>\$ 151</u> |                                   | <u>\$ —</u> |       | <u>\$ 2,503</u> |

(a) As of March 31, 2018, there was accumulated impairment of \$171 million related to the Intermediates and Solvents reportable segment.

(b) Relates to the acquisition of Vornia Limited during the six months ended March 31, 2018. See Note C for more information.

*Other intangible assets*

Intangible assets principally consist of trademarks and trade names, intellectual property and customer and supplier relationships. Intangible assets classified as finite are amortized on a straight-line basis over their estimated useful lives. The cost of trademarks and trade names is amortized principally over 3 to 25 years, intellectual property over 5 to 25 years, and customer and supplier relationships over 3 to 24 years.

Ashland annually reviews indefinite-lived intangible assets for possible impairment or whenever events or changes in circumstances indicate that carrying amounts may not be recoverable.



**ASHLAND GLOBAL HOLDINGS INC. AND CONSOLIDATED SUBSIDIARIES**  
**NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS**

Intangible assets were comprised of the following as of March 31, 2018 and September 30, 2017.

| (In millions)                           | March 31, 2018        |                          |                     |
|---|-----------------------|--------------------------|---------------------|
|   | Gross carrying amount | Accumulated amortization | Net carrying amount |
| Definite-lived intangibles              |                       |                          |                     |
| Trademarks and trade names              | \$ 67                 | \$ (23)                  | \$ 44               |
| Intellectual property                   | 773                   | (354)                    | 419                 |
| Customer and supplier relationships     | 786                   | (260)                    | 526                 |
| <b>Total definite-lived intangibles</b> | <b>1,626</b>          | <b>(637)</b>             | <b>989</b>          |
| Indefinite-lived intangibles            |                       |                          |                     |
| Trademarks and trade names              | 301                   | —                        | 301                 |
| <b>Total intangible assets</b>          | <b>\$ 1,927</b>       | <b>\$ (637)</b>          | <b>\$ 1,290</b>     |
|   |                       |                          |                     |
| (In millions)                           | September 30, 2017    |                          |                     |
|   | Gross carrying amount | Accumulated amortization | Net carrying amount |
| Definite-lived intangibles              |                       |                          |                     |
| Trademarks and trade names              | \$ 67                 | \$ (22)                  | \$ 45               |
| Intellectual property                   | 757                   | (326)                    | 431                 |
| Customer and supplier relationships     | 777                   | (235)                    | 542                 |
| <b>Total definite-lived intangibles</b> | <b>1,601</b>          | <b>(583)</b>             | <b>1,018</b>        |
| Indefinite-lived intangibles            |                       |                          |                     |
| Trademarks and trade names              | 301                   | —                        | 301                 |
| <b>Total intangible assets</b>          | <b>\$ 1,902</b>       | <b>\$ (583)</b>          | <b>\$ 1,319</b>     |

Amortization expense recognized on intangible assets was \$24 million and \$19 million for the three months ended March 31, 2018 and 2017, respectively, and \$48 million and \$38 million for the six months ended March 31, 2018 and 2017, respectively, and is included in the selling, general and administrative expense caption of the Statements of Consolidated Comprehensive Income (Loss). Estimated amortization expense for future periods is \$95 million in 2018 (includes six months actual and six months estimated), \$91 million in 2019, \$90 million in 2020, \$90 million in 2021 and \$88 million in 2022. The amortization expense for future periods is an estimate. Actual amounts may change from such estimated amounts due to fluctuations in foreign currency exchange rates, additional intangible asset acquisitions and divestitures, potential impairment, accelerated amortization, or other events.

**NOTE H – DEBT**

The following table summarizes Ashland's current and long-term debt as of the dates reported in the Condensed Consolidated Balance Sheets.

**ASHLAND GLOBAL HOLDINGS INC. AND CONSOLIDATED SUBSIDIARIES**  
**NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS**

| (In millions)  | March 31, 2018  | September 30, 2017 |
|--|-----------------|--------------------|
| 4.750% notes, due 2022                                       | \$ 1,082        | \$ 1,082           |
| Term Loan B, due 2024  | 596             | 599                |
| 6.875% notes, due 2043                                       | 376             | 376                |
| Revolving Credit Facility                                    | —               | 173                |
| Term Loan A, due 2022  | 250             | 250                |
| Term Loan A, due 2020  | 250             | 250                |
| Accounts receivable securitization                           | 48              | 56                 |
| 6.50% junior subordinated notes, due 2029                    | 51              | 51                 |
| Medium-term notes, due 2019, interest of 9.4%                | 5               | 5                  |
| Other (a)  | (20)            | (23)               |
| <b>Total debt</b>  | <b>2,638</b>    | <b>2,819</b>       |
| Short-term debt (includes current portion of long-term debt) | (59)            | (235)              |
| <b>Long-term debt (less current portion)</b>                 | <b>\$ 2,579</b> | <b>\$ 2,584</b>    |

(a) Other includes \$23 million and \$25 million of debt issuance cost discounts as of March 31, 2018 and September 30, 2017, respectively.

The scheduled aggregate maturities of long-term debt by year (including the current portion and excluding debt issuance costs) are as follows: \$3 million remaining in 2018, \$11 million in 2019, \$269 million in 2020, \$56 million in 2021 and \$1,279 million in 2022.

**Ashland Financing Activities**

*Accounts receivable securitization*

During March 2018, the termination date of the accounts receivable securitization facility was extended from March 2018 to March 2020. The available funding for qualified receivables under the accounts receivable securitization facility increased from \$100 million to \$115 million. No other changes to the agreement are expected to have a significant impact to Ashland's results of operations and financial position.

*Cash repatriation*

During January 2018, Ashland repatriated approximately \$300 million in cash that was primarily used to repay the outstanding balance of the 2017 Revolving Credit Facility and a portion of the accounts receivable securitization during the current quarter.

*2017 Credit Agreement*

On May 17, 2017, in conjunction with the closing of the Pharmachem acquisition, Ashland entered into a secured credit agreement (the 2017 Credit Agreement) with a group of lenders. The 2017 Credit Agreement provided for (i) a \$250 million three-year term loan A facility (the Three-Year TLA Facility), (ii) a \$250 million five-year term loan A facility (the Five-Year TLA Facility and together with the Three-Year TLA Facility, the TLA Facilities) and (iii) a \$680 million five-year revolving credit facility (including a \$125 million letter of credit sublimit) (the 2017 Revolving Credit Facility). Proceeds of borrowings under the TLA Facilities were used solely to finance the acquisition of Pharmachem, while the proceeds of the 2017 Revolving Credit Facility were used to finance, in part, the acquisition of Pharmachem, to refinance the 2015 Senior Credit Agreement and for general corporate purposes. On May 19, 2017, Ashland entered into Amendment No. 1 to the 2017 Credit Agreement, which increased the aggregate commitments under the 2017 Revolving Credit Facility from \$680 million to \$800 million.

At Ashland's option, loans issued under the 2017 Credit Agreement bear interest at either LIBOR or an alternate base rate, in each case plus the applicable interest rate margin. Loans bear interest at LIBOR plus 1.75% per annum, in the case of LIBOR borrowings, or at the alternate base rate plus 0.75%, in the alternative, through and including the date of delivery of a quarterly compliance certificate and thereafter the interest rate will fluctuate between LIBOR plus 1.375% per annum and LIBOR plus 2.500% per annum (or between the alternate base rate plus 0.375% per annum and the alternate base rate plus 1.500% per annum), based upon Ashland's secured facilities ratings or the consolidated net leverage ratio (as defined in

---

**ASHLAND GLOBAL HOLDINGS INC. AND CONSOLIDATED SUBSIDIARIES**  
**NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS**

---

the 2017 Credit Agreement) (whichever yields a lower applicable interest rate margin) at such time. In addition, Ashland was required to pay fees of 0.25% per annum on the daily unused amount of the 2017 Revolving Credit Facility through and including the date of delivery of a compliance certificate, and thereafter the fee rate will fluctuate between 0.175% and 0.40% per annum, based upon Ashland's secured facilities rating or the consolidated net leverage ratio (whichever yields a lower applicable rate). The TLA Facilities may be prepaid at any time without premium. The Three-Year TLA Facility will not amortize and will be due on May 17, 2020. The Five-Year TLA Facility will not amortize in each of the first, second and third years and will amortize at a rate of 20% per annum in each of the fourth and fifth years (payable in equal quarterly installments), with the outstanding balance of the Five-Year TLA Facility to be paid on May 17, 2022.

On June 14, 2017, Ashland entered into Amendment No. 2 to the 2017 Credit Agreement, which provided for a new \$600 million seven-year senior secured term loan B facility (the 2017 TLB Facility). At Ashland's option, loans issued under the 2017 TLB Facility bear interest at either (x) LIBOR plus 2.00% per annum or (y) an alternate base rate plus 1.00% per annum. The 2017 TLB Facility may be prepaid at any time. The 2017 TLB Facility amortizes at a rate of 1.00% per annum (payable in equal quarterly installments) with the outstanding balance to be paid on May 17, 2024.

*6.50% junior subordinated notes due 2029*

In December 2016, Hercules LLC (Hercules) (formerly Hercules Incorporated), an indirect wholly-owned subsidiary of Ashland, repurchased, through a cash tender offer (the Tender Offer), \$182 million of the aggregate principal par value amount of its 6.50% junior subordinated notes due 2029 (2029 notes) for an aggregate purchase price of \$177 million. As a result of the Tender Offer, the carrying value of the 2029 notes was reduced by \$90 million and Ashland recognized a \$92 million charge related to accelerated accretion of the recorded debt discount (compared to the total par value) and \$5 million of a net gain related to the repayment of the debt. The charge and net gain are included in the net interest and other financing expense caption of the Statements of Consolidated Comprehensive Income (Loss) for the six months ended March 31, 2017.

*Open market repurchases of 4.750% notes due 2022 and 3.875% notes due 2018*

During the six months ended March 31, 2017, Ashland executed open market repurchases of its 4.750% notes due 2022 (2022 notes) and its 3.875% notes due 2018 (2018 notes). As a result of these repurchases, the carrying values of the 2022 notes and 2018 notes were reduced by \$39 million and \$41 million, respectively. Ashland recognized a \$3 million charge related to premiums paid in the open market repurchases and accelerated amortization of previously capitalized debt issuance costs, which is included in the net interest and other financing expense caption of the Statements of Consolidated Comprehensive Income (Loss) for the six months ended March 31, 2017.

**Remaining borrowing capacity**

The borrowing capacity remaining under the 2017 Revolving Credit Facility was \$752 million due to a reduction of \$48 million for letters of credit outstanding at March 31, 2018. Ashland's total borrowing capacity at March 31, 2018 was \$819 million, which included \$67 million of available capacity from the accounts receivable securitization facility.

**Covenants related to current Ashland debt agreements**

Ashland's debt contains usual and customary representations, warranties and affirmative and negative covenants, including financial covenants for leverage and interest coverage ratios, limitations on liens, additional subsidiary indebtedness, restrictions on subsidiary distributions, investments, mergers, sale of assets and restricted payments and other customary limitations. As of March 31, 2018, Ashland is in compliance with all debt agreement covenant restrictions.

The maximum consolidated net leverage ratio permitted under Ashland's most recent credit agreement (the 2017 Credit Agreement) is 4.5. At March 31, 2018, Ashland's calculation of the consolidated net leverage ratio was 3.8.

---

**ASHLAND GLOBAL HOLDINGS INC. AND CONSOLIDATED SUBSIDIARIES**  
**NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS**

---

The minimum required consolidated interest coverage ratio under the 2017 Credit Agreement during its entire duration is 3.0. At March 31, 2018, Ashland's calculation of the interest coverage ratio was 4.8.

**NOTE I – INCOME TAXES**

*Tax Law Changes*

The Tax Cuts and Jobs Act (Tax Act) was enacted on December 22, 2017. The Tax Act reduces the U.S. federal corporate tax rate from 35% to 21%, requires companies to pay a one-time transition tax on earnings of certain foreign subsidiaries that were previously tax deferred and creates new taxes on certain foreign sourced earnings. At March 31, 2018, Ashland has not completed the internal accounting assessment for the tax effects of enactment of the Tax Act; however, Ashland determined a reasonable estimate of the effects on our existing deferred tax balances and the one-time transition tax. Ashland recognized a provisional amount for the six months ended March 31, 2018, which is included as a component of income tax expense from continuing operations. Ashland recorded net unfavorable tax adjustments of \$16 million during the six months ended March 31, 2018 primarily related to deferred tax rate changes and a one-time transition tax assessed on foreign cash and unremitted earnings.

*Provisional amounts - Deferred and other income tax assets and liabilities*

Ashland remeasured certain deferred tax assets and liabilities based on the rates at which they are expected to reverse in the future, which is generally 21%. However, Ashland is still analyzing certain aspects of the Tax Act and refining certain calculations, which could potentially affect the measurement of these balances or potentially give rise to new deferred tax amounts. The provisional amount recorded related to the remeasurement of the deferred tax balance was a favorable tax adjustment of \$126 million during the six months ended March 31, 2018.

*Provisional amounts - Foreign tax effects*

The one-time transition tax is based on Ashland's total post-1986 earnings and profits (E&P) of foreign subsidiaries that were previously deferred from U.S. income taxes. Ashland recorded a provisional amount for this one-time transition tax liability of \$142 million during the six months ended March 31, 2018, which is primarily included within the other liabilities caption on the Condensed Consolidated Balance Sheet. Ashland has not yet completed its calculation of the total post-1986 E&P for these foreign subsidiaries. In addition, the transition tax is based in part on the amount of those earnings held in cash and other specified assets. This amount may change when Ashland finalizes the calculation of post-1986 foreign E&P previously deferred from U.S. federal taxation and finalizes the amounts held in cash or other specified assets. No additional income taxes have been provided for any remaining undistributed foreign earnings not subject to the transition tax, or any additional outside basis difference inherent in these entities, as these amounts continue to be indefinitely reinvested in foreign operations. Ashland determined that the amount of unrecognized deferred tax liability related to any remaining undistributed foreign earnings not subject to the transition tax and additional outside basis difference in these entities (i.e., basis difference in excess of that subject to the one-time transition tax) is not practicable at this time.

*Current fiscal year*

Ashland's effective tax rate in any interim period is subject to adjustments related to discrete items and the mix of domestic and foreign operating results. The overall effective tax rate was 1% and 20% for the three and six months ended March 31, 2018, respectively. The current quarter tax rate was primarily impacted by income mix and a favorable tax discrete adjustment of \$4 million related to a deferred tax rate change for a foreign entity. In addition to these current quarter items, the current six month period tax rate was significantly impacted by net unfavorable tax discrete adjustments of \$16 million related to the Tax Act.

---

**ASHLAND GLOBAL HOLDINGS INC. AND CONSOLIDATED SUBSIDIARIES**  
**NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS**

---

*Prior fiscal year*

The overall effective tax rate was a benefit of 21% for the three months ended March 31, 2017 and 55% for the six months ended March 31, 2017. The prior quarter and six month period tax rate was impacted by income mix and net favorable tax discrete items of \$4 million primarily related to unrecognized tax benefits due to lapse of the statute of limitations.

*Unrecognized tax benefits*

Changes in unrecognized tax benefits are summarized as follows for the six months ended March 31, 2018.

| <u>(In millions)</u>   |               |
|--|---------------|
| <b>Balance at October 1, 2017</b>                              | \$ 194        |
| Increases related to positions taken on items from prior years | 3             |
| Decreases related to positions taken on items from prior years | (1)           |
| Increases related to positions taken in the current year       | 6             |
| Lapse of statute of limitations                                | (1)           |
| <b>Balance at March 31, 2018</b>                               | <u>\$ 201</u> |

From a combination of statute expirations and audit settlements in the next twelve months, Ashland expects a decrease in the amount accrued for uncertain tax positions of between \$21 million and \$31 million for continuing operations. It is reasonably possible that there could be other material changes to the amount of uncertain tax positions due to activities of the taxing authorities, settlement of audit issues or the reassessment of existing uncertain tax positions; however, Ashland is not able to estimate the impact of these items at this time.

**NOTE J - EMPLOYEE BENEFIT PLANS**

For the six months ended March 31, 2018, Ashland contributed \$6 million to its non-U.S. pension plans and \$1 million to its U.S. pension plans. Ashland expects to make additional contributions of approximately \$2 million to its non-U.S. plans during the remainder of 2018.

*Plan Remeasurements*

Effective January 1, 2017, Ashland discontinued certain post-employment health and life insurance benefits. The effect of these plan changes resulted in a remeasurement gain of \$2 million recorded within the other net period benefit income caption on the Statement of Consolidated Comprehensive Income (Loss) for the six months ended March 31, 2017.

*Components of net periodic benefit costs (income)*

The following table details the components of pension and other postretirement benefit costs for continuing operations.

**ASHLAND GLOBAL HOLDINGS INC. AND CONSOLIDATED SUBSIDIARIES**  
**NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS**

| (In millions)                             | Pension benefits |             | Other postretirement benefits |               |
|---|------------------|-------------|-------------------------------|---------------|
|   | 2018             | 2017        | 2018                          | 2017          |
| <b>Three months ended March 31</b>        |                  |             |                               |               |
| Service cost (a)                          | \$ 2             | \$ 2        | \$ —                          | \$ —          |
| Interest cost (b)                         | 2                | 2           | —                             | —             |
| Expected return on plan assets (b)        | (3)              | (2)         | —                             | —             |
| Total net periodic benefit costs          | <u>\$ 1</u>      | <u>\$ 2</u> | <u>\$ —</u>                   | <u>\$ —</u>   |
| <b>Six months ended March 31</b>          |                  |             |                               |               |
| Service cost (a)                          | \$ 4             | \$ 4        | \$ 1                          | \$ —          |
| Interest cost (b)                         | 5                | 4           | —                             | 1             |
| Expected return on plan assets (b)        | (6)              | (6)         | —                             | —             |
| Actuarial gain (b)                        | —                | —           | —                             | (2)           |
| Total net periodic benefit costs (income) | <u>\$ 3</u>      | <u>\$ 2</u> | <u>\$ 1</u>                   | <u>\$ (1)</u> |

(a) Service cost was not impacted by new accounting guidance adopted in 2018 and is therefore still classified within the selling, general and administrative expense and cost of sales captions on the Statements of Consolidated Comprehensive Income (Loss). See Note A for additional information.

(b) These components are now classified within the other net periodic benefit income caption on the Statements of Consolidated Comprehensive Income (Loss) due to the adoption of new accounting guidance in the current quarter. See Note A for additional information.

For segment reporting purposes, service cost for continuing operations is proportionately allocated to each segment, excluding the Unallocated and other segment, while all other costs for continuing operations are recorded within the other net periodic benefit income caption on the Statements of Consolidated Comprehensive Income (Loss).

**NOTE K – LITIGATION, CLAIMS AND CONTINGENCIES**

**Asbestos litigation**

Ashland and Hercules have liabilities from claims alleging personal injury caused by exposure to asbestos. To assist in developing and annually updating independent reserve estimates for future asbestos claims and related costs given various assumptions, Ashland retained third party actuarial experts. Prior to 2018, Ashland retained Hamilton, Rabinovitz & Associates, Inc. (HR&A). During 2018, Ashland transitioned these responsibilities to Nathan Associates, Inc. (Nathan). The processes and methodologies used by Nathan are similar to the ones historically employed by HR&A. The methodology used by Nathan to project future asbestos costs is based largely on recent experience, including claim-filing and settlement rates, disease mix, enacted legislation, open claims and litigation defense. The claim experience of Ashland and Hercules are separately compared to the results of previously conducted third party epidemiological studies estimating the number of people likely to develop asbestos-related diseases. Those studies were undertaken in connection with national analyses of the population expected to have been exposed to asbestos. Using that information, Nathan estimates a range of the number of future claims that may be filed, as well as the related costs that may be incurred in resolving those claims. Changes in asbestos-related liabilities and receivables are recorded on an after-tax basis within the discontinued operations caption in the Statements of Consolidated Comprehensive Income (Loss).

*Ashland asbestos-related litigation*

The claims alleging personal injury caused by exposure to asbestos asserted against Ashland result primarily from indemnification obligations undertaken in 1990 in connection with the sale of Riley. The amount and timing of settlements and number of open claims can fluctuate from period to period. A summary of Ashland asbestos claims activity, excluding Hercules claims, follows.

**ASHLAND GLOBAL HOLDINGS INC. AND CONSOLIDATED SUBSIDIARIES**  
**NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS**

| (In thousands)                  | Six months ended |           | Years ended September 30 |           |           |
|---------------------------------|------------------|-----------|--------------------------|-----------|-----------|
|                                 | March 31         |           | 2017                     | 2016      | 2015      |
|                                 | 2018             | 2017      | 2017                     | 2016      | 2015      |
| Open claims - beginning of year | 54               | 57        | 57                       | 60        | 65        |
| New claims filed                | 1                | 1         | 2                        | 2         | 2         |
| Claims settled                  | —                | —         | (1)                      | —         | —         |
| Claims dismissed                | (2)              | (2)       | (4)                      | (5)       | (7)       |
| Open claims - end of period     | <u>53</u>        | <u>56</u> | <u>54</u>                | <u>57</u> | <u>60</u> |

*Ashland asbestos-related liability*

From the range of estimates, Ashland records the amount it believes to be the best estimate of future payments for litigation defense and claim settlement costs, which generally approximates the mid-point of the estimated range of exposure from model results. Ashland reviews this estimate and related assumptions quarterly and annually updates the results of a non-inflated, non-discounted approximate 50-year model developed with the assistance of Nathan.

During the most recent annual update of this estimate completed during the June 2017 quarter, it was determined that the liability for Ashland asbestos-related claims should be increased by \$36 million. Total reserves for asbestos claims were \$402 million at March 31, 2018 compared to \$419 million at September 30, 2017.

A progression of activity in the asbestos reserve is presented in the following table.

| (In millions)                        | Six months ended |               | Years ended September 30 |               |               |
|--------------------------------------|------------------|---------------|--------------------------|---------------|---------------|
|                                      | March 31         |               | 2017                     | 2016          | 2015          |
|                                      | 2018             | 2017          | 2017                     | 2016          | 2015          |
| Asbestos reserve - beginning of year | \$ 419           | \$ 415        | \$ 415                   | \$ 409        | \$ 438        |
| Reserve adjustment                   | —                | —             | 36                       | 37            | —             |
| Amounts paid                         | (17)             | (18)          | (32)                     | (31)          | (29)          |
| Asbestos reserve - end of period (a) | <u>\$ 402</u>    | <u>\$ 397</u> | <u>\$ 419</u>            | <u>\$ 415</u> | <u>\$ 409</u> |

(a) Included \$34 million classified in accrued expenses and other liabilities on the Condensed Consolidated Balance Sheets as of March 31, 2018 and September 30, 2017.

*Ashland asbestos-related receivables*

Ashland has insurance coverage for certain litigation defense and claim settlement costs incurred in connection with its asbestos claims, and coverage-in-place agreements exist with the insurance companies that provide substantially all of the coverage that will be accessed.

For the Ashland asbestos-related obligations, Ashland has estimated the value of probable insurance recoveries associated with its asbestos reserve based on management's interpretations and estimates surrounding the available or applicable insurance coverage, including an assumption that all solvent insurance carriers remain solvent. Substantially all of the estimated receivables from insurance companies are expected to be due from domestic insurers, all of which are solvent.

At March 31, 2018, Ashland's receivable for recoveries of litigation defense and claim settlement costs from insurers amounted to \$149 million (excluding the Hercules receivable for asbestos claims) compared to \$155 million at September 30, 2017. During the June 2017 quarter, the annual update of the model used for purposes of valuing the asbestos reserve and its impact on valuation of future recoveries from insurers was completed. This model update resulted in a \$15 million increase in the receivable for probable insurance recoveries.

**ASHLAND GLOBAL HOLDINGS INC. AND CONSOLIDATED SUBSIDIARIES**  
**NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS**

A progression of activity in the Ashland insurance receivable is presented in the following table.

| (In millions)                            | Six months ended |               | Years ended September 30 |               |               |
|--|------------------|---------------|--------------------------|---------------|---------------|
|  | March 31         |               | 2017                     | 2016          | 2015          |
|  | 2018             | 2017          |                          |               |               |
| Insurance receivable - beginning of year | \$ 155           | \$ 151        | \$ 151                   | \$ 150        | \$ 402        |
| Receivable adjustment                    | —                | —             | 15                       | 16            | (3)           |
| Insurance settlement                     | —                | (5)           | (5)                      | (4)           | (227)         |
| Amounts collected                        | (6)              | (2)           | (6)                      | (11)          | (22)          |
| Insurance receivable - end of period (a) | <u>\$ 149</u>    | <u>\$ 144</u> | <u>\$ 155</u>            | <u>\$ 151</u> | <u>\$ 150</u> |

(a) Included \$14 million classified in accounts receivable on the Condensed Consolidated Balance Sheets as of March 31, 2018 and September 30, 2017.

*Hercules asbestos-related litigation*

Hercules has liabilities from claims alleging personal injury caused by exposure to asbestos. Such claims typically arise from alleged exposure to asbestos fibers from resin encapsulated pipe and tank products which were sold by one of Hercules' former subsidiaries to a limited industrial market. The amount and timing of settlements and number of open claims can fluctuate from period to period. A summary of Hercules' asbestos claims activity follows.

| (In thousands)                  | Six months ended |           | Years ended September 30 |           |           |
|---------------------------------|------------------|-----------|--------------------------|-----------|-----------|
|                                 | March 31         |           | 2017                     | 2016      | 2015      |
|                                 | 2018             | 2017      |                          |           |           |
| Open claims - beginning of year | 12               | 15        | 15                       | 20        | 21        |
| New claims filed                | 1                | 1         | 1                        | 1         | 1         |
| Claims dismissed                | (1)              | (3)       | (4)                      | (6)       | (2)       |
| Open claims - end of period     | <u>12</u>        | <u>13</u> | <u>12</u>                | <u>15</u> | <u>20</u> |

*Hercules asbestos-related liability*

From the range of estimates, Ashland records the amount it believes to be the best estimate of future payments for litigation defense and claim settlement costs, which generally approximates the mid-point of the estimated range of exposure from model results. Ashland reviews this estimate and related assumptions quarterly and annually updates the results of a non-inflated, non-discounted approximate 50-year model developed with the assistance of Nathan. As a result of the most recent annual update of this estimate, completed during the June 2017 quarter, it was determined that the liability for Hercules asbestos-related claims should be increased by \$16 million. Total reserves for asbestos claims were \$311 million at March 31, 2018 compared to \$323 million at September 30, 2017.

A progression of activity in the asbestos reserve is presented in the following table.

| (In millions)                        | Six months ended |               | Years ended September 30 |               |               |
|--------------------------------------|------------------|---------------|--------------------------|---------------|---------------|
|                                      | March 31         |               | 2017                     | 2016          | 2015          |
|                                      | 2018             | 2017          |                          |               |               |
| Asbestos reserve - beginning of year | \$ 323           | \$ 321        | \$ 321                   | \$ 311        | \$ 329        |
| Reserve adjustments                  | —                | —             | 16                       | 25            | 4             |
| Amounts paid                         | (12)             | (5)           | (14)                     | (15)          | (22)          |
| Asbestos reserve - end of period (a) | <u>\$ 311</u>    | <u>\$ 316</u> | <u>\$ 323</u>            | <u>\$ 321</u> | <u>\$ 311</u> |

(a) Included \$14 million classified in accrued expenses and other liabilities on the Condensed Consolidated Balance Sheets as of March 31, 2018 and September 30, 2017.



**ASHLAND GLOBAL HOLDINGS INC. AND CONSOLIDATED SUBSIDIARIES**  
**NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS**

*Hercules asbestos-related receivables*

For the Hercules asbestos-related obligations, certain reimbursement obligations pursuant to coverage-in-place agreements with insurance carriers exist. As a result, any increases in the asbestos reserve have been partially offset by probable insurance recoveries. Ashland has estimated the value of probable insurance recoveries associated with its asbestos reserve based on management's interpretations and estimates surrounding the available or applicable insurance coverage, including an assumption that all solvent insurance carriers remain solvent. The estimated receivable consists exclusively of solvent domestic insurers.

As of March 31, 2018 and September 30, 2017, the receivables from insurers amounted to \$68 million. During the June 2017 quarter, the annual update of the model used for purposes of valuing the asbestos reserve and its impact on valuation of future recoveries from insurers was completed. This model update resulted in a \$5 million increase in the receivable for probable insurance recoveries.

A progression of activity in the Hercules insurance receivable is presented in the following table.

| (In millions)                            | Six months ended |              | Years ended September 30 |              |              |
|--|------------------|--------------|--------------------------|--------------|--------------|
|  | March 31         |              | 2017                     | 2016         | 2015         |
|  | 2018             | 2017         | 2017                     | 2016         | 2015         |
| Insurance receivable - beginning of year | \$ 68            | \$ 63        | \$ 63                    | \$ 56        | \$ 77        |
| Receivable adjustment                    | —                | —            | 5                        | 7            | 1            |
| Insurance settlement                     | —                | —            | —                        | —            | (22)         |
| Insurance receivable - end of period     | <u>\$ 68</u>     | <u>\$ 63</u> | <u>\$ 68</u>             | <u>\$ 63</u> | <u>\$ 56</u> |

*Asbestos litigation cost projection*

Projecting future asbestos costs is subject to numerous variables that are extremely difficult to predict. In addition to the significant uncertainties surrounding the number of claims that might be received, other variables include the type and severity of the disease alleged by each claimant, the long latency period associated with asbestos exposure, mortality rates, dismissal rates, costs of medical treatment, the impact of bankruptcies of other companies that are co-defendants in claims, uncertainties surrounding the litigation process from jurisdiction to jurisdiction and from case to case, and the impact of potential changes in legislative or judicial standards. Furthermore, any predictions with respect to these variables are subject to even greater uncertainty as the projection period lengthens. Considering these inherent uncertainties, Ashland believes that the asbestos reserves for Ashland and Hercules represent the best estimate within a range of possible outcomes. As a part of the process to develop these estimates of future asbestos costs, a range of long-term cost models was developed. These models are based on national studies that predict the number of people likely to develop asbestos-related diseases and are heavily influenced by assumptions regarding long-term inflation rates for indemnity payments and legal defense costs, as well as other variables mentioned previously. Ashland has currently estimated in various models ranging from approximately 40 to 50 year periods that it is reasonably possible that total future litigation defense and claim settlement costs on an inflated and undiscounted basis could range as high as approximately \$660 million for the Ashland asbestos-related litigation (current reserve of \$402 million) and approximately \$510 million for the Hercules asbestos-related litigation (current reserve of \$311 million), depending on the combination of assumptions selected in the various models. If actual experience is worse than projected, relative to the number of claims filed, the severity of alleged disease associated with those claims or costs incurred to resolve those claims, or actuarial refinement or improvements to the assumptions used within these models are initiated, Ashland may need to further increase the estimates of the costs associated with asbestos claims and these increases could be material over time.

**ASHLAND GLOBAL HOLDINGS INC. AND CONSOLIDATED SUBSIDIARIES**  
**NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS**

**Environmental remediation and asset retirement obligations**

Ashland is subject to various federal, state and local environmental laws and regulations that require environmental assessment or remediation efforts (collectively environmental remediation) at multiple locations. At March 31, 2018, such locations included 83 waste treatment or disposal sites where Ashland has been identified as a potentially responsible party under Superfund or similar state laws, 117 current and former operating facilities (including certain operating facilities conveyed as part of the MAP Transaction) and about 1,225 service station properties, of which 36 are being actively remediated.

Ashland's reserves for environmental remediation and related environmental litigation amounted to \$164 million at March 31, 2018 compared to \$163 million at September 30, 2017, of which \$122 million at March 31, 2018 and \$121 million at September 30, 2017 were classified in other noncurrent liabilities on the Condensed Consolidated Balance Sheets. The remaining reserves were classified in accrued expenses and other liabilities on the Condensed Consolidated Balance Sheets.

The following table provides a reconciliation of the changes in the environmental remediation reserves during the six months ended March 31, 2018 and 2017.

| (In millions)                              | Six months ended |               |
|--|------------------|---------------|
|  | March 31         |               |
|  | 2018             | 2017          |
| Reserve - beginning of period              | \$ 163           | \$ 177        |
| Disbursements                              | (16)             | (15)          |
| Revised obligation estimates and accretion | 17               | 5             |
| Reserve - end of period                    | <u>\$ 164</u>    | <u>\$ 167</u> |

The total reserves for environmental remediation reflect Ashland's estimates of the most likely costs that will be incurred over an extended period to remediate identified conditions for which the costs are reasonably estimable, without regard to any third-party recoveries. Engineering studies, probability techniques, historical experience and other factors are used to identify and evaluate remediation alternatives and their related costs in determining the estimated reserves for environmental remediation. Ashland continues to discount certain environmental sites and regularly adjusts its reserves as environmental remediation continues. Ashland has estimated the value of its probable insurance recoveries associated with its environmental reserve based on management's interpretations and estimates surrounding the available or applicable insurance coverage. At March 31, 2018 and September 30, 2017, Ashland's recorded receivable for these probable insurance recoveries was \$14 million and \$15 million, respectively, of which \$13 million at March 31, 2018 and \$14 million at September 30, 2017 were classified in other noncurrent assets on the Condensed Consolidated Balance Sheets.

Components of environmental remediation expense included within the selling, general and administrative expense caption of the Statements of Consolidated Comprehensive Income (Loss) are presented in the following table for the three and six months ended March 31, 2018 and 2017.

**ASHLAND GLOBAL HOLDINGS INC. AND CONSOLIDATED SUBSIDIARIES**  
**NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS**

| (In millions)                                 | Three months ended |      | Six months ended |       |
|---|--------------------|------|------------------|-------|
|   | March 31           |      | March 31         |       |
|   | 2018               | 2017 | 2018             | 2017  |
| Environmental expense                         | \$ 4               | \$ 1 | \$ 16            | \$ 5  |
| Accretion                                     | —                  | —    | 1                | —     |
| Legal expense                                 | 2                  | 4    | 3                | 5     |
| Total expense                                 | 6                  | 5    | 20               | 10    |
| Insurance receivable (a)                      | (1)                | —    | (1)              | —     |
| Total expense, net of receivable activity (b) | \$ 5               | \$ 5 | \$ 19            | \$ 10 |

(a) Activity of \$0 denotes value less than \$1 million.

(b) Net expense of \$1 million for both the three and six months ended March 31, 2018, and \$1 million and \$2 million for the three and six months ended March 31, 2017, respectively, relates to divested businesses which qualified for treatment as discontinued operations and for which certain environmental liabilities were retained by Ashland. These amounts are classified within the income from discontinued operations caption of the Statements of Consolidated Comprehensive Income (Loss).

Environmental remediation reserves are subject to numerous inherent uncertainties that affect Ashland's ability to estimate its share of the costs. Such uncertainties involve the nature and extent of contamination at each site, the extent of required cleanup efforts under existing environmental regulations, widely varying costs of alternate cleanup methods, changes in environmental regulations, the potential effect of continuing improvements in remediation technology, and the number and financial strength of other potentially responsible parties at multiparty sites. Although it is not possible to predict with certainty the ultimate costs of environmental remediation, Ashland currently estimates that the upper end of the reasonably possible range of future costs for identified sites could be as high as approximately \$409 million. The largest reserve for any site is approximately 15% of the remediation reserve.

**Other legal proceedings and claims**

In addition to the matters described above, there are other various claims, lawsuits and administrative proceedings pending or threatened against Ashland and its current and former subsidiaries. Such actions are with respect to commercial matters, product liability, toxic tort liability, and other environmental matters, which seek remedies or damages, some of which are for substantial amounts. While Ashland cannot predict with certainty the outcome of such actions, it believes that adequate reserves have been recorded and losses already recognized with respect to such actions were immaterial as of March 31, 2018 and September 30, 2017. There is a reasonable possibility that a loss exceeding amounts already recognized may be incurred related to these actions; however, Ashland believes that such potential losses were immaterial as of March 31, 2018.

**NOTE L – EARNINGS PER SHARE**

The following is the computation of basic and diluted earnings per share (EPS) from continuing operations attributable to Ashland. Stock appreciation rights (SARs), stock options and warrants available to purchase shares outstanding for each reporting period whose grant price was greater than the average market price of Ashland Common Stock for each applicable period were not included in the computation of income from continuing operations per diluted share because the effect of these instruments would be antidilutive. The total number of these shares outstanding was approximately 0.7 million and 0.1 million at March 31, 2018 and 2017, respectively. Earnings per share is reported under the treasury stock method.

**ASHLAND GLOBAL HOLDINGS INC. AND CONSOLIDATED SUBSIDIARIES**  
**NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS**

| (In millions, except per share data)                | Three months ended |         | Six months ended |           |
|---|--------------------|---------|------------------|-----------|
|   | March 31           |         | March 31         |           |
|   | 2018               | 2017    | 2018             | 2017      |
| <b>Numerator</b>                                    |                    |         |                  |           |
| Numerator for basic and diluted EPS -               |                    |         |                  |           |
| Income (loss) from continuing operations            | \$ 66              | \$ 29   | \$ 59            | \$ (37)   |
| <b>Denominator</b>                                  |                    |         |                  |           |
| Denominator for basic EPS - Weighted-average        |                    |         |                  |           |
| common shares outstanding                           | 63                 | 62      | 63               | 62        |
| Share based awards convertible to common shares (a) | 1                  | 1       | 1                | —         |
| Denominator for diluted EPS - Adjusted weighted-    |                    |         |                  |           |
| average shares and assumed conversions              | 64                 | 63      | 64               | 62        |
| <b>EPS from continuing operations</b>               |                    |         |                  |           |
| Basic   | \$ 1.06            | \$ 0.46 | \$ 0.94          | \$ (0.59) |
| Diluted   | 1.04               | 0.46    | 0.93             | (0.59)    |

(a) As a result of the loss from continuing operations attributable to Ashland during the six months ended March 31, 2017, the effect of the share-based awards convertible to common shares would be antidilutive. In accordance with U.S. GAAP, they have been excluded from the diluted EPS calculation.

**NOTE M – EQUITY ITEMS**

**Stock repurchase programs**

In April 2015, Ashland's Board of Directors approved a \$1 billion share repurchase authorization that was set to expire on December 31, 2017 (the 2015 stock repurchase program). During September 2017, Ashland's Board of Directors extended the 2015 stock repurchase program indefinitely, at which point \$500 million of share repurchase authorization remained under the 2015 stock repurchase program.

During March 2018, Ashland's Board of Directors approved a new \$1 billion stock repurchase program, which replaced the 2015 stock repurchase program. Under the new program, Ashland's common shares may be repurchased in open market transactions, privately negotiated transactions or pursuant to one or more accelerated stock repurchase programs or Rule 10b5-1 plans. As of March 31, 2018, \$1 billion remained available for repurchase under this authorization.

**Stockholder dividends**

In May 2017, subsequent to the final distribution of Valvoline Inc.'s common stock, the Board of Directors of Ashland announced a quarterly cash dividend of 22.5 cents per share to eligible stockholders at record which was paid for quarterly dividends in the first and second quarters of fiscal 2018 and the third and fourth quarters of fiscal 2017. This represented a reduction from the previous quarterly dividend of 39 cents per share which was paid for quarterly dividends in the first and second quarters of fiscal 2017.

**Accumulated other comprehensive income (loss)**

Components of other comprehensive income (loss) recorded in the Statements of Consolidated Comprehensive Income (Loss) are presented below, before tax and net of tax effects.

**ASHLAND GLOBAL HOLDINGS INC. AND CONSOLIDATED SUBSIDIARIES**  
**NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS**

| (In millions)  | 2018         |                       |              | 2017           |                       |                |
|--|--------------|-----------------------|--------------|----------------|-----------------------|----------------|
|  | Before tax   | Tax (expense) benefit | Net of tax   | Before tax     | Tax (expense) benefit | Net of tax     |
| <b>Three months ended March 31</b>                           |              |                       |              |                |                       |                |
| Other comprehensive income (loss)                            |              |                       |              |                |                       |                |
| Unrealized translation gain                                  | \$ 55        | \$ —                  | \$ 55        | \$ 58          | \$ 2                  | \$ 60          |
| Amortization of unrecognized prior service credit (a)        | —            | —                     | —            | (3)            | 1                     | (2)            |
| Net change in available-for-sale securities:                 |              |                       |              |                |                       |                |
| Unrealized loss  | (5)          | 1                     | (4)          | 9              | (2)                   | 7              |
| Reclassification adjustment for gains included in net income | (3)          | 1                     | (2)          | (2)            | 1                     | (1)            |
| Total other comprehensive income                             | <u>\$ 47</u> | <u>\$ 2</u>           | <u>\$ 49</u> | <u>\$ 62</u>   | <u>\$ 2</u>           | <u>\$ 64</u>   |
| <b>Six months ended March 31</b>                             |              |                       |              |                |                       |                |
| Other comprehensive income (loss)                            |              |                       |              |                |                       |                |
| Unrealized translation gain (loss)                           | \$ 58        | \$ —                  | \$ 58        | \$ (92)        | \$ 6                  | \$ (86)        |
| Amortization of unrecognized prior service credit (a)        | —            | —                     | —            | (6)            | 2                     | (4)            |
| Net change in available-for-sale securities:                 |              |                       |              |                |                       |                |
| Unrealized gain  | 6            | (1)                   | 5            | 9              | (2)                   | 7              |
| Reclassification adjustment for gains included in net income | (4)          | 1                     | (3)          | (2)            | 1                     | (1)            |
| Total other comprehensive income (loss)                      | <u>\$ 60</u> | <u>\$ —</u>           | <u>\$ 60</u> | <u>\$ (91)</u> | <u>\$ 7</u>           | <u>\$ (84)</u> |

(a) For the three and six months ended March 31, 2017, the amortization of unrecognized prior services credits was related to pension and other postretirement benefit plans that transferred to Valvoline and was classified within the discontinued operations caption on the Statements of Consolidated Comprehensive Income (Loss).

**NOTE N – STOCK INCENTIVE PLANS**

Ashland has stock incentive plans under which key employees or directors are granted stock appreciation rights (SARs), performance awards or nonvested stock awards. Each program is typically a long-term incentive plan designed to link employee compensation with increased shareholder value or reward superior performance and encourage continued employment with Ashland. Ashland recognizes compensation expense for the grant date fair value of stock-based awards over the applicable vesting period.

The components of Ashland's pretax stock-based compensation expense included in continuing operations are as follows:

| (In millions)            | Three months ended March 31 |             | Six months ended March 31 |              |
|--------------------------|-----------------------------|-------------|---------------------------|--------------|
|                          | 2018 (a)                    | 2017 (b)    | 2018 (a)                  | 2017 (b)     |
| SARs                     | \$ 2                        | \$ 2        | \$ 3                      | \$ 3         |
| Nonvested stock awards   | 5                           | 3           | 11                        | 7            |
| Performance share awards | 2                           | 2           | 6                         | 4            |
|                          | <u>\$ 9</u>                 | <u>\$ 7</u> | <u>\$ 20</u>              | <u>\$ 14</u> |

(a) Included \$2 million and \$4 million of expense related to cash-settled nonvested restricted stock awards and \$1 million and \$3 million of expense related to cash-settled performance units during the three and six months ended March 31, 2018, respectively.

(b) Included \$2 million and \$3 million of expense related to cash-settled nonvested restricted stock awards and \$1 million and \$2 million of expense related to cash-settled performance units during the three and six months ended March 31, 2017, respectively.

**SARs**

SARs are granted to employees or directors at a price equal to the fair market value of the stock on the date of grant and typically become exercisable over periods of one to three years. Unexercised SARs lapse ten

---

**ASHLAND GLOBAL HOLDINGS INC. AND CONSOLIDATED SUBSIDIARIES**  
**NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS**

---

years and one month after the date of grant. No SARs granted for the three months ended March 31, 2018 and 2017. SARs granted for the six months ended March 31, 2018 and 2017 were 470 thousand and 422 thousand, respectively. As of March 31, 2018, there was \$11 million of total unrecognized compensation costs related to SARs. That cost is expected to be recognized over a weighted-average period of 2.2 years. Ashland estimates the fair value of SARs granted using the Black-Scholes option-pricing model. This model requires several assumptions, which Ashland has developed and updates based on historical trends and current market observations. The accuracy of these assumptions is critical to the estimate of fair value for these equity instruments.

**Nonvested stock awards**

Nonvested stock awards are granted to employees or directors at a price equal to the fair market value of the stock on the date of grant and generally vest over a one-to-five-year period. However, such shares or units are subject to forfeiture upon termination of service before the vesting period ends. Only nonvested stock awards granted in the form of shares entitle employees or directors to vote the shares. Dividends on nonvested stock awards granted are in the form of additional units or shares of nonvested stock awards, which are subject to vesting and forfeiture provisions.

*Stock-settled nonvested stock awards*

Nonvested stock awards granted in the form of shares were 2 thousand and 3 thousand for the three months ended March 31, 2018 and 2017, respectively, and 144 thousand and 84 thousand for the six months ended March 31, 2018 and 2017, respectively. As of March 31, 2018, there was \$10 million of total unrecognized compensation costs related to these nonvested stock awards. That cost is expected to be recognized over a weighted-average period of 2.0 years.

*Cash-settled nonvested stock awards*

Certain nonvested stock awards are granted to employees and are settled in cash upon vesting. As of March 31, 2018, 229 thousand cash-settled nonvested stock awards were outstanding. The value of these cash-settled nonvested stock awards changes in connection with changes in the fair market value of the Ashland Common Stock. These awards generally vest over a period of three years. The expense recognized related to cash-settled nonvested stock awards was \$2 million during both the three months ended March 31, 2018 and 2017, and \$4 million and \$3 million during the six months ended March 31, 2018 and 2017, respectively.

*Executive performance incentive and retention program*

During 2016, certain executives were granted performance-based restricted shares of Ashland in order to provide an incentive to remain employed in the period after the full separation. At March 31, 2018, there were 61 thousand shares outstanding in connection with these awards, which includes forfeitures and the cumulative value of forfeitable dividends. The expense recognition for these awards commenced upon completing the full separation of Valvoline which occurred on May 12, 2017, as discussed further in Note B, and resulted in \$1 million and \$3 million of expense for the three and six months ended March 31, 2018, respectively. As of March 31, 2018, there was \$6 million of total unrecognized compensation costs related to these awards.

**Performance awards**

Ashland sponsors a long-term incentive plan that awards performance shares/units to certain key employees that are primarily tied to Ashland's overall financial performance relative to internal targets. Additionally, certain outstanding performance awards are tied to Ashland's overall financial performance relative to the financial performance of selected industry peer groups. Awards are granted annually, with each award covering a three-year vesting period.

For awards granted in fiscal 2016, each performance share/unit is convertible to one share of Ashland Common Stock. These plans are recorded as a component of stockholders' equity in the Condensed Consolidated Balance Sheets. Performance measures used to determine the actual number of performance shares issuable upon vesting include an equal weighting of Ashland's total shareholder return (TSR)

---

**ASHLAND GLOBAL HOLDINGS INC. AND CONSOLIDATED SUBSIDIARIES**  
**NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS**

---

performance and Ashland's return on investment (ROI) performance as compared to the internal targets. TSR relative to peers is considered a market condition while ROI is considered a performance condition under applicable U.S. GAAP.

For awards granted in fiscal 2017 and 2018, the performance measure used to determine the actual number of performance shares/units issuable upon vesting is the financial performance of Ashland compared to award targets. The financial performance award metric is considered a performance condition under applicable U.S. GAAP. Additionally, the actual number of performance shares/units issuable upon vesting can be potentially increased or decreased based on a TSR performance modifier relative to peers of Ashland. For awards granted in fiscal 2017, each performance unit will be settled in cash based on the fair value of Ashland common stock. For awards granted in fiscal 2018, each performance share/unit is convertible to one share of Ashland Common Stock.

Nonvested performance shares/units do not entitle employees to vote the shares or to receive any dividends thereon. No performance shares/units were granted for the three months ended March 31, 2018 and 2017. Performance shares/units granted for the six months ended March 31, 2018 and 2017 were 101 thousand and 56 thousand, respectively. As of March 31, 2018, there was \$15 million of total unrecognized compensation costs related to performance shares/units. That cost is expected to be recognized over a weighted-average period of 2.0 years.

**NOTE O – REPORTABLE SEGMENT INFORMATION**

Ashland determines its reportable segments based on how operations are managed internally for the products and services sold to customers, including how the results are reviewed by the chief operating decision maker, which includes determining resource allocation methodologies used for reportable segments. Operating income is the primary measure on the Statements of Consolidated Comprehensive Income (Loss) that is reviewed by the chief operating decision maker in assessing each reportable segment's financial performance. Ashland does not aggregate operating segments to arrive at these reportable segments.

*Change in Reportable Segments*

Subsequent to completing the separation from Valvoline Inc. on May 12, 2017, Ashland's operations are managed by the chief operating decision maker within the following three reportable segments: Specialty Ingredients, Composites and Intermediates and Solvents. As a result, the financial information for the new reportable segments (Composites and Intermediates and Solvents) has been disclosed for all periods presented. Prior to the separation from Valvoline Inc., Composites and Intermediates and Solvents were reporting units included within the previous Ashland Performance Materials reportable segment.

*Reportable segment business descriptions*

Specialty Ingredients is a global leader in cellulose ethers, vinyl pyrrolidones and biofunctionals. It offers industry-leading products, technologies and resources for solving formulation and product-performance challenges. Specialty Ingredients uses natural, synthetic and semisynthetic polymers derived from cellulose ethers, vinyl pyrrolidones, acrylic polymers, polyester and polyurethane-based adhesives, and plant and seed extract. Specialty Ingredients' end markets offer comprehensive and innovative solutions for today's demanding consumer and industrial applications. Key customers include: pharmaceutical companies; makers of personal care products, food and beverages; makers of nutraceuticals and supplements; manufacturers of paint, coatings and construction materials; packaging and converting; and oilfield service companies. On May 17, 2017, Ashland completed its acquisition of the stock of Pharmachem, a leading provider of quality ingredients to the global health and wellness industries and high-value differentiated products to fragrance and flavor houses. With 14 manufacturing facilities in the United States and Mexico, New Jersey-based Pharmachem develops, manufactures and supplies custom and branded nutritional and fragrance products. See Note C for more information.

Composites is a global leader in unsaturated polyester resins, vinyl ester resins and gelcoats. The Composites business manufactures and sells a broad range of general-purpose and high-performance grades

**ASHLAND GLOBAL HOLDINGS INC. AND CONSOLIDATED SUBSIDIARIES**  
**NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS**

of unsaturated polyester and vinyl ester resins, gelcoats and low-profile additives for the reinforced plastics industry. The products in the Composites business provide an array of functional properties including corrosion resistance, fire retardance, ultraviolet resistance, water and chemical resistance, high mechanical strength, impact and scratch resistance and high strength-to-weight ratios. Key end markets include transportation, construction, marine and infrastructure. In addition, the business manufactures and sells molten maleic anhydride for the manufacture of a variety of products such as unsaturated polyester resins, copolymers, lubricating oil additives, alkenyl succinic anhydrides, malic acid, fumaric acid and numerous derivative chemicals. Key markets include composites, personal care, dispersants and paper sizing.

Intermediates and Solvents is a leading producer of 1,4 butanediol (BDO) and related derivatives, including tetrahydrofuran and n-methylpyrrolidone. These products are used as chemical intermediates in the production of engineering polymers and polyurethanes, and as specialty process solvents in a wide array of applications including electronics, pharmaceuticals, water filtration membranes and more. Butanediol is also supplied to Ashland's Specialty Ingredients business for use as a raw material.

Unallocated and Other generally includes items such as certain significant company-wide restructuring activities, including internal separation costs, and legacy costs or adjustments that relate to divested businesses that are no longer operated by Ashland.

*Reportable segment results*

Results of Ashland's reportable segments are presented based on its management and internal accounting structure. The structure is specific to Ashland; therefore, the financial results of Ashland's reportable segments are not necessarily comparable with similar information for other comparable companies. Ashland allocates all significant costs to its reportable segments except for certain significant company-wide restructuring activities and other costs or adjustments that relate to former businesses that Ashland no longer operates. The service cost component of pension and other postretirement benefits costs is allocated to each reportable segment on a ratable basis; while the remaining components of pension and other postretirement benefits costs are recorded within the other net periodic benefit income caption on the Statements of Consolidated Comprehensive Income (Loss). Ashland refines its expense allocation methodologies to the reportable segments from time to time as internal accounting practices are improved, more refined information becomes available and the industry or market changes. Significant revisions to Ashland's methodologies are adjusted for all segments on a retrospective basis.

The following table presents various financial information for each reportable segment for the three and six months ended March 31, 2018 and 2017.

| (In millions - unaudited)      | Three months ended<br>March 31 |               | Six months ended<br>March 31 |                 |
|--------------------------------|--------------------------------|---------------|------------------------------|-----------------|
|                                | 2018                           | 2017          | 2018                         | 2017            |
| <b>SALES</b>                   |                                |               |                              |                 |
| Specialty Ingredients          | \$ 646                         | \$ 544        | \$ 1,196                     | \$ 1,026        |
| Composites                     | 238                            | 186           | 456                          | 351             |
| Intermediates and Solvents     | 90                             | 76            | 164                          | 133             |
|                                | <u>\$ 974</u>                  | <u>\$ 806</u> | <u>\$ 1,816</u>              | <u>\$ 1,510</u> |
| <b>OPERATING INCOME (LOSS)</b> |                                |               |                              |                 |
| Specialty Ingredients          | \$ 89                          | \$ 74         | \$ 131                       | \$ 114          |
| Composites                     | 19                             | 13            | 36                           | 29              |
| Intermediates and Solvents     | 4                              | (3)           | 13                           | (11)            |
| Unallocated and other          | (17)                           | (31)          | (47)                         | (64)            |
|                                | <u>\$ 95</u>                   | <u>\$ 53</u>  | <u>\$ 133</u>                | <u>\$ 68</u>    |



## FORWARD-LOOKING STATEMENTS

This Form 10-Q contains forward-looking statements including, without limitation, statements made under the caption “Management’s Discussion and Analysis of Financial Condition and Results of Operation” (MD&A), within the meaning of Section 27A of the Securities Act of 1933, as amended and Section 21E of the Securities Exchange Act of 1934, as amended. Ashland has identified some of these forward-looking statements with words such as “anticipates,” “believes,” “expects,” “estimates,” “is likely,” “predicts,” “projects,” “forecasts,” “objectives,” “may,” “will,” “should,” “plans” and “intends” and the negative of these words or other comparable terminology. In addition, Ashland may from time to time make forward-looking statements in its annual reports, quarterly reports and other filings with the Securities and Exchange Commission (SEC), news releases and other written and oral communications. These forward-looking statements are based on Ashland’s expectations and assumptions, as of the date such statements are made, regarding Ashland’s future operating performance and financial condition, as well as the economy and other future events or circumstances. Ashland’s expectations and assumptions include, without limitation, those mentioned within the MD&A, internal forecasts and analyses of current and future market conditions and trends, management plans and strategies, operating efficiencies and economic conditions (such as prices, supply and demand, cost of raw materials, and the ability to recover raw-material cost increases through price increases), and risks and uncertainties associated with the following: the program to eliminate certain existing corporate and Specialty Ingredients expenses (including the possibility that such cost eliminations may not occur or may take longer to implement than anticipated); the expected divestiture of its Composites segment and for the butanediol (BDO) manufacturing facility in Marl, Germany, and related merchant Intermediates and Solvents (I&S) products (including, in each case, the possibility that a transaction may not occur or that, if a transaction does occur, Ashland may not realize the anticipated benefits from such transaction); the impact of acquisitions and/or divestitures Ashland has made or may make, including the acquisition of Pharmachem (including the possibility that Ashland may not realize the anticipated benefits from such transactions); Ashland’s substantial indebtedness (including the possibility that such indebtedness and related restrictive covenants may adversely affect Ashland’s future cash flows, results of operations, financial condition and its ability to repay debt); Ashland’s ability to generate sufficient cash to finance its stock repurchase plans; the potential that Ashland does not realize all of the expected benefits of the separation of its Valvoline business; the potential that the Tax Cuts and Jobs Act enacted on December 22, 2017 will have a negative impact on Ashland’s financial results, and severe weather, natural disasters, cyber events and legal proceedings and claims (including product recalls, environmental and asbestos matters). Various risks and uncertainties may cause actual results to differ materially from those stated, projected or implied by any forward-looking statements, including, without limitation, risks and uncertainties affecting Ashland that are contained in “Use of estimates, risks and uncertainties” in Note A of Notes to Consolidated Financial Statements and in Item 1A in its most recent Form 10-K filed with the SEC, which is available on Ashland’s website at <http://investor.ashland.com> or on the SEC’s website at <http://www.sec.gov>. Ashland believes its expectations and assumptions are reasonable, but there can be no assurance that the expectations reflected herein will be achieved. Unless legally required, Ashland undertakes no obligation to update any forward-looking statements made in this Form 10-Q whether as a result of new information, future events or otherwise. Information on Ashland’s website is not incorporated into or a part of this Form 10-Q.

## ITEM 2. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

### ASHLAND GLOBAL HOLDINGS INC. AND CONSOLIDATED SUBSIDIARIES MANAGEMENT'S DISCUSSION AND ANALYSIS

The following discussion should be read in conjunction with the Condensed Consolidated Financial Statements and the accompanying Notes to Condensed Consolidated Financial Statements herein.

#### BUSINESS OVERVIEW

##### Ashland profile

Ashland is a premier global leader in providing specialty chemical solutions to customers in a wide range of consumer and industrial markets, including adhesives, architectural coatings, construction, energy, food and beverage, personal care and pharmaceutical. With approximately 6,500 employees worldwide, Ashland serves customers in more than 100 countries.

Ashland's sales generated outside of North America were 60% for both the three and six months ended March 31, 2018 and 2017. Sales by region expressed as a percentage of total consolidated sales for the three and six months ended March 31 were as follows:

| Sales by Geography    | Three months ended<br>March 31 |             | Six months ended<br>March 31 |             |
|-----------------------|--------------------------------|-------------|------------------------------|-------------|
|                       | 2018                           | 2017        | 2018                         | 2017        |
| North America (a)     | 40%                            | 40%         | 40%                          | 40%         |
| Europe                | 37%                            | 33%         | 36%                          | 32%         |
| Asia Pacific          | 16%                            | 18%         | 16%                          | 19%         |
| Latin America & other | 7%                             | 9%          | 8%                           | 9%          |
|                       | <u>100%</u>                    | <u>100%</u> | <u>100%</u>                  | <u>100%</u> |

(a) Ashland includes only U.S. and Canada in its North America designation.

##### Reportable segments

Subsequent to completing the separation from Valvoline Inc., Ashland's businesses are managed within the following three reportable segments: Specialty Ingredients, Composites and Intermediates and Solvents. For further descriptions of each reportable segment, see "Results of Operations – Reportable Segment Review" beginning on page 48.

The contribution to sales by each reportable segment expressed as a percentage of total consolidated sales for the three and six months ended March 31 were as follows:

| Sales by Reportable Segment | Three months ended<br>March 31 |             | Six months ended<br>March 31 |             |
|-----------------------------|--------------------------------|-------------|------------------------------|-------------|
|                             | 2018                           | 2017        | 2018                         | 2017        |
| Specialty Ingredients       | 67%                            | 68%         | 66%                          | 68%         |
| Composites                  | 24%                            | 23%         | 25%                          | 23%         |
| Intermediates and Solvents  | 9%                             | 9%          | 9%                           | 9%          |
|                             | <u>100%</u>                    | <u>100%</u> | <u>100%</u>                  | <u>100%</u> |

## **KEY DEVELOPMENTS**

### **Business results**

Ashland's net income was \$73 million in the current quarter compared to \$105 million in the prior year quarter. Ashland's Adjusted EBITDA increased by 30% to \$179 million (see U.S. GAAP reconciliation on page 40). The increase in Adjusted EBITDA was due to growth across all three reportable segments with Specialty Ingredients reporting an increase of \$26 million and Composites and Intermediates and Solvents each reporting an increase of \$7 million. Excluding the acquisition of Pharmachem, the increase in profitability for Specialty Ingredients compared to the prior year quarter was primarily driven by improvements in volume and mix and favorable foreign currency exchange. The increase in profitability for both Composites and Intermediates and Solvents was primarily driven by improvements in product pricing.

### **Composites segment and Intermediates and Solvents plant**

On March 20, 2018, Ashland announced that it will explore strategic alternatives for its Composites segment and the Intermediates and Solvents' manufacturing facility in Marl, Germany. Ashland currently expects to divest these assets, which will improve the cost structure and streamline decision making, while becoming more customer focused and accelerating adjusted EBITDA margin growth.

On May 1, 2018, Ashland also announced a program to eliminate a total of \$120 million of existing corporate and Specialty Ingredients selling, general and administrative expenses, along with facility-related costs. Under this program:

- Approximately \$70 million of corporate costs allocated to the Composites business and to the butanediol manufacturing facility in Marl, Germany, are expected to be offset or eliminated through transfers and reductions.
- Approximately \$50 million of additional costs are expected to be eliminated to drive improved profitability in Specialty Ingredients and accelerate achievement of its adjusted EBITDA margin target of 25-27 percent.

Ashland expects to achieve the full run-rate savings by the end of calendar year 2019.

### **Tax law changes**

The Tax Cuts and Jobs Act (Tax Act) was enacted on December 22, 2017. The Tax Act reduces the U.S. federal corporate tax rate from 35% to 21%, requires companies to pay a one-time transition tax on earnings of certain foreign subsidiaries that were previously tax deferred and creates new taxes on certain foreign sourced earnings. At March 31, 2018, Ashland has not completed the internal accounting assessment for the tax effects of enactment of the Tax Act; however, Ashland determined a reasonable estimate of the effects on our existing deferred tax balances and the one-time transition tax. Ashland recognized a provisional amount for the six months ended March 31, 2018, which is included as a component of income tax expense from continuing operations. Ashland recorded net unfavorable tax adjustments of \$16 million primarily related to deferred tax rate changes and a one-time transition tax assessed on foreign cash and unremitted earnings.

### **Stock repurchase program**

During March 2018, Ashland's Board of Directors approved a new \$1 billion stock repurchase program, which replaced the 2015 stock repurchase program that had \$500 million of authorization remaining. Under the new program, Ashland's common shares may be repurchased in open market transactions, privately negotiated transactions or pursuant to one or more accelerated stock repurchase programs or Rule 10b5-1 plans.

## RESULTS OF OPERATIONS – CONSOLIDATED REVIEW

### *Use of non-GAAP measures*

Ashland has included within this document the following non-GAAP measures, on both a consolidated and reportable segment basis, which are not defined within U.S. GAAP and do not purport to be alternatives to net income or cash flows from operating activities as a measure of operating performance or cash flows:

- EBITDA - net income (loss), plus income tax expense (benefit), net interest and other financing expenses, and depreciation and amortization.
- Adjusted EBITDA - EBITDA adjusted for noncontrolling interests, discontinued operations, net gain (loss) on acquisitions and divestitures, other income and (expense) and key items (including the remeasurement gains and losses related to pension and other postretirement plans).
- Adjusted EBITDA margin - Adjusted EBITDA, which can include pro forma adjustments, divided by sales.
- Adjusted diluted earnings per share (EPS) - income (loss) from continuing operations, adjusted for key items, net of tax, divided by the average outstanding diluted shares for the applicable period.
- Free cash flow - operating cash flows less capital expenditures and certain other adjustments as applicable.

Management believes the use of EBITDA and Adjusted EBITDA measures on a consolidated and reportable segment basis assists investors in understanding the ongoing operating performance by presenting comparable financial results between periods. Ashland believes that by removing the impact of depreciation and amortization and excluding certain non-cash charges, amounts spent on interest and taxes and certain other charges that are highly variable from year to year, EBITDA and Adjusted EBITDA provide Ashland's investors with performance measures that reflect the impact to operations from trends in changes in sales, margin and operating expenses, providing a perspective not immediately apparent from net income and operating income. The adjustments Ashland makes to derive the non-GAAP measures of EBITDA and Adjusted EBITDA exclude items which may cause short-term fluctuations in net income and operating income and which Ashland does not consider to be the fundamental attributes or primary drivers of its business. EBITDA and Adjusted EBITDA provide disclosure on the same basis as that used by Ashland's management to evaluate financial performance on a consolidated and reportable segment basis and provide consistency in our financial reporting, facilitate internal and external comparisons of Ashland's historical operating performance and its business units and provide continuity to investors for comparability purposes.

The Adjusted diluted EPS metric enables Ashland to demonstrate what effect key items have on an earnings per diluted share basis by taking income (loss) from continuing operations, adjusted for key items after tax that have been identified in the Adjusted EBITDA table, and dividing by the average outstanding diluted shares for the applicable period. Ashland's management believes this presentation is helpful to illustrate how the key items have impacted this metric during the applicable period.

The free cash flow metric enables Ashland to provide a better indication of the ongoing cash being generated that is ultimately available for both debt and equity holders as well as other investment opportunities. Unlike cash flow provided by operating activities, free cash flow includes the impact of capital expenditures from continuing operations, providing a more complete picture of cash generation. Free cash flow has certain limitations, including that it does not reflect adjustment for certain non-discretionary cash flows such as mandatory debt repayments. The amount of mandatory versus discretionary expenditures can vary significantly between periods.

Although Ashland provides forward-looking guidance for Adjusted EBITDA, Adjusted diluted EPS and free cash flow, Ashland is not reaffirming or providing forward-looking guidance for U.S. GAAP-reported financial measures or a reconciliation of forward-looking non-GAAP financial measures to the most

---

## ASHLAND GLOBAL HOLDINGS INC. AND CONSOLIDATED SUBSIDIARIES MANAGEMENT'S DISCUSSION AND ANALYSIS

---

directly comparable U.S. GAAP measure because it is unable to predict with reasonable certainty the ultimate outcome of certain significant items that affect these metrics such as domestic and international economic, political, legislative, regulatory and legal actions. In addition, certain economic conditions, such as recessionary trends, inflation, interest and monetary exchange rates, government fiscal policies and changes in the prices of certain key raw materials, can have a significant effect on operations and are difficult to predict with certainty.

These non-GAAP measures should be considered supplemental in nature and should not be construed as more significant than comparable measures defined by U.S. GAAP. Limitations associated with the use of these non-GAAP measures include that these measures do not present all of the amounts associated with our results as determined in accordance with U.S. GAAP. The non-GAAP measures provided are used by Ashland management and may not be determined in a manner consistent with the methodologies used by other companies. EBITDA and Adjusted EBITDA provide a supplemental presentation of Ashland's operating performance on a consolidated and reportable segment basis. Adjusted EBITDA generally includes adjustments for items that impact comparability between periods. In addition, certain financial covenants related to Ashland's 2017 Credit Agreement are based on similar non-GAAP measures and are defined further in the sections that reference this metric.

In accordance with U.S. GAAP, Ashland recognizes actuarial gains and losses for defined benefit pension and other postretirement benefit plans annually in the fourth quarter of each fiscal year and whenever a plan is determined to qualify for a remeasurement during a fiscal year. Actuarial gains and losses occur when actual experience differs from the estimates used to allocate the change in value of pension and other postretirement benefit plans to expense throughout the year or when assumptions change, as they may each year. Significant factors that can contribute to the recognition of actuarial gains and losses include changes in discount rates used to remeasure pension and other postretirement obligations on an annual basis or upon a qualifying remeasurement, differences between actual and expected returns on plan assets and other changes in actuarial assumptions, for example, the life expectancy of plan participants. Management believes Adjusted EBITDA, which includes the expected return on pension plan assets yet excludes both the actual return on pension plan assets and the impact of actuarial gains and losses, provides investors with a meaningful supplemental presentation of Ashland's operating performance (see the Adjusted EBITDA reconciliation table on page 40 for additional details on exact amounts included within this non-GAAP measure related to pension and other postretirement plans.) Management believes these actuarial gains and losses are primarily financing activities that are more reflective of changes in current conditions in global financial markets (and in particular interest rates) that are not directly related to the underlying business. For further information on the actuarial assumptions and plan assets referenced above, see Note M of the Notes to Consolidated Financial Statements within the 2017 Form 10-K.

### ***Consolidated review***

#### *Net income*

Ashland's net income is primarily affected by results within operating income, net interest and other financing expense, income taxes, discontinued operations and other significant events or transactions that are unusual or nonrecurring.

Current Quarter - Key financial results for the three months ended March 31, 2018 and 2017 included the following:

- Ashland's net income attributable to Ashland amounted to \$73 million and \$92 million for the three months ended March 31, 2018 and 2017, respectively, or \$1.15 and \$1.47 diluted earnings per share, respectively.
- Ashland's net income attributable to noncontrolling interest amounted to \$13 million for the three months ended March 31, 2017 and reflects the noncontrolling interest of Valvoline Inc. before the final separation occurred on May 12, 2017.

---

**ASHLAND GLOBAL HOLDINGS INC. AND CONSOLIDATED SUBSIDIARIES**  
**MANAGEMENT'S DISCUSSION AND ANALYSIS**

---

- Discontinued operations, which are reported net of taxes, resulted in income of \$7 million and \$76 million during the three months ended March 31, 2018 and 2017, respectively. The activity within discontinued operations for the three months ended March 31, 2017 includes the operating results of Valvoline Inc.
- Income from continuing operations, which excludes results from discontinued operations, amounted to \$66 million and \$29 million for the three months ended March 31, 2018 and 2017, respectively.
- The effective income tax rates were 1% and a benefit of 21% for the three months ended March 31, 2018 and 2017, respectively, and were impacted by certain discrete items in both the current and prior year quarters.
- Ashland incurred pretax net interest and other financing expense of \$29 million for each of the three months ended March 31, 2018 and 2017.
- Operating income was \$95 million and \$53 million for the three months ended March 31, 2018 and 2017, respectively.

Year-to-Date - Key financial results for the six months ended March 31, 2018 and 2017 included the following:

- Ashland's net income attributable to Ashland amounted to \$69 million and \$91 million for the six months ended March 31, 2018 and 2017, respectively, or \$1.08 and \$1.47 diluted earnings per share, respectively.
- Ashland's net income attributable to noncontrolling interest amounted to \$24 million for the six months ended March 31, 2017 and reflects the noncontrolling interest of Valvoline Inc. before the final distribution occurred on May 12, 2017.
- Discontinued operations, which are reported net of taxes, resulted in income of \$10 million and \$152 million during the six months ended March 31, 2018 and 2017, respectively. The activity within discontinued operations for the six months ended March 31, 2017 includes the operating results of Valvoline Inc.
- Income (loss) from continuing operations, which excludes results from discontinued operations, amounted to income of \$59 million and a loss of \$37 million for the six months ended March 31, 2018 and 2017, respectively.
- The effective income tax rates were 20% and 55% for the six months ended March 31, 2018 and 2017, respectively, and were impacted by certain discrete items in both the current and prior year periods.
- Ashland incurred pretax net interest and other financing expense of \$59 million and \$152 million for the six months ended March 31, 2018 and 2017, respectively. The prior year period was impacted by \$92 million of net charges associated with debt financing activity.
- Operating income was \$133 million and \$68 million for the six months ended March 31, 2018 and 2017, respectively.

For further information on the items reported above, see the discussion in the comparative Statements of Consolidated Comprehensive Income (Loss) caption review analysis.

*Operating income*

Current Quarter - Operating income amounted to \$95 million and \$53 million for the three months ended March 31, 2018 and 2017, respectively. The current and prior year quarters' operating income included certain key items that were excluded to arrive at Adjusted EBITDA. These key items are summarized as follows:

---

**ASHLAND GLOBAL HOLDINGS INC. AND CONSOLIDATED SUBSIDIARIES**  
**MANAGEMENT'S DISCUSSION AND ANALYSIS**

---

- Separation, restructuring and other costs and accelerated depreciation include the following:
  - \$4 million of accelerated depreciation related to the planned closure of an office building during the three months ended March 31, 2018;
  - \$4 million of integration costs related to the acquisition of Pharmachem for the three months ended March 31, 2018;
  - \$2 million and \$19 million of costs related to the separation of Valvoline during the three months ended March 31, 2018 and 2017, respectively (which included \$1 million of accelerated depreciation during the three months ended March 31, 2017); and
  - \$2 million of accelerated depreciation for the termination of a contract at a manufacturing facility during the three months ended March 31, 2018; and
- \$5 million of income related to proceeds from a legal settlement during the three months ended March 31, 2018.

Operating income for the three months ended March 31, 2018 and 2017 included depreciation and amortization of \$76 million and \$66 million, respectively (which excluded accelerated depreciation of \$6 million and \$1 million for the three months ended March 31, 2018 and 2017, respectively).

Year-to-Date - Operating income amounted to \$133 million and \$68 million for the six months ended March 31, 2018 and 2017, respectively. The current and prior year periods' operating income included certain key items that were excluded to arrive at Adjusted EBITDA. In addition to the key items within the current and prior year quarters previously discussed, the following are also excluded on a year-to-date basis:

- Separation, restructuring and other costs and accelerated depreciation include the following additional key items:
  - an additional \$6 million and \$23 million of costs related to the separation of Valvoline during the six months ended March 31, 2018 and 2017, respectively;
  - an additional \$4 million of accelerated depreciation related to the planned closure of an office building during the six months ended March 31, 2018;
  - an additional \$2 million of integration costs related to the acquisition of Pharmachem for the six months ended March 31, 2018;
  - an additional \$2 million of accelerated depreciation for the termination of a contract at a manufacturing facility during the six months ended March 31, 2018; and
  - \$1 million of severance and other restructuring charges for the closure of a manufacturing plant during the six months ended March 31, 2018;
- \$11 million of environmental charges during the six months ended March 31, 2018;
- a \$5 million charge for a legal reserve during the six months ended March 31, 2017; and
- a remeasurement gain of \$2 million associated with the discontinuation of certain post-employment health and life insurance benefits during the six months ended March 31, 2017.

Operating income for the six months ended March 31, 2018 and 2017 included depreciation and amortization of \$149 million and \$133 million, respectively (which excluded accelerated depreciation of \$12 million and \$1 million for the six months ended March 31, 2018 and 2017, respectively).

*EBITDA, Adjusted EBITDA and Key Items*

EBITDA totaled \$179 million and \$195 million for the three months ended March 31, 2018 and 2017, respectively, and \$292 million and \$355 million for the six months ended March 31, 2018 and 2017, respectively. EBITDA and Adjusted EBITDA results in the table below have been prepared to illustrate the

**ASHLAND GLOBAL HOLDINGS INC. AND CONSOLIDATED SUBSIDIARIES**  
**MANAGEMENT'S DISCUSSION AND ANALYSIS**

ongoing effects of Ashland's operations, which exclude certain key items and the impact of Ashland's previous noncontrolling interest in Valvoline Inc.

| (In millions)                                    | Three months ended<br>March 31 |        | Six months ended<br>March 31 |        |
|--|--------------------------------|--------|------------------------------|--------|
|  | 2018                           | 2017   | 2018                         | 2017   |
| Net income                                       | \$ 73                          | \$ 105 | \$ 69                        | \$ 115 |
| Income tax expense (benefit)                     | 1                              | (5)    | 15                           | (45)   |
| Net interest and other financing expense         | 29                             | 29     | 59                           | 152    |
| Depreciation and amortization (a)                | 76                             | 66     | 149                          | 133    |
| EBITDA   | 179                            | 195    | 292                          | 355    |
| Income from discontinued operations (net of tax) | (7)                            | (76)   | (10)                         | (152)  |
| Key items included in EBITDA:                    |                                |        |                              |        |
| Separation, restructuring and other costs        | 6                              | 18     | 15                           | 41     |
| Accelerated depreciation                         | 6                              | 1      | 12                           | 1      |
| Legal settlement/reserve                         | (5)                            | —      | (5)                          | 5      |
| Environmental reserve adjustments                | —                              | —      | 11                           | —      |
| Gain on post-employment plan remeasurement       | —                              | —      | —                            | (2)    |
| Total key items included in EBITDA               | 7                              | 19     | 33                           | 45     |
| Adjusted EBITDA                                  | \$ 179                         | \$ 138 | \$ 315                       | \$ 248 |
| Total key items included in EBITDA               | \$ 7                           | \$ 19  | \$ 33                        | \$ 45  |
| Debt refinancing costs (b)                       | —                              | —      | —                            | 92     |
| Total key items, before tax                      | \$ 7                           | \$ 19  | \$ 33                        | \$ 137 |

(a) Excludes \$6 million and \$1 million of accelerated depreciation for the three months ended March 31, 2018 and 2017, respectively, and \$12 million and \$1 million of accelerated depreciation for the six months ended March 31, 2018 and 2017, respectively.

(b) Debt refinancing costs during the six months ended March 31, 2017 primarily related to accelerated accretion from the tender offer of the 2029 notes and were recorded within the net interest and other financing expense caption on the Statement of Consolidated Comprehensive Income (Loss).

*Diluted EPS and Adjusted Diluted EPS*

The following table reflects the U.S. GAAP calculation for the income (loss) from continuing operations adjusted for the cumulative diluted EPS effect for key items after tax that have been identified in the Adjusted EBITDA table in the previous section. Key items are defined as the financial effects from significant transactions that may have caused short-term fluctuations in net income and/or operating income which Ashland believes do not accurately reflect Ashland's underlying business performance and trends. The Adjusted EPS for the income (loss) from continuing operations in the following table has been prepared to illustrate the ongoing effects of Ashland's operations. Management believes investors and analysts use this financial measure in assessing Ashland's business performance and that presenting this non-GAAP measure on a consolidated basis assists investors in better understanding Ashland's ongoing business performance and enhancing their ability to compare period-to-period financial results.



**ASHLAND GLOBAL HOLDINGS INC. AND CONSOLIDATED SUBSIDIARIES**  
**MANAGEMENT'S DISCUSSION AND ANALYSIS**

|  | Three months ended |         | Six months ended |           |
|--|--------------------|---------|------------------|-----------|
|  | March 31           |         | March 31         |           |
|  | 2018               | 2017    | 2018             | 2017      |
| Diluted EPS from continuing operations (as reported)       | \$ 1.04            | \$ 0.46 | \$ 0.93          | \$ (0.59) |
| Key items, before tax:                                     |                    |         |                  |           |
| Separation, restructuring and other costs                  | 0.19               | 0.32    | 0.42             | 0.69      |
| Legal settlement/reserve                                   | (0.07)             | —       | (0.07)           | 0.07      |
| Environmental reserve adjustments                          | —                  | —       | 0.18             | —         |
| Gain on post-employment plan remeasurement                 | —                  | —       | —                | (0.04)    |
| Debt refinancing costs                                     | —                  | —       | —                | 1.48      |
| Key items, before tax                                      | 0.12               | 0.32    | 0.53             | 2.20      |
| Tax effect of key items (a)                                | (0.03)             | (0.08)  | (0.14)           | (0.79)    |
| Key items, after tax                                       | 0.09               | 0.24    | 0.39             | 1.41      |
| Tax specific key items:                                    |                    |         |                  |           |
| Deferred tax rate changes                                  | (0.07)             | —       | (2.06)           | —         |
| One-time transition tax                                    | —                  | —       | 2.22             | —         |
| Other  | —                  | —       | —                | 0.01      |
| Tax specific key items (b)                                 | (0.07)             | —       | 0.16             | 0.01      |
| Total key items  | 0.02               | 0.24    | 0.55             | 1.42      |
| Adjusted diluted EPS from continuing operations (non-GAAP) | \$ 1.06            | \$ 0.70 | \$ 1.48          | \$ 0.83   |

(a) Represents the diluted EPS impact from the tax effect of the key items that are previously identified above.

(b) Represents the diluted EPS impact from tax specific financial transactions, tax law changes or other matters that fall within the definition of tax specific key items. For additional explanation of these tax specific key items, see the income tax expense (benefit) discussion within the following caption review section.

*Statements of Consolidated Comprehensive Income (Loss) – caption review*

A comparative analysis of the Statements of Consolidated Comprehensive Income (Loss) by caption is provided as follows for the three and six months ended March 31, 2018 and 2017.

| (In millions) | Three months ended March 31 |        |        | Six months ended March 31 |          |        |
|---------------|-----------------------------|--------|--------|---------------------------|----------|--------|
|               | 2018                        | 2017   | Change | 2018                      | 2017     | Change |
| <b>Sales</b>  | \$ 974                      | \$ 806 | \$ 168 | \$ 1,816                  | \$ 1,510 | \$ 306 |

The following table provides a reconciliation of the change in sales between the three and six months ended March 31, 2018 and 2017.

| (In millions)                 | Three months ended | Six months ended |
|-------------------------------|--------------------|------------------|
|                               | March 31, 2018     | March 31, 2018   |
| Acquisitions and divestitures | \$ 73              | \$ 136           |
| Currency exchange             | 41                 | 62               |
| Pricing                       | 34                 | 63               |
| Volume                        | 18                 | 37               |
| Product mix                   | 2                  | 8                |
| Change in sales               | \$ 168             | \$ 306           |

**Current Quarter** - Sales for the current quarter increased \$168 million compared to the prior year quarter. The acquisition of Pharmachem within the Specialty Ingredients reportable segment increased sales by \$63 million, or 8%, while the net impact of other acquisitions and divestitures increased sales by \$10 million. Favorable foreign currency exchange increased sales by \$41 million, or 5%, while improvement in pricing increased sales by \$34 million, or 4%. Higher volumes and changes in product mix increased sales by \$18 million and \$2 million, respectively.

**ASHLAND GLOBAL HOLDINGS INC. AND CONSOLIDATED SUBSIDIARIES**  
**MANAGEMENT'S DISCUSSION AND ANALYSIS**

Year-to-Date - Sales for the current period increased \$306 million compared to the prior year period. The acquisition of Pharmachem within the Specialty Ingredients reportable segment increased sales by \$121 million, 8%, while the net impact of other acquisitions and divestitures increased sales by \$15 million. Improvements in pricing increased sales by \$63 million, or 4%, while favorable foreign currency exchange increased sales by \$62 million. Higher volumes and changes in product mix increased sales by \$37 million and \$8 million, respectively.

| (In millions)                             | Three months ended March 31 |        |        | Six months ended March 31 |          |        |
|---|-----------------------------|--------|--------|---------------------------|----------|--------|
|   | 2018                        | 2017   | Change | 2018                      | 2017     | Change |
| <b>Cost of sales</b>                      | \$ 699                      | \$ 578 | \$ 121 | \$ 1,312                  | \$ 1,093 | \$ 219 |
| <b>Gross profit as a percent of sales</b> | 28.2%                       | 28.3%  |        | 27.8%                     | 27.6%    |        |

Fluctuations in cost of sales are driven primarily by raw material prices, volume and changes in product mix, currency exchange, acquisitions and divestitures and other certain charges incurred as a result of changes or events within the businesses or restructuring activities. The following table provides a quantified reconciliation of the changes in cost of sales between the three and six months ended March 31, 2018 and 2017.

| (In millions)                           | Three months ended<br>March 31, 2018 | Six months ended<br>March 31, 2018 |
|---|--------------------------------------|------------------------------------|
| Changes in:                             |                                      |                                    |
| Acquisitions and divestitures           | \$ 54                                | \$ 104                             |
| Production costs                        | 32                                   | 50                                 |
| Currency exchange                       | 27                                   | 43                                 |
| Volume                                  | 6                                    | 16                                 |
| Product mix                             | 2                                    | 5                                  |
| Severance and other restructuring costs | —                                    | 1                                  |
| <b>Change in cost of sales</b>          | <u>\$ 121</u>                        | <u>\$ 219</u>                      |

Current Quarter - Cost of sales for the current quarter increased \$121 million compared to the prior year quarter. The Pharmachem acquisition increased cost of sales by \$45 million, or 8%, while the net impact of other acquisitions and divestitures increased cost of sales by \$9 million. Unfavorable production costs and foreign currency exchange increased cost of sales by \$32 million, or 6%, and \$27 million, or 5%, respectively. Higher volumes and changes in product mix increased cost of sales by \$6 million and \$2 million, respectively.

Year-to-Date - Cost of sales for the current period increased \$219 million compared to the prior year period. The Pharmachem acquisition increased cost of sales by \$90 million, or 8%, while the net impact of other acquisitions and divestitures increased cost of sales by \$14 million. Unfavorable production costs and foreign currency exchange increased cost of sales by \$50 million, or 5%, and \$43 million, or 4%, respectively. Higher volumes and changes in product mix increased cost of sales by \$16 million and \$5 million, respectively, while the current period also included \$1 million of severance and other restructuring charges related to a plant closure.

| (In millions)                                      | Three months ended March 31 |        |        | Six months ended March 31 |        |        |
|--|-----------------------------|--------|--------|---------------------------|--------|--------|
|  | 2018                        | 2017   | Change | 2018                      | 2017   | Change |
| <b>Selling, general and administrative expense</b> | \$ 163                      | \$ 155 | \$ 8   | \$ 334                    | \$ 312 | \$ 22  |
| <b>As a percent of sales</b>                       | 16.7%                       | 19.2%  |        | 18.4%                     | 20.7%  |        |

Current Quarter - Selling, general and administrative expense for the current quarter increased \$8 million compared to the prior year quarter with expenses as a percent of sales decreasing 2.5 percentage points.

**ASHLAND GLOBAL HOLDINGS INC. AND CONSOLIDATED SUBSIDIARIES**  
**MANAGEMENT'S DISCUSSION AND ANALYSIS**

Key drivers of the fluctuation in selling, general and administrative expense compared to the prior year quarter were:

- \$9 million of incremental costs related to Pharmachem's operations and \$4 million of Pharmachem integration costs during the current quarter;
- an increase of \$5 million due to foreign currency exchange in the current quarter;
- \$4 million of accelerated depreciation related to the planned closure of an office building during the current quarter;
- an increase of \$3 million due to higher employee-related costs in the current quarter; and
- \$2 million of costs related to the separation of Valvoline during the current quarter compared to \$19 million in the prior year quarter.

Year-to-Date - Selling, general and administrative expense for the current period increased \$22 million compared to the prior year period with expenses as a percent of sales decreasing 2.3 percentage points. Key drivers of the fluctuation in selling, general and administrative expense compared to the prior year period were:

- \$20 million of incremental costs related to Pharmachem's operations and \$6 million of Pharmachem integration costs during the current period;
- \$18 million and \$8 million in net environmental-related expenses during the current and prior year periods, respectively;
- an increase of \$10 million due to foreign currency exchange in the current period;
- \$8 million of accelerated depreciation related to the planned closure of an office building during the current period;
- \$8 million of costs related to the separation of Valvoline during the current period compared to \$42 million in the prior year period;
- an increase of \$7 million due to higher employee-related costs in the current period; and
- a \$5 million charge for a legal reserve during the prior year period.

| (In millions)                           | Three months ended March 31 |       |        | Six months ended March 31 |       |        |
|---|-----------------------------|-------|--------|---------------------------|-------|--------|
|   | 2018                        | 2017  | Change | 2018                      | 2017  | Change |
| <b>Research and development expense</b> | \$ 21                       | \$ 21 | \$ —   | \$ 43                     | \$ 41 | \$ 2   |

Current Quarter - Research and development expense remained relatively consistent with the prior year quarter.

Year-to-Date - Research and development expense remained relatively consistent with the prior year period.

| (In millions)                  | Three months ended March 31 |             |             | Six months ended March 31 |             |             |
|--------------------------------|-----------------------------|-------------|-------------|---------------------------|-------------|-------------|
|                                | 2018                        | 2017        | Change      | 2018                      | 2017        | Change      |
| <b>Equity and other income</b> |                             |             |             |                           |             |             |
| Equity income (a)              | \$ —                        | \$ —        | \$ —        | \$ —                      | \$ —        | \$ —        |
| Other income                   | 4                           | 1           | 3           | 6                         | 4           | 2           |
|                                | <u>\$ 4</u>                 | <u>\$ 1</u> | <u>\$ 3</u> | <u>\$ 6</u>               | <u>\$ 4</u> | <u>\$ 2</u> |

(a) Activity of \$0 denotes value less than \$1 million.

**ASHLAND GLOBAL HOLDINGS INC. AND CONSOLIDATED SUBSIDIARIES**  
**MANAGEMENT'S DISCUSSION AND ANALYSIS**

Current Quarter – Other income increased compared to the prior year quarter primarily due to the current quarter including \$5 million of proceeds from a legal settlement, partially offset by \$2 million of accelerated depreciation for the termination of a contract at a manufacturing facility.

Year-to-Date – Excluding the impact from the items previously discussed in the current quarter analysis, other income remained relatively consistent compared with the prior year period.

| (In millions)  | Three months ended March 31 |              |             | Six months ended March 31 |               |                |
|--|-----------------------------|--------------|-------------|---------------------------|---------------|----------------|
|  | 2018                        | 2017         | Change      | 2018                      | 2017          | Change         |
| <b>Net interest and other financing expense (income)</b> |                             |              |             |                           |               |                |
| Interest expense   | \$ 34                       | \$ 31        | \$ 3        | \$ 68                     | \$ 157        | \$ (89)        |
| Interest income  | (1)                         | (1)          | —           | (3)                       | (2)           | (1)            |
| Available-for-sale securities income                     | (5)                         | (4)          | (1)         | (8)                       | (7)           | (1)            |
| Other financing costs                                    | 1                           | 3            | (2)         | 2                         | 4             | (2)            |
|  | <u>\$ 29</u>                | <u>\$ 29</u> | <u>\$ —</u> | <u>\$ 59</u>              | <u>\$ 152</u> | <u>\$ (93)</u> |

Current Quarter - Net interest and other financing expense remained consistent with the prior year quarter. Available-for-sale securities income of \$5 million and \$4 million during the current and the prior year quarters, respectively, represents investment income and realized gains related to restricted investments discussed in Note E of the Notes to Condensed Consolidated Financial Statements.

Year-to-Date - Net interest and other financing expense decreased \$93 million during the current period compared to the prior year period. The current period decrease in interest expense of \$89 million was primarily due to the prior year period including \$92 million of accelerated accretion related to the December 2016 tender offer of the 2029 notes. Available-for-sale securities income of \$8 million and \$7 million during the current and the prior year periods, respectively, represents investment income and realized gains related to restricted investments discussed in Note E of the Notes to Condensed Consolidated Financial Statements.

| (In millions)                            | Three months ended March 31 |      |        | Six months ended March 31 |      |        |
|--|-----------------------------|------|--------|---------------------------|------|--------|
|  | 2018                        | 2017 | Change | 2018                      | 2017 | Change |
| <b>Other net periodic benefit income</b> | \$ 1                        | \$ — | \$ 1   | \$ 1                      | \$ 3 | \$ (2) |

Current Quarter – Other net periodic benefit income remained relatively consistent with the prior year quarter.

Year-to-Date - The decrease in other net periodic benefit income compared to the prior year period primarily related to a \$2 million gain on the remeasurement of certain post-employment health and life insurance benefit plans that were discontinued during the prior year period.

| (In millions)                   | Three months ended March 31 |      |        | Six months ended March 31 |      |        |
|---------------------------------|-----------------------------|------|--------|---------------------------|------|--------|
|                                 | 2018                        | 2017 | Change | 2018                      | 2017 | Change |
| <b>Net loss on divestitures</b> | \$ —                        | \$ — | \$ —   | \$ 1                      | \$ 1 | \$ —   |

Current Quarter - There was no activity during the current and prior year quarters.

Year-to-Date - The activity in the current and prior year periods primarily related to post-closing adjustments for certain divestitures.

**ASHLAND GLOBAL HOLDINGS INC. AND CONSOLIDATED SUBSIDIARIES**  
**MANAGEMENT'S DISCUSSION AND ANALYSIS**

| (In millions)                       | Three months ended March 31 |        |        | Six months ended March 31 |         |        |
|-------------------------------------|-----------------------------|--------|--------|---------------------------|---------|--------|
|                                     | 2018                        | 2017   | Change | 2018                      | 2017    | Change |
| <b>Income tax expense (benefit)</b> | \$ 1                        | \$ (5) | \$ 6   | \$ 15                     | \$ (45) | \$ 60  |
| <b>Effective tax rate</b>           | 1%                          | (21)%  |        | 20%                       | 55%     |        |

**Current Quarter** - Ashland's effective tax rate in any interim period is subject to adjustments related to discrete items and the mix of domestic and foreign operating results. The overall effective tax rate was 1% for the three months ended March 31, 2018 and was primarily impacted by income mix and a favorable tax discrete adjustment of \$4 million related to a deferred tax rate change for a foreign entity.

The overall effective tax rate was a benefit of 21% for the three months ended March 31, 2017 and was impacted by income mix and net favorable tax discrete items of \$4 million primarily related to unrecognized tax benefits due to lapse of the statute of limitations.

**Year-to-Date** - The overall effective tax rate was 20% for the six months ended March 31, 2018 and was primarily impacted by income mix, a deferred tax rate change for a foreign entity and net unfavorable tax discrete adjustments of \$16 million related to the Tax Act. These net unfavorable adjustments included deferred tax rate changes and a one-time transition tax assessed on foreign cash and unremitted earnings.

The overall effective tax rate was 55% for the six months ended March 31, 2017 and was impacted by income mix and net favorable tax discrete items of \$4 million primarily related to unrecognized tax benefits due to lapse of the statute of limitations.

*Adjusted income tax expense (benefit)*

Key items are defined as the financial effects from significant transactions that may have caused short-term fluctuations in net income and/or operating income which Ashland believes do not accurately reflect Ashland's underlying business performance and trends. Tax specific key items are defined as the financial effects from tax specific financial transactions, tax law changes or other matters that fall within the definition of key items as previously described. The effective tax rate, excluding key items, which is a non-GAAP measure, has been prepared to illustrate the ongoing tax effects of Ashland's operations. Management believes investors and analysts use this financial measure in assessing Ashland's business performance and that presenting this non-GAAP measure on a consolidated basis assists investors in better understanding Ashland's ongoing business performance and enhancing their ability to compare period-to-period financial results.

The effective tax rate during the three and six months ended March 31, 2018 and 2017 was significantly impacted by the following tax specific key items:

- a favorable adjustment of \$4 million related to a deferred tax rate change for a foreign entity during the three months ended March 31, 2018;
- a favorable adjustment of \$126 million for the remeasurement of the domestic deferred tax balances resulting from the enactment of the Tax Cuts and Jobs Act (Tax Act) during the six months ended March 31, 2018; and
- an unfavorable adjustment of \$142 million for a one-time transition tax resulting from the enactment of the Tax Act during the six months ended March 31, 2018.

The following table is a calculation of the effective tax rate, excluding these key items.

**ASHLAND GLOBAL HOLDINGS INC. AND CONSOLIDATED SUBSIDIARIES**  
**MANAGEMENT'S DISCUSSION AND ANALYSIS**

| (In millions)   | Three months ended<br>March 31 |              | Six months ended<br>March 31 |              |
|---|--------------------------------|--------------|------------------------------|--------------|
|   | 2018                           | 2017         | 2018                         | 2017         |
| Income (loss) from continuing operations                  |                                |              |                              |              |
| before income taxes                                       | \$ 67                          | \$ 24        | \$ 74                        | \$ (82)      |
| Key items (pre-tax) (a)                                   | 7                              | 19           | 33                           | 137          |
| <b>Adjusted income from continuing operations</b>         |                                |              |                              |              |
| <b>before income taxes</b>                                | <u>\$ 74</u>                   | <u>\$ 43</u> | <u>\$ 107</u>                | <u>\$ 55</u> |
| Income tax expense (benefit)                              | \$ 1                           | \$ (5)       | \$ 15                        | \$ (45)      |
| Income tax rate adjustments:                              |                                |              |                              |              |
| Tax effect of key items                                   | 2                              | 5            | 10                           | 49           |
| Tax specific key items: (b)                               |                                |              |                              |              |
| Deferred tax rate changes                                 | 4                              | —            | 130                          | —            |
| One-time transition tax                                   | —                              | —            | (142)                        | —            |
| Other   | —                              | —            | —                            | (1)          |
| Total income tax rate adjustments                         | 6                              | 5            | (2)                          | 48           |
| <b>Adjusted income tax expense</b>                        | <u>\$ 7</u>                    | <u>\$ —</u>  | <u>\$ 13</u>                 | <u>\$ 3</u>  |
| <b>Effective tax rate, excluding key items (Non-GAAP)</b> | 9%                             | —%           | 12%                          | 5%           |

(a) See Adjusted EBITDA reconciliation table previously disclosed in this Management, Discussion and Analysis for a summary of the key items, before tax.  
(b) For additional information on the effect that these tax specific key items had on EPS, see the Adjusted Diluted EPS table previously disclosed in this Management, Discussion and Analysis.

| (In millions)                              | Three months ended March 31 |              |                | Six months ended March 31 |               |                 |
|--|-----------------------------|--------------|----------------|---------------------------|---------------|-----------------|
|  | 2018                        | 2017         | Change         | 2018                      | 2017          | Change          |
| <b>Income from discontinued operations</b> |                             |              |                |                           |               |                 |
| <b>(net of taxes)</b>                      |                             |              |                |                           |               |                 |
| Valvoline                                  | \$ 4                        | \$ 73        | \$ (69)        | \$ 7                      | \$ 149        | \$ (142)        |
| Asbestos-related litigation                | 3                           | —            | 3              | 3                         | —             | 3               |
| Water Technologies                         | —                           | 3            | (3)            | —                         | 3             | (3)             |
|  | <u>\$ 7</u>                 | <u>\$ 76</u> | <u>\$ (69)</u> | <u>\$ 10</u>              | <u>\$ 152</u> | <u>\$ (142)</u> |

**Current Quarter** - As a result of the full separation of Valvoline Inc. on May 12, 2017, the operating results related to Valvoline Inc., including the operating results of the former Valvoline reportable segment, have been reflected as discontinued operations (net of tax) within the Statement of Consolidated Comprehensive Income (Loss). The activity within the current quarter primarily represents subsequent adjustments that were made in conjunction with the Tax Matters Agreement. See Note B for more information on the Tax Matters Agreement. During the prior year quarter, Valvoline's sales and pre-tax operating income included in discontinued operations were \$514 million and \$117 million, respectively.

The current quarter also included \$3 million of income related to receipts from insurance carriers for asbestos-related litigation while the prior year quarter included a tax adjustment related to the sale of Ashland Water Technologies.

**Year-to-Date** - The Valvoline activity within the current period represents subsequent adjustments that were made in conjunction with the Tax Matters Agreement. During the prior year period, Valvoline's sales and pre-tax operating income included in discontinued operations were \$1,003 million and \$237 million, respectively.

**ASHLAND GLOBAL HOLDINGS INC. AND CONSOLIDATED SUBSIDIARIES**  
**MANAGEMENT'S DISCUSSION AND ANALYSIS**

| (In millions)   | Three months ended March 31 |       |         | Six months ended March 31 |       |         |
|---|-----------------------------|-------|---------|---------------------------|-------|---------|
|   | 2018                        | 2017  | Change  | 2018                      | 2017  | Change  |
| <b>Net income attributable to noncontrolling interest</b> | \$ —                        | \$ 13 | \$ (13) | \$ —                      | \$ 24 | \$ (24) |

Since Ashland's ownership interest in Valvoline Inc. was approximately 83% until the final separation on May 12, 2017, the amount of net income attributable to the outside stockholders' of approximately 17% noncontrolling interest in Valvoline Inc. is presented within this caption on the Statement of Consolidated Comprehensive Income (Loss) for the three and six months ended March 31, 2017.

*Other comprehensive income (loss)*

A comparative analysis of the components of other comprehensive income (loss) is provided below for the three and six months ended March 31, 2018 and 2017.

| (In millions)   | Three months ended March 31 |              |                | Six months ended March 31 |                |               |
|---|-----------------------------|--------------|----------------|---------------------------|----------------|---------------|
|   | 2018                        | 2017         | Change         | 2018                      | 2017           | Change        |
| <b>Other comprehensive income (loss) (net of taxes)</b> |                             |              |                |                           |                |               |
| Unrealized translation gain (loss)                      | \$ 55                       | \$ 60        | \$ (5)         | \$ 58                     | \$ (86)        | \$ 144        |
| Pension and postretirement obligation adjustment        | —                           | (2)          | 2              | —                         | (4)            | 4             |
| Net change in available-for-sale securities             | (6)                         | 6            | (12)           | 2                         | 6              | (4)           |
|   | <u>\$ 49</u>                | <u>\$ 64</u> | <u>\$ (15)</u> | <u>\$ 60</u>              | <u>\$ (84)</u> | <u>\$ 144</u> |

**Current Quarter** - Total other comprehensive income, net of tax, for the current quarter decreased \$15 million compared to the prior year quarter as a result of the following components:

- For the three months ended March 31, 2018, the change in unrealized gain from foreign currency translation adjustments was \$55 million compared to a gain of \$60 million for the three months ended March 31, 2017. The fluctuations in unrealized translation gains and losses are primarily due to translating foreign subsidiary financial statements from local currencies to U.S. Dollars.
- For the three months ended March 31, 2018, the net change in available-for-sale securities related to restricted investments amounted to a loss of \$6 million compared to a gain of \$6 million during the three months ended March 31, 2017.
- The pension and postretirement obligation adjustment was \$2 million for the three months ended March 31, 2017. This amount related to amortization of unrecognized prior services credits for pension and other postretirement benefit plans and was reclassified into net income during the prior year quarter.

**Year-to-Date** - Total other comprehensive income (loss), net of tax, for the current period increased \$144 million compared to the prior year period as a result of the following components:

- For the six months ended March 31, 2018, the change in unrealized gain (loss) from foreign currency translation adjustments was a gain of \$58 million compared to a loss of \$86 million for the six months ended March 31, 2017. The fluctuations in unrealized translation gains and losses are primarily due to translating foreign subsidiary financial statements from local currencies to U.S. Dollars.
- The net change in available-for-sale securities related to restricted investments amounted to gains of \$2 million and \$6 million during the six months ended March 31, 2018 and 2017, respectively.
- The pension and postretirement obligation adjustment was \$4 million for the six months ended March 31, 2017. This amount related to amortization of unrecognized prior services credits for pension and other postretirement benefit plans and was reclassified into net income during the prior year period.

**RESULTS OF OPERATIONS – REPORTABLE SEGMENT REVIEW**

Subsequent to completing the separation from Valvoline Inc. on May 12, 2017, Ashland's operations are managed within the following three reportable segments: Specialty Ingredients, Composites and Intermediates and Solvents.

Results of Ashland's reportable segments are presented based on its management and internal accounting structure. The structure is specific to Ashland; therefore, the financial results of Ashland's reportable segments are not necessarily comparable with similar information for other comparable companies. Ashland allocates all significant costs to its reportable segments except for certain significant company-wide restructuring activities and other costs or adjustments that relate to former businesses that Ashland no longer operates. The service cost component of pension and other postretirement benefits costs is allocated to each reportable segment on a ratable basis; while the remaining components of pension and other postretirement benefits costs are recorded within the other net periodic benefit income caption on the Statements of Consolidated Comprehensive Income (Loss). Ashland refines its expense allocation methodologies to the reportable segments from time to time as internal accounting practices are improved, more refined information becomes available and the industry or market changes. Significant revisions to Ashland's methodologies are adjusted for all segments on a retrospective basis.

The EBITDA and Adjusted EBITDA amounts presented within this business section are provided as a means to enhance the understanding of financial measurements that Ashland has internally determined to be relevant measures of comparison for each segment. Each of these non-GAAP measures is defined as follows: EBITDA (operating income (loss) plus depreciation and amortization), Adjusted EBITDA (EBITDA adjusted for key items, which may include pro forma effects for significant acquisitions or divestitures, as applicable), and Adjusted EBITDA margin (Adjusted EBITDA, which may include pro forma adjustments, divided by sales or sales adjusted for pro forma results). Ashland does not allocate items to each reportable segment below operating income, such as interest expense and income taxes. As a result, reportable segment EBITDA and Adjusted EBITDA are reconciled directly to operating income since it is the most directly comparable caption to the Statements of Consolidated Comprehensive Income (Loss).



**ASHLAND GLOBAL HOLDINGS INC. AND CONSOLIDATED SUBSIDIARIES**  
**MANAGEMENT'S DISCUSSION AND ANALYSIS**

The following table discloses sales, operating income, depreciation and amortization and statistical operating information by reportable segment for the three and six months ended March 31, 2018 and 2017.

| (In millions)                        | Three months ended<br>March 31 |               | Six months ended<br>March 31 |                 |
|--------------------------------------|--------------------------------|---------------|------------------------------|-----------------|
|                                      | 2018                           | 2017          | 2018                         | 2017            |
| <b>Sales</b>                         |                                |               |                              |                 |
| Specialty Ingredients                | \$ 646                         | \$ 544        | \$ 1,196                     | \$ 1,026        |
| Composites                           | 238                            | 186           | 456                          | 351             |
| Intermediates and Solvents           | 90                             | 76            | 164                          | 133             |
|                                      | <u>\$ 974</u>                  | <u>\$ 806</u> | <u>\$ 1,816</u>              | <u>\$ 1,510</u> |
| <b>Operating income (loss)</b>       |                                |               |                              |                 |
| Specialty Ingredients                | \$ 89                          | \$ 74         | \$ 131                       | \$ 114          |
| Composites                           | 19                             | 13            | 36                           | 29              |
| Intermediates and Solvents           | 4                              | (3)           | 13                           | (11)            |
| Unallocated and other                | (17)                           | (31)          | (47)                         | (64)            |
|                                      | <u>\$ 95</u>                   | <u>\$ 53</u>  | <u>\$ 133</u>                | <u>\$ 68</u>    |
| <b>Depreciation and amortization</b> |                                |               |                              |                 |
| Specialty Ingredients                | \$ 64                          | \$ 53         | \$ 126                       | \$ 107          |
| Composites                           | 6                              | 5             | 11                           | 10              |
| Intermediates and Solvents           | 8                              | 8             | 15                           | 16              |
| Unallocated and other                | 4                              | 1             | 9                            | 1               |
|                                      | <u>\$ 82</u>                   | <u>\$ 67</u>  | <u>\$ 161</u>                | <u>\$ 134</u>   |
| <b>Operating information</b>         |                                |               |                              |                 |
| Specialty Ingredients                |                                |               |                              |                 |
| Sales per shipping day               | \$ 10.1                        | \$ 8.5        | \$ 9.6                       | \$ 8.2          |
| Metric tons sold (thousands)         | 84.0                           | 80.7          | 157.0                        | 153.3           |
| Gross profit as a percent of sales   | 33.6%                          | 34.8%         | 32.6%                        | 33.5%           |
| Composites                           |                                |               |                              |                 |
| Sales per shipping day               | \$ 3.7                         | \$ 2.9        | \$ 3.6                       | \$ 2.8          |
| Metric tons sold (thousands)         | 97.1                           | 84.7          | 188.3                        | 163.1           |
| Gross profit as a percent of sales   | 18.9%                          | 18.5%         | 18.6%                        | 19.7%           |
| Intermediates and Solvents           |                                |               |                              |                 |
| Sales per shipping day               | \$ 1.4                         | \$ 1.2        | \$ 1.3                       | \$ 1.1          |
| Metric tons sold (thousands)         | 38.0                           | 43.2          | 70.7                         | 75.4            |
| Gross profit as a percent of sales   | 13.4%                          | 5.5%          | 17.0%                        | 2.8%            |

(a) Gross profit is defined as sales, less cost of sales divided by sales.

Sales by region expressed as a percentage of reportable segment sales for the three and six months ended March 31, 2018 and 2017 were as follows. Ashland includes only U.S. and Canada in its North American designation.

| Sales by Geography    | Three months ended March 31, 2018 |             |                               | Six months ended March 31, 2018 |             |                               |
|-----------------------|-----------------------------------|-------------|-------------------------------|---------------------------------|-------------|-------------------------------|
|                       | Specialty<br>Ingredients          | Composites  | Intermediates<br>and Solvents | Specialty<br>Ingredients        | Composites  | Intermediates<br>and Solvents |
| North America         | 40%                               | 46%         | 20%                           | 40%                             | 45%         | 20%                           |
| Europe                | 34%                               | 35%         | 64%                           | 33%                             | 35%         | 62%                           |
| Asia Pacific          | 17%                               | 12%         | 14%                           | 18%                             | 13%         | 15%                           |
| Latin America & other | 9%                                | 7%          | 2%                            | 9%                              | 7%          | 3%                            |
|                       | <u>100%</u>                       | <u>100%</u> | <u>100%</u>                   | <u>100%</u>                     | <u>100%</u> | <u>100%</u>                   |

**ASHLAND GLOBAL HOLDINGS INC. AND CONSOLIDATED SUBSIDIARIES**  
**MANAGEMENT'S DISCUSSION AND ANALYSIS**

| Sales by Geography    | Three months ended March 31, 2017 |             |                            | Six months ended March 31, 2017 |             |                            |
|-----------------------|-----------------------------------|-------------|----------------------------|---------------------------------|-------------|----------------------------|
|                       | Specialty Ingredients             | Composites  | Intermediates and Solvents | Specialty Ingredients           | Composites  | Intermediates and Solvents |
| North America         | 39%                               | 49%         | 22%                        | 39%                             | 48%         | 22%                        |
| Europe                | 31%                               | 30%         | 57%                        | 30%                             | 29%         | 57%                        |
| Asia Pacific          | 20%                               | 14%         | 18%                        | 21%                             | 15%         | 18%                        |
| Latin America & other | 10%                               | 7%          | 3%                         | 10%                             | 8%          | 3%                         |
|                       | <u>100%</u>                       | <u>100%</u> | <u>100%</u>                | <u>100%</u>                     | <u>100%</u> | <u>100%</u>                |

**Specialty Ingredients**

Specialty Ingredients is a global leader in cellulose ethers, vinyl pyrrolidones and biofunctionals. It offers industry-leading products, technologies and resources for solving formulation and product-performance challenges. Specialty Ingredients uses natural, synthetic and semisynthetic polymers derived from cellulose ethers, vinyl pyrrolidones, acrylic polymers, polyester and polyurethane-based adhesives, and plant and seed extract. Specialty Ingredients' end markets offer comprehensive and innovative solutions for today's demanding consumer and industrial applications. Key customers include: pharmaceutical companies; makers of personal care products, food and beverages; makers of nutraceuticals and supplements; manufacturers of paint, coatings and construction materials; packaging and converting; and oilfield service companies.

On May 17, 2017, Ashland completed its acquisition of the stock of Pharmachem, a leading provider of quality ingredients to the global health and wellness industries and high-value differentiated products to fragrance and flavor houses. With annual revenues of approximately \$300 million and 14 manufacturing facilities in the United States and Mexico, New Jersey-based Pharmachem develops, manufactures and supplies custom and branded nutritional and fragrance products. See Note C within the Notes to Condensed Consolidated Financial Statements for more information.

Additionally, Ashland completed the transfer of its ownership interest in a consolidated joint venture during the third quarter of fiscal 2017.

*March 2018 quarter compared to March 2017 quarter*

Specialty Ingredients' sales increased \$102 million to \$646 million in the current quarter. The acquisition of Pharmachem increased sales by \$63 million, or 12%. Favorable foreign currency exchange increased sales by \$24 million, while volume and mix combined to increase sales by \$22 million. In addition, improved product pricing increased sales by \$3 million. These increases were partially offset by a decrease of \$10 million from divestitures which was primarily related to the transfer of ownership interest in a consolidated joint venture.

Gross profit during the current quarter increased \$28 million compared to the prior year quarter. The acquisition of Pharmachem increased gross profit by \$18 million while improved volume and mix combined to increase gross profit by \$11 million. Favorable foreign currency exchange increased gross profit by \$12 million. These increases were partially offset by the net impact of pricing and costs which decreased gross profit by \$12 million and the joint venture divestiture which decreased gross profit by \$1 million. In total, gross profit margin during the current quarter decreased 1.2 percentage points as compared to the prior year quarter to 33.6%.

Selling, general and administrative expenses (which include research and development expenses throughout the reportable segment discussion and analysis) increased \$11 million in the current quarter as compared to the prior year quarter largely due to incremental costs of \$9 million related to Pharmachem's operations. The remaining increase in selling, general and administrative expenses was primarily due to foreign currency exchange. Equity and other income decreased \$2 million compared to the prior year quarter due to accelerated depreciation during the current quarter related to the termination of a contract at a manufacturing facility.

---

**ASHLAND GLOBAL HOLDINGS INC. AND CONSOLIDATED SUBSIDIARIES**  
**MANAGEMENT'S DISCUSSION AND ANALYSIS**

---

Operating income totaled \$89 million for the current quarter compared to \$74 million in the prior year quarter. Current quarter EBITDA increased \$24 million to \$151 million, while Adjusted EBITDA increased \$26 million to \$153 million. Adjusted EBITDA margin increased 0.4 percentage points in the current quarter to 23.7%.

*Fiscal 2018 year-to-date compared to fiscal 2017 year-to-date*

Specialty Ingredients' sales increased \$170 million to \$1,196 million in the current period. The acquisition of Pharmachem increased sales by \$121 million, or 12%. Favorable foreign currency exchange increased sales by \$35 million, while volume and mix combined to increase sales by \$31 million. In addition, improved product pricing increased sales by \$4 million. These increases were partially offset by a decrease of \$21 million from divestitures which was primarily related to the transfer of ownership interest in a consolidated joint venture.

Gross profit during the current quarter increased \$47 million compared to the prior year period. The acquisition of Pharmachem increased gross profit by \$31 million while improved volume and mix combined to increase gross profit by \$19 million. Favorable foreign currency exchange increased gross profit by \$16 million. These increases were partially offset by the net impact of pricing and costs which decreased gross profit by \$17 million and the joint venture divestiture which decreased gross profit by \$2 million. In total, gross profit margin during the current period decreased 0.9 percentage points as compared to the prior year period to 32.6%.

Selling, general and administrative expenses increased \$26 million in the current period as compared to the prior year period largely due to incremental costs of \$20 million related to Pharmachem's operations. The remaining increase in selling, general and administrative expenses was primarily due to higher employee-related costs and unfavorable foreign currency exchange. Equity and other income decreased \$4 million compared to the prior year period due to accelerated depreciation during the current period related to the termination of a contract at a manufacturing facility.

Operating income totaled \$131 million for the current period compared to \$114 million in the prior year period. Current period EBITDA increased \$32 million to \$253 million, while Adjusted EBITDA increased \$37 million to \$258 million. Adjusted EBITDA margin increased 0.1 percentage points in the current period to 21.6%.

*EBITDA and Adjusted EBITDA reconciliation*

The following EBITDA presentation for the three and six months ended March 31, 2018 and 2017 below is provided as a means to enhance the understanding of financial measurements that Ashland has internally determined to be relevant measures of comparison for the results of Specialty Ingredients. Adjusted EBITDA results have been prepared to illustrate the ongoing effects of Ashland's operations, which exclude certain key items. The key items within the current quarter and period related to accelerated depreciation for the termination of a contract at a manufacturing facility and severance and other restructuring charges for the closure of a manufacturing plant. There were no unusual or key items that affected comparability for EBITDA during the prior year quarter or prior year period.

**ASHLAND GLOBAL HOLDINGS INC. AND CONSOLIDATED SUBSIDIARIES**  
**MANAGEMENT'S DISCUSSION AND ANALYSIS**

| (In millions)                           | Three months ended |        | Six months ended |        |
|---|--------------------|--------|------------------|--------|
|   | March 31           |        | March 31         |        |
|   | 2018               | 2017   | 2018             | 2017   |
| Operating income                        | \$ 89              | \$ 74  | \$ 131           | \$ 114 |
| Depreciation and amortization (a)       | 62                 | 53     | 122              | 107    |
| EBITDA                                  | 151                | 127    | 253              | 221    |
| Accelerated depreciation                | 2                  | —      | 4                | —      |
| Severance and other restructuring costs | —                  | —      | 1                | —      |
| Adjusted EBITDA                         | \$ 153             | \$ 127 | \$ 258           | \$ 221 |

(a) Excludes \$2 million and \$4 million of accelerated depreciation for the three and six months ended March 31, 2018.

**Composites**

Composites is a global leader in unsaturated polyester resins, vinyl ester resins and gelcoats. The Composites business manufactures and sells a broad range of general-purpose and high-performance grades of unsaturated polyester and vinyl ester resins, gelcoats and low-profile additives for the reinforced plastics industry. The products in the Composites business provide an array of functional properties including corrosion resistance, fire retardance, ultraviolet resistance, water and chemical resistance, high mechanical strength, impact and scratch resistance and high strength-to-weight ratios. Key end markets include transportation, construction, marine and infrastructure. In addition, the business manufactures and sells molten maleic anhydride for the manufacture of a variety of products such as unsaturated polyester resins, copolymers, lubricating oil additives, alkenyl succinic anhydrides, malic acid, fumaric acid and numerous derivative chemicals. Key markets include composites, personal care, dispersants and paper sizing.

*March 2018 quarter compared to March 2017 quarter*

Composites' sales increased \$52 million to \$238 million in the current quarter. The acquisition of an unsaturated polyester resins manufacturing facility in the third of quarter of fiscal 2017 increased sales by \$20 million, or 11%, while improved product pricing increased sales by \$17 million, or 9%. Favorable foreign currency exchange increased sales by \$10 million, while improved volume and mix increased sales by \$5 million as metric tons sold increased to 97.1 thousand in the current quarter.

Gross profit increased \$11 million in the current quarter compared to the prior year quarter. The net effects of pricing and costs increased gross profit by \$6 million. The facility acquisition and favorable foreign currency exchange each increased gross profit by \$2 million, while changes in volume and mix combined to increase gross profit by \$1 million. In total, gross profit margin increased 0.4 percentage points as compared to the prior year quarter to 18.9%.

Selling, general and administrative expenses during the current quarter increased \$5 million compared to the prior year quarter primarily due to higher employee-related costs and unfavorable foreign currency exchange. Equity and other income remained consistent with the prior year quarter.

Operating income totaled \$19 million in the current quarter compared to \$13 million in the prior year quarter. EBITDA increased \$7 million to \$25 million in the current quarter, while EBITDA margin increased 0.8 percentage points in the current quarter to 10.5%.

*Fiscal 2018 year-to-date compared to fiscal 2017 year-to-date*

Composites' sales increased \$105 million to \$456 million in the current period. The acquisition of an unsaturated polyester resins manufacturing facility and improved product pricing each increased sales by \$36 million, or 10%. Improved volume and mix increased sales by \$17 million, as metric tons sold increased to 188.3 thousand in the current period, while favorable foreign currency exchange increased sales by \$16 million.

Gross profit increased \$15 million in the current period compared to the prior year period. The net effects of pricing and costs increased gross profit by \$5 million, while changes in volume and mix combined to

---

**ASHLAND GLOBAL HOLDINGS INC. AND CONSOLIDATED SUBSIDIARIES**  
**MANAGEMENT'S DISCUSSION AND ANALYSIS**

---

increase gross profit by \$4 million. The facility acquisition and favorable foreign currency exchange each increased gross profit by \$3 million. In total, gross profit margin decreased 1.1 percentage points as compared to the prior year period to 18.6%.

Selling, general and administrative expenses during the current period increased \$9 million compared to the prior year period primarily due to higher employee-related costs and unfavorable foreign currency exchange. Equity and other income increased \$1 million compared to the prior year period.

Operating income totaled \$36 million in the current period compared to \$29 million in the prior year quarter. EBITDA increased \$8 million to \$47 million in the current period, while EBITDA margin decreased 0.8 percentage points in the current period to 10.3%.

*EBITDA and Adjusted EBITDA reconciliation*

The following EBITDA presentation for the three and six months ended March 31, 2018 and 2017 below is provided as a means to enhance the understanding of financial measurements that Ashland has internally determined to be relevant measures of comparison for the results of Composites. There were no unusual or key items that affected comparability for EBITDA during the current and prior year quarters or periods.

| (In millions)                 | Three months ended |       | Six months ended |       |
|-------------------------------|--------------------|-------|------------------|-------|
|                               | March 31           |       | March 31         |       |
|                               | 2018               | 2017  | 2018             | 2017  |
| Operating income              | \$ 19              | \$ 13 | \$ 36            | \$ 29 |
| Depreciation and amortization | 6                  | 5     | 11               | 10    |
| EBITDA                        | \$ 25              | \$ 18 | \$ 47            | \$ 39 |

**Intermediates and Solvents**

Intermediates and Solvents is a leading producer of 1,4 butanediol (BDO) and related derivatives, including tetrahydrofuran and n-methylpyrrolidone. These products are used as chemical intermediates in the production of engineering polymers and polyurethanes, and as specialty process solvents in a wide array of applications including electronics, pharmaceuticals, water filtration membranes and more. Butanediol is also supplied to Ashland's Specialty Ingredients business for use as a raw material.

*March 2018 quarter compared to March 2017 quarter*

Intermediates and Solvents' sales increased \$14 million to \$90 million in the current quarter. Improved product pricing increased sales by \$14 million, while favorable foreign currency exchange increased sales by \$7 million. The combination of lower volumes and unfavorable mix decreased sales by \$7 million

Gross profit increased \$7 million during the current quarter compared to the prior year quarter. The net impact of pricing and costs increased gross profit by \$13 million primarily due to improvements in product pricing. Higher facility turn around costs in the current quarter resulted in a \$6 million decrease in gross profit as a result of a significant planned plant shutdown that occurred in the current quarter. In total, gross profit margin increased 7.9 percentage points as compared to the prior year quarter to 13.4%.

Selling, general and administrative expenses remained consistent with the prior year quarter.

Operating income totaled \$4 million in the current quarter as compared to a loss of \$3 million in the prior year quarter. EBITDA increased \$7 million to \$12 million in the current quarter, while EBITDA margin increased 6.7 percentage points in the current quarter to 13.3%.

**ASHLAND GLOBAL HOLDINGS INC. AND CONSOLIDATED SUBSIDIARIES**  
**MANAGEMENT'S DISCUSSION AND ANALYSIS**

*Fiscal 2018 year-to-date compared to fiscal 2017 year-to-date*

Intermediates and Solvents' sales increased \$31 million to \$164 million in the current period. Improved product pricing increased sales by \$23 million while favorable foreign currency exchange increased sales by \$11 million. The combination of lower volumes and unfavorable mix decreased sales by \$3 million.

Gross profit increased \$24 million during the current period compared to the prior year period. The net impact of pricing and costs increased gross profit by \$20 million primarily due to improvements in product pricing. Lower facility turn around costs in the current period resulted in an \$3 million increase in gross profit. Volume declines were more than offset by product mix improvements to increase gross profit by \$1 million. In total, gross profit margin increased 14.2 percentage points as compared to the prior year period to 17.0%.

Selling, general and administrative expenses remained consistent with the prior year period.

Operating income totaled \$13 million in the current period as compared to a loss of \$11 million in the prior year period. EBITDA increased \$23 million to \$28 million in the current period, while EBITDA margin increased 13.3 percentage points in the current period to 17.1%.

*EBITDA and Adjusted EBITDA reconciliation*

The following EBITDA presentation for the three and six months ended March 31, 2018 and 2017 is provided as a means to enhance the understanding of financial measurements that Ashland has internally determined to be relevant measures of comparison for the results of Intermediates and Solvents. There were no unusual or key items that affected comparability for EBITDA during the current and prior year quarters or periods.

| (In millions)                 | Three months ended<br>March 31 |             | Six months ended<br>March 31 |             |
|-------------------------------|--------------------------------|-------------|------------------------------|-------------|
|                               | 2018                           | 2017        | 2018                         | 2017        |
| Operating income (loss)       | \$ 4                           | \$ (3)      | \$ 13                        | \$ (11)     |
| Depreciation and amortization | 8                              | 8           | 15                           | 16          |
| EBITDA                        | <u>\$ 12</u>                   | <u>\$ 5</u> | <u>\$ 28</u>                 | <u>\$ 5</u> |

**Unallocated and other**

The following table summarizes the key components of the Unallocated and other segment's operating income (loss) for the three and six months ended March 31, 2018 and 2017.

| (In millions)                | Three months ended<br>March 31 |                | Six months ended<br>March 31 |                |
|------------------------------|--------------------------------|----------------|------------------------------|----------------|
|                              | 2018                           | 2017           | 2018                         | 2017           |
| Restructuring activities (a) | \$ (12)                        | \$ (23)        | \$ (26)                      | \$ (47)        |
| Environmental expenses       | (4)                            | (4)            | (18)                         | (8)            |
| Legal settlement/reserve     | 5                              | —              | 5                            | (5)            |
| Other expense                | (6)                            | (4)            | (8)                          | (4)            |
| Total expense                | <u>\$ (17)</u>                 | <u>\$ (31)</u> | <u>\$ (47)</u>               | <u>\$ (64)</u> |

(a) Includes separation, severance, integration and stranded divestiture costs.

*March 2018 quarter compared to March 2017 quarter*

Unallocated and other recorded expense of \$17 million and \$31 million for the three months ended March 31, 2018 and 2017, respectively. The current and prior year quarters included charges for restructuring activities of \$12 million and \$23 million, respectively, which were comprised of the following items:

---

**ASHLAND GLOBAL HOLDINGS INC. AND CONSOLIDATED SUBSIDIARIES**  
**MANAGEMENT'S DISCUSSION AND ANALYSIS**

---

- \$4 million of accelerated depreciation related to the planned closure of an office building during the current quarter;
- \$4 million of integration costs related to the acquisition of Pharmachem during the current quarter;
- \$2 million and \$19 million of costs related to the separation of Valvoline during the current and prior year quarters, respectively; and
- \$2 million and \$4 million of stranded divestiture costs during the current and prior year quarters, respectively.

The remaining unallocated items primarily included environmental expenses of \$4 million during both the current and prior year quarters and \$5 million of income related to proceeds from a legal settlement during the current quarter.

*Fiscal 2018 year-to-date compared to fiscal 2017 year-to-date*

Unallocated and other recorded expense of \$47 million and \$64 million for the six months ended March 31, 2018 and 2017, respectively. The current and prior year periods included charges for restructuring activities of \$26 million and \$47 million, respectively, which were comprised of the following items:

- \$8 million of accelerated depreciation related to the planned closure of an office building during the current period;
- \$6 million of integration costs related to the acquisition of Pharmachem during the current period;
- \$8 million and \$42 million of costs related to the separation of Valvoline during the current and prior year periods, respectively; and
- \$4 million and \$5 million of stranded divestiture costs during the current and prior year periods, respectively.

The remaining unallocated items during the current period primarily included \$18 million for environmental expenses and \$5 million of income related to proceeds from a legal settlement while the remaining items during the prior year period primarily included \$8 million for environmental expenses and \$5 million of expense for a legal reserve.

**FINANCIAL POSITION****Liquidity**

Ashland had \$225 million in cash and cash equivalents as of March 31, 2018, of which \$207 million was held by foreign subsidiaries and had no significant limitations that would prohibit remitting the funds to satisfy corporate obligations. In certain circumstances, if such amounts were repatriated to the United States, additional taxes might need to be accrued and paid depending on the source of the earnings remitted. Ashland currently has no plans to repatriate any amounts for which additional taxes would need to be accrued. However, due to the recent Tax Act, Ashland will be reassessing this position in future quarters.

Ashland's cash flows from operating, investing and financing activities, as reflected in the Statements of Condensed Consolidated Cash Flows, are summarized as follows for the six months ended March 31, 2018 and 2017.

**ASHLAND GLOBAL HOLDINGS INC. AND CONSOLIDATED SUBSIDIARIES**  
**MANAGEMENT'S DISCUSSION AND ANALYSIS**

| (In millions)   | Six months ended |                 |
|---|------------------|-----------------|
|   | March 31         |                 |
|   | 2018             | 2017            |
| <b>Cash provided (used) by:</b>                                       |                  |                 |
| Operating activities from continuing operations                       | \$ —             | \$ (2)          |
| Investing activities from continuing operations                       | (100)            | (63)            |
| Financing activities from continuing operations                       | (220)            | (473)           |
| Discontinued operations   | (24)             | (36)            |
| Effect of currency exchange rate changes on cash and cash equivalents | 3                | (10)            |
| Net decrease in cash and cash equivalents                             | <u>\$ (341)</u>  | <u>\$ (584)</u> |

*Operating activities*

The following discloses the cash flows associated with Ashland's operating activities for the six months ended March 31, 2018 and 2017.

| (In millions)   | Six months ended |               |
|---|------------------|---------------|
|   | March 31         |               |
|   | 2018             | 2017          |
| <b>Cash flows provided (used) by operating activities from continuing operations</b>                |                  |               |
| Net income  | \$ 69            | \$ 115        |
| Income from discontinued operations (net of income taxes)   | (10)             | (152)         |
| Adjustments to reconcile income from continuing operations to cash flows from operating activities: |                  |               |
| Depreciation and amortization   | 161              | 134           |
| Original issue discount and debt issuance costs amortization  | 4                | 97            |
| Deferred income taxes   | 4                | —             |
| Stock based compensation expense  | 13               | 9             |
| Excess tax benefit on stock based compensation  | 2                | 2             |
| Gain on early retirement of debt  | —                | (3)           |
| Realized gains and investment income on available-for-sale securities                               | (8)              | (7)           |
| Net loss on divestitures  | 1                | 1             |
| Pension contributions   | (7)              | (4)           |
| Gain on post-employment plan remeasurement  | —                | (2)           |
| Change in operating assets and liabilities (a)  | (229)            | (192)         |
| Total cash flows used by operating activities from continuing operations                            | <u>\$ —</u>      | <u>\$ (2)</u> |

(a) Excludes changes resulting from operations acquired or sold.

Cash flows used from operating activities from continuing operations, a major source of Ashland's liquidity, amounted to zero and a cash outflow of \$2 million in the current and prior year periods, respectively.

*Operating Activities - Operating Assets and Liabilities*

The cash results during each period are primarily driven by net income (loss), excluding discontinued operation results, adjusted for certain non-cash items including depreciation and amortization (including original issue discount and debt issuance cost amortization), as well as changes in working capital, which are fluctuations within accounts receivable, inventory, trade payables and accrued expenses. Ashland continues to emphasize working capital management as a high priority and focus.



**ASHLAND GLOBAL HOLDINGS INC. AND CONSOLIDATED SUBSIDIARIES**  
**MANAGEMENT'S DISCUSSION AND ANALYSIS**

Changes in net working capital accounted for outflows of \$189 million and \$68 million for the six months ended March 31, 2018 and 2017, respectively, and were driven by the following:

- Accounts receivable - There were cash outflows of \$108 million and \$49 million during the current and prior year periods, respectively, which were primarily due to increased sales compared to the prior year period.
- Inventory – There was a cash outflow of \$18 million and a cash inflow of \$9 million during the current and prior year periods, respectively, which were primarily due to sales volumes and inventory management strategies.
- Trade and other payables - There were cash outflows of \$63 million and \$28 million during the current and prior year periods, respectively, which were primarily driven by seasonal declines in trade payables and incentive compensation payouts from the prior year paid during the first quarter of each fiscal year.

The remaining outflows within changes in operating assets and liabilities of \$40 million and \$124 million in the current and prior year periods, respectively, relate primarily to adjustments to certain accruals and long-term assets and liabilities as well as income taxes received and paid.

*Operating Activities - Summary*

Operating cash flows for the current period included income from continuing operations of \$59 million, noncash adjustments of \$161 million for depreciation and amortization and \$4 million for debt issuance cost amortization.

Operating cash flows for the prior year period included a loss from continuing operations of \$37 million million and noncash adjustments of \$134 million for depreciation and amortization and \$97 million for original issue discount and debt issuance cost amortization, including \$92 million of accelerated accretion related to the tender offer of the 2029 notes.

*Investing activities*

The following discloses the cash flows associated with Ashland's investing activities for the six months ended March 31, 2018 and 2017.

| (In millions)  | Six months ended |                |
|--|------------------|----------------|
|  | March 31         |                |
|  | 2018             | 2017           |
| <b>Cash flows provided (used) by investing activities from continuing operations</b> |                  |                |
| Additions to property, plant and equipment   | \$ (60)          | \$ (73)        |
| Proceeds from disposal of property, plant and equipment                              | 1                | —              |
| Purchase of operations - net of cash acquired  | (11)             | —              |
| Proceeds (uses) from sale of operations  | 1                | (1)            |
| Life insurance payments  | (37)             | —              |
| Net purchase of funds restricted for specific transactions                           | (8)              | (2)            |
| Reimbursement from restricted investments  | 17               | 12             |
| Proceeds from sales of available-for-sale securities                                 | 17               | 19             |
| Purchase of available-for-sale securities  | (17)             | (19)           |
| Proceeds from the settlement of derivative instruments                               | —                | 4              |
| Payments for the settlement of derivative instruments                                | (3)              | (3)            |
| Total cash flows used by investing activities from continuing operations             | <u>\$ (100)</u>  | <u>\$ (63)</u> |

Cash used by investing activities was \$100 million and \$63 million for the current and prior year periods, respectively. The significant cash investing activities for the current period primarily related to cash outflows of \$60 million for property additions compared to \$73 million in the prior year period. The

**ASHLAND GLOBAL HOLDINGS INC. AND CONSOLIDATED SUBSIDIARIES**  
**MANAGEMENT'S DISCUSSION AND ANALYSIS**

current period also included cash outflows of \$37 million related to payments for a corporate-owned life insurance policy loan and \$11 million for the purchase of Vornia Limited.

*Financing activities*

The following discloses the cash flows associated with Ashland's financing activities for the six months ended March 31, 2018 and 2017.

| (In millions)  | Six months ended<br>March 31 |                 |
|--|------------------------------|-----------------|
|  | 2018                         | 2017            |
| <b>Cash flows provided (used) by financing activities from continuing operations</b> |                              |                 |
| Repayment of long-term debt  | \$ (3)                       | \$ (254)        |
| Premium on long-term debt  | —                            | (5)             |
| Repayment of short-term debt   | (181)                        | (151)           |
| Debt issuance costs  | —                            | (2)             |
| Cash dividends paid  | (28)                         | (48)            |
| Stock based compensation employee withholding taxes paid in cash                     | (8)                          | (13)            |
| Total cash flows used by financing activities from continuing operations             | <u>\$ (220)</u>              | <u>\$ (473)</u> |

Cash flows used by financing activities was \$220 million for the current period as compared to \$473 million for the prior year period.

Significant cash financing activities for the current period included short-term debt net repayments of \$181 million related to the 2017 Revolving Credit Facility and the accounts receivable securitization. The outstanding balance of the 2017 Revolving Credit Facility and a portion of the accounts receivable securitization were repaid using approximately \$300 million of cash that was repatriated in January 2018. The current period included cash dividends paid of \$0.45 per share, for a total of \$28 million.

Significant cash financing activities for the prior year period included cash outflows of \$254 million related to the repayments of a portion of the 2029 notes, 2022 notes and 2018 notes. Additionally, the prior year period included short-term debt net repayments of \$151 million, which was primarily related to the \$150 million full repayment of a term loan held by a foreign subsidiary. The prior year period included cash dividends paid of \$0.78 per share, for a total of \$48 million.

The following discloses the cash flows associated with Ashland's discontinued operations for the six months ended March 31, 2018 and 2017.

| (In millions)  | Six months ended<br>March 31 |                |
|--|------------------------------|----------------|
|  | 2018                         | 2017           |
| <b>Cash provided (used) by discontinued operations</b> |                              |                |
| Operating cash flows                                   | \$ (24)                      | \$ 60          |
| Investing cash flows                                   | —                            | (79)           |
| Financing cash flows                                   | —                            | (17)           |
| Total cash used by discontinued operations             | <u>\$ (24)</u>               | <u>\$ (36)</u> |

Cash flows for discontinued operations in the current period primarily related to previously divested businesses, including net payments of asbestos and environmental liabilities.

Cash flows for discontinued operations in the prior year period primarily relate to net cash outflows of \$15 million related to the activity of Valvoline Inc. The remaining cash flows in the prior year period related to other previously divested businesses, including net payments of asbestos and environmental liabilities.

**ASHLAND GLOBAL HOLDINGS INC. AND CONSOLIDATED SUBSIDIARIES**  
**MANAGEMENT'S DISCUSSION AND ANALYSIS**

*Free cash flow and other liquidity resources*

The following represents Ashland's calculation of free cash flow for the disclosed periods. Free cash flow does not reflect adjustments for certain non-discretionary cash flows such as mandatory debt repayments.

| (In millions)  | Six months ended |                |
|--|------------------|----------------|
|  | March 31         |                |
|  | 2018             | 2017           |
| Total cash flows used by operating activities from continuing operations | \$ —             | \$ (2)         |
| Adjustments:   |                  |                |
| Additions to property, plant and equipment                               | (60)             | (73)           |
| Free cash flows (a)  | <u>\$ (60)</u>   | <u>\$ (75)</u> |

(a) Includes \$29 million and \$40 million of restructuring payments for the six months ended March 31, 2018 and 2017, respectively.

At March 31, 2018, working capital (current assets minus current liabilities, excluding long-term debt due within one year) amounted to \$1,012 million, compared to \$941 million at September 30, 2017. Liquid assets (cash, cash equivalents and accounts receivable) amounted to 132% and 122% of current liabilities at March 31, 2018 and September 30, 2017, respectively.

The following summary reflects Ashland's cash and unused borrowing capacity as of March 31, 2018 and September 30, 2017.

| (In millions)                               | March 31 | September 30 |
|---|----------|--------------|
|   | 2018     | 2017         |
| <b>Cash and investment securities</b>       |          |              |
| Cash and cash equivalents                   | \$ 225   | \$ 566       |
| <b>Unused borrowing capacity</b>            |          |              |
| 2017 Revolving credit facility              | \$ 752   | \$ 579       |
| Accounts receivable securitization facility | 67       | 35           |

The borrowing capacity remaining under the 2017 Revolving Credit Facility was \$752 million due to a reduction of \$48 million for letters of credit outstanding at March 31, 2018. In total, Ashland's available liquidity position, which includes cash, the revolving credit facility and the accounts receivable securitization facility, was \$1,044 million at March 31, 2018, compared to \$1,180 million at September 30, 2017.

**Capital resources**

*Debt*

The following summary reflects Ashland's debt as of March 31, 2018 and September 30, 2017.

| (In millions)  | March 31        | September 30    |
|--|-----------------|-----------------|
|  | 2018            | 2017            |
| Short-term debt (includes current portion of long-term debt)               | \$ 59           | \$ 235          |
| Long-term debt (less current portion and debt issuance cost discounts) (a) | 2,579           | 2,584           |
| Total debt   | <u>\$ 2,638</u> | <u>\$ 2,819</u> |

(a) Includes \$23 million and \$25 million of debt issuance cost discounts as of March 31, 2018 and September 30, 2017, respectively.

---

**ASHLAND GLOBAL HOLDINGS INC. AND CONSOLIDATED SUBSIDIARIES**  
**MANAGEMENT'S DISCUSSION AND ANALYSIS**

---

The current portion of long-term debt was \$11 million at March 31, 2018. Debt as a percent of capital employed was 43% at March 31, 2018 and 45% at September 30, 2017. At March 31, 2018, Ashland's total debt had an outstanding principal balance of \$2,713 million, discounts of \$52 million, and debt issuance costs of \$23 million. The scheduled aggregate maturities of long-term debt by year (including the current portion and excluding debt issuance costs) are as follows: \$3 million remaining in 2018, \$11 million in 2019, \$269 million in 2020, \$56 million in 2021 and \$1,279 million in 2022.

***Financing Activities***

*Accounts receivable securitization*

During March 2018, the termination date of the accounts receivable securitization facility was extended from March 2018 to March 2020. The available funding for qualified receivables under the accounts receivable securitization facility increased from \$100 million to \$115 million. No other changes are expected to have a significant impact to Ashland's results of operations and financial position.

*2017 Credit Agreement*

On May 17, 2017, in conjunction with the closing of the Pharmachem acquisition, Ashland entered into a secured credit agreement (the 2017 Credit Agreement) with a group of lenders. The 2017 Credit Agreement provided for (i) a \$250 million three-year term loan A facility (the Three-Year TLA Facility), (ii) a \$250 million five-year term loan A facility (the Five-Year TLA Facility and together with the Three-Year TLA Facility, the TLA Facilities) and (iii) a \$680 million five-year revolving credit facility (including a \$125 million letter of credit sublimit) (the 2017 Revolving Credit Facility). Proceeds of borrowings under the TLA Facilities were used solely to finance the acquisition of Pharmachem, while the proceeds of the 2017 Revolving Credit Facility were used to finance, in part, the acquisition of Pharmachem, to refinance the 2015 Senior Credit Agreement and for general corporate purposes. On May 19, 2017, Ashland entered into Amendment No. 1 to the 2017 Credit Agreement, which increased the aggregate commitments under the 2017 Revolving Credit Facility from \$680 million to \$800 million.

At Ashland's option, loans issued under the 2017 Credit Agreement bear interest at either LIBOR or an alternate base rate, in each case plus the applicable interest rate margin. Loans bear interest at LIBOR plus 1.75% per annum, in the case of LIBOR borrowings, or at the alternate base rate plus 0.75%, in the alternative, through and including the date of delivery of a quarterly compliance certificate and thereafter the interest rate will fluctuate between LIBOR plus 1.375% per annum and LIBOR plus 2.500% per annum (or between the alternate base rate plus 0.375% per annum and the alternate base rate plus 1.500% per annum), based upon Ashland's secured facilities ratings or the consolidated net leverage ratio (as defined in the 2017 Credit Agreement) (whichever yields a lower applicable interest rate margin) at such time. In addition, Ashland was required to pay fees of 0.25% per annum on the daily unused amount of the 2017 Revolving Credit Facility through and including the date of delivery of a compliance certificate, and thereafter the fee rate will fluctuate between 0.175% and 0.40% per annum, based upon Ashland's secured facilities rating or the consolidated net leverage ratio (whichever yields a lower applicable rate). The TLA Facilities may be prepaid at any time without premium. The Three-Year TLA Facility will not amortize and will be due on May 17, 2020. The Five-Year TLA Facility will not amortize in each of the first, second and third years and will amortize at a rate of 20% per annum in each of the fourth and fifth years (payable in equal quarterly installments), with the outstanding balance of the Five-Year TLA Facility to be paid on May 17, 2022.

On June 14, 2017, Ashland entered into Amendment No. 2 to the 2017 Credit Agreement, which provided for a new \$600 million seven-year senior secured term loan B facility (the 2017 TLB Facility). At Ashland's option, loans issued under the 2017 TLB Facility bear interest at either (x) LIBOR plus 2.00% per annum or (y) an alternate base rate plus 1.00% per annum. The 2017 TLB Facility may be prepaid at any time. The 2017 TLB Facility amortizes at a rate of 1.00% per annum (payable in equal quarterly installments) with the outstanding balance to be paid on May 17, 2024.

---

**ASHLAND GLOBAL HOLDINGS INC. AND CONSOLIDATED SUBSIDIARIES**  
**MANAGEMENT'S DISCUSSION AND ANALYSIS**

---

*6.50% junior subordinated notes due 2029*

In December 2016, Hercules LLC (Hercules) (formerly Hercules Incorporated), an indirect wholly-owned subsidiary of Ashland, repurchased, through a cash tender offer (the Tender Offer), \$182 million of the aggregate principal par value amount of its 6.50% junior subordinated notes due 2029 (2029 notes) for an aggregate purchase price of \$177 million. As a result of the Tender Offer, the carrying value of the 2029 notes was reduced by \$90 million and Ashland recognized a \$92 million charge related to accelerated accretion of the recorded debt discount (compared to the total par value) and \$5 million of a net gain related to the repayment of the debt. The charge and net gain are included in the net interest and other financing expense caption of the Statements of Consolidated Comprehensive Income (Loss) for the six months ended March 31, 2017.

*Open market repurchases of 4.750% notes due 2022 and 3.875% notes due 2018*

During the six months ended March 31, 2017, Ashland executed open market repurchases of its 4.750% notes due 2022 (2022 notes) and its 3.875% notes due 2018 (2018 notes). As a result of these repurchases, the carrying values of the 2022 notes and 2018 notes were reduced by \$39 million and \$41 million, respectively. Ashland recognized a \$3 million charge related to premiums paid in the open market repurchases and accelerated amortization of previously capitalized debt issuance costs, which is included in the net interest and other financing expense caption of the Statements of Consolidated Comprehensive Income (Loss) for the six months ended March 31, 2017.

*Ashland credit ratings*

Ashland's corporate credit rating with Standard & Poor's is BB, while Moody's Investor Services is Ba2. Moody's Investor Services and Standard & Poor's outlooks both remained at stable. Subsequent changes to these ratings may have an effect on Ashland's borrowing rate or ability to access capital markets in the future.

*Ashland debt covenant restrictions*

Ashland's most recent credit agreement (the 2017 Credit Agreement) contains usual and customary representations, warranties and affirmative and negative covenants, including financial covenants for leverage and interest coverage ratios, limitations on liens, additional subsidiary indebtedness, restrictions on subsidiary distributions, investments, mergers, sale of assets and restricted payments and other customary limitations. As of March 31, 2018, Ashland is in compliance with all debt agreement covenant restrictions under the 2017 Credit Agreement.

The maximum consolidated net leverage ratio permitted under the 2017 Credit Agreement is 4.5. The 2017 Credit Agreement defines the consolidated net leverage ratio as the ratio of consolidated indebtedness minus unrestricted cash and cash equivalents to consolidated EBITDA (Covenant Adjusted EBITDA) for any measurement period. In general, the 2017 Credit Agreement defines Covenant Adjusted EBITDA as net income plus consolidated interest charges, taxes, depreciation and amortization expense, fees and expenses related to capital market transactions and proposed or actual acquisitions and divestitures, restructuring and integration charges, noncash stock and equity compensation expense, and any other nonrecurring expenses or losses that do not represent a cash item in such period or any future period; less any noncash gains or other items increasing net income. The computation of Covenant Adjusted EBITDA differs from the calculation of EBITDA and Adjusted EBITDA, which have been reconciled on page 40. In general, consolidated indebtedness includes debt plus all purchase money indebtedness, banker's acceptances and bank guaranties, deferred purchase price of property or services, attributable indebtedness and guarantees.

The minimum required consolidated interest coverage ratio under the 2017 Credit Agreement is 3.0. The 2017 Credit Agreement defines the consolidated interest coverage ratio as the ratio of Covenant Adjusted EBITDA to consolidated interest charges for any measurement period.

---

**ASHLAND GLOBAL HOLDINGS INC. AND CONSOLIDATED SUBSIDIARIES**  
**MANAGEMENT'S DISCUSSION AND ANALYSIS**

---

At March 31, 2018, Ashland's calculation of the consolidated net leverage ratio was 3.8, which is below the maximum consolidated ratio permitted under the 2017 Credit Agreement of 4.5. At March 31, 2018, Ashland's calculation of the consolidated interest coverage ratio was 4.8, which exceeds the minimum required consolidated ratio of 3.0.

The average change in Covenant Adjusted EBITDA of \$100 million would have an approximate 0.6x effect on the consolidated net leverage ratio and a 0.8x effect on the consolidated interest coverage ratio. The average change in consolidated indebtedness of \$100 million would affect the consolidated leverage ratio by approximately 0.2x.

**Additional capital resources***Cash projection*

Ashland projects that cash flow from operations and other available financial resources such as cash on hand and revolving credit should be sufficient to meet investing and financing requirements to enable Ashland to comply with the covenants and other terms of its financing obligations. These projections are based on various assumptions that include, but are not limited to: operational results, capital expenditures, working capital needs and tax payments and receipts.

*Total equity*

Total equity increased \$105 million since September 30, 2017 to \$3,511 million at March 31, 2018. The increase of \$105 million was due to net income of \$69 million, deferred translation gains of \$58 million, \$4 million for common shares issued under stock incentive and other plans, and a \$2 million net increase in available-for-sale securities. These increases were partially offset by cash dividends of \$28 million.

*Stock repurchase program*

In April 2015, Ashland's Board of Directors approved a \$1 billion share repurchase authorization that was set to expire on December 31, 2017 (the 2015 stock repurchase program). During September 2017, Ashland's Board of Directors extended the 2015 stock repurchase program indefinitely, at which point \$500 million of share repurchase authorization remained under the 2015 stock repurchase program.

During March 2018, Ashland's Board of Directors approved a new \$1 billion stock repurchase program, which replaced the 2015 stock repurchase program. Under the new program, Ashland's common shares may be repurchased in open market transactions, privately negotiated transactions or pursuant to one or more accelerated stock repurchase programs or Rule 10b5-1 plans. As of March 31, 2018, \$1 billion remained available for repurchase under this authorization.

*Stockholder dividends*

In May 2017, subsequent to the final distribution of Valvoline Inc.'s common stock, the Board of Directors of Ashland announced a quarterly cash dividend of 22.5 cents per share to eligible stockholders at record which was paid for quarterly dividends in the first and second quarters of fiscal 2018 and the third and fourth quarters of fiscal 2017. This represented a reduction from the previous quarterly dividend of 39 cents per share which was paid for quarterly dividends in the first and second quarters of fiscal 2017.

*Capital expenditures*

Capital expenditures were \$60 million for the six months ended March 31, 2018 and averaged approximately \$217 million during the last three fiscal years.

*Contractual obligations and commitments*

As a result of the Tax Act that was enacted during December 2017, Ashland has currently estimated and identified that the one-time transition tax related to the new law is estimated to be approximately \$160 million payable over eight years, with the first payment of approximately \$13 million due during the first quarter of fiscal year 2019. Ashland will continue to reassess this estimate in future periods.

---

**ASHLAND GLOBAL HOLDINGS INC. AND CONSOLIDATED SUBSIDIARIES**  
**MANAGEMENT'S DISCUSSION AND ANALYSIS**

---

In addition, during January 2018, Ashland repatriated approximately \$300 million in cash that was used to repay existing debt. There were no other significant changes to the contractual obligations table as presented at September 30, 2017.

**CRITICAL ACCOUNTING POLICIES**

The preparation of Ashland's Condensed Consolidated Financial Statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, sales and expenses, and the disclosures of contingent assets and liabilities. Significant items that are subject to such estimates and assumptions include, but are not limited to, long-lived assets (including goodwill and other intangible assets), income taxes, other liabilities and receivables associated with asbestos litigation and environmental remediation. These accounting policies are discussed in detail in "Management's Discussion and Analysis – Critical Accounting Policies" in Ashland's Annual Report on Form 10-K for the fiscal year ended September 30, 2017. Although management bases its estimates on historical experience and various other assumptions that are believed to be reasonable under the circumstances, actual results could differ significantly from the estimates under different assumptions or conditions. Management has reviewed the estimates affecting these items with the Audit Committee of Ashland's Board of Directors. No material changes have been made to the valuation techniques during the six months ended March 31, 2018.

**OUTLOOK**

*Fiscal Year 2018*

Ashland updated its financial outlook for fiscal 2018 as shown in the table below.

|                              | <b>Prior FY 2018 Outlook</b> | <b>Updated FY 2018 Outlook</b> |
|------------------------------|------------------------------|--------------------------------|
| <b>Adjusted EBITDA</b>       |                              |                                |
| Specialty Ingredients        | \$560 - \$590 million        | \$565 - \$585 million          |
| Composites                   | \$85 - \$95 million          | \$90 - \$100 million           |
| Intermediates & Solvents     | \$40 - \$50 million          | \$50 - \$60 million            |
| Unallocated and other        | (\$35 - \$45 million)        | No change                      |
| <b>Key Operating Metrics</b> |                              |                                |
| Free cash flow               | >\$220 million               | No change                      |
| Adjusted diluted EPS         | \$2.90 - \$3.10              | \$3.30 - \$3.50                |
| <b>Corporate Items</b>       |                              |                                |
| Depreciation & amortization  | ~\$290 million               | ~\$300 million                 |
| Interest expense             | \$125 - \$135 million        | \$123 - \$128 million          |
| Effective tax rate           | 16 - 20%                     | 13 - 17%                       |
| Capital expenditures         | \$195 - \$205 million        | No change                      |
| Diluted share count          | ~64 million                  | No change                      |

*Third Quarter of 2018*

For the third quarter of fiscal 2018, Ashland expects Adjusted diluted EPS to be in the range of \$0.95-\$1.05 per diluted share, compared to \$0.83 in the prior-year period. This estimate assumes an effective tax rate of 17% for the third quarter.

---

**ASHLAND GLOBAL HOLDINGS INC. AND CONSOLIDATED SUBSIDIARIES  
MANAGEMENT'S DISCUSSION AND ANALYSIS**

---

**ITEM 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK**

Ashland's market risk exposure at March 31, 2018 is generally consistent with the types of market risk exposures presented in Ashland's Annual Report on Form 10-K for the fiscal year ended September 30, 2017.

**ITEM 4. CONTROLS AND PROCEDURES**

*Disclosure Controls and Procedures* - As of the end of the period covered by this quarterly report, Ashland, under the supervision and with the participation of its management, including Ashland's Chief Executive Officer and its Chief Financial Officer, evaluated the effectiveness of Ashland's disclosure controls and procedures pursuant to Rule 13a-15(b) and 15d-15(b) promulgated under the Securities Exchange Act of 1934, as amended. Based upon that evaluation, the Chief Executive Officer and Chief Financial Officer concluded that the disclosure controls and procedures were effective as of March 31, 2018.

*Changes in Internal Control over Financial Reporting* - During the six months ended March 31, 2018, there were no significant changes in Ashland's internal control over financial reporting, or in other factors, that occurred during the period covered by this quarterly report that have materially affected, or are reasonably likely to materially affect, Ashland's internal control over financial reporting.

During the June 2017 quarter, Ashland completed its purchase of Pharmachem. Although management believes appropriate internal controls and procedures have been maintained, Pharmachem's controls and procedures for the recording, processing, and summarizing of financial information have not been fully evaluated by Ashland's management as of March 31, 2018. As such, there is a risk that deficiencies may exist and not yet be identified that could constitute significant deficiencies or in the aggregate, a material weakness related to Pharmachem's businesses.



## PART II – OTHER INFORMATION

### ITEM 1. LEGAL PROCEEDINGS

The following is a description of Ashland's material legal proceedings.

#### *Asbestos-Related Litigation*

Ashland is subject to liabilities from claims alleging personal injury caused by exposure to asbestos. Such claims result primarily from indemnification obligations undertaken in 1990 in connection with the sale of Riley Stoker Corporation (Riley), a former subsidiary. Although Riley was neither a producer nor a manufacturer of asbestos, its industrial boilers contained some asbestos-containing components provided by other companies.

Hercules LLC (formerly Hercules Incorporated), an indirect wholly-owned subsidiary of Ashland, is also subject to liabilities from asbestos-related personal injury lawsuits involving claims which typically arise from alleged exposure to asbestos fibers from resin encapsulated pipe and tank products which were sold by one of Hercules' former subsidiaries to a limited industrial market.

Ashland and Hercules are also defendants in lawsuits alleging exposure to asbestos at facilities formerly or presently owned or operated by Ashland or Hercules.

For additional detailed information regarding liabilities arising from asbestos-related litigation, see Note K of Notes to Condensed Consolidated Financial Statements in this quarterly report on Form 10-Q.

#### *Environmental Proceedings*

(a) *CERCLA and Similar State Law Sites* - Under the Comprehensive Environmental Response, Compensation and Liability Act of 1980 and similar state laws, Ashland and its subsidiaries may be subject to joint and several liability for cleanup costs in connection with alleged releases of hazardous substances at sites where it has been identified as a "potentially responsible party" (PRP). As of March 31, 2018, Ashland and its subsidiaries have been identified as a PRP by U.S. federal and state authorities, or by private parties seeking contribution, for the cost of environmental investigation and/or cleanup at 83 waste treatment or disposal sites. These sites are currently subject to ongoing investigation and remedial activities, overseen by the United States Environmental Protection Agency (USEPA) or a state agency, in which Ashland or its subsidiaries are typically participating as a member of a PRP group. Generally, the types of relief sought include remediation of contaminated soil and/or groundwater, reimbursement for past costs of site cleanup and administrative oversight and/or long-term monitoring of environmental conditions at the sites. The ultimate costs are not predictable with assurance.

(b) *Hattiesburg, Mississippi Resource Conservation and Recovery Act Matter* - In November 2008, the Mississippi Department of Environmental Quality (MDEQ) issued a Notice of Violation to Hercules' now-closed Hattiesburg, Mississippi manufacturing facility alleging that a process water impoundment basin at the facility had been operated as a hazardous waste storage and treatment facility without a permit in violation of the Resource Conservation and Recovery Act. In May 2011, the USEPA issued an inspection report from a September 2010 inspection with allegations similar to those of the MDEQ and promulgated an information request. Ashland has been working with the MDEQ and USEPA to settle this matter in the context of the shutdown and ongoing remediation of the Hattiesburg facility. The USEPA proposed a settlement penalty in excess of \$100,000. While it is reasonable to believe that this matter will involve a penalty from the MDEQ and/or the USEPA exceeding \$100,000, the potential penalty with respect to this enforcement matter should not be material to Ashland.

(c) *Lower Passaic River, New Jersey Matters* - Ashland, through two formerly owned facilities, and ISP, through a now-closed facility, have been identified as PRPs, along with approximately 70 other companies (the Cooperating Parties Group or the CPG), in a May 2007 Administrative Order of Consent (AOC) with the USEPA. The parties are required to perform a remedial investigation and feasibility study (RI/FS) of the entire 17 miles of the Passaic River. In June 2007, the USEPA separately commenced a Focused Feasibility Study (FFS) as an interim measure. In accordance with the 2007 AOC, in June 2012 the CPG voluntarily entered into another AOC for an interim removal action focused solely at mile 10.9 of the Passaic River. The allocations for the 2007 AOC and the 2012 removal action are based on interim allocations, are immaterial and have been accrued. In April 2014, the USEPA released the FFS. The CPG submitted the Draft RI/FS Report on April 30, 2015. The USEPA has released the FFS Record of Decision for the lower 8 miles and recently reached an agreement with Occidental to conduct and pay for the remedial design. The USEPA has advised that it will be working to secure similar agreements with other PRPs. The release of the FFS Record of Decision did not have a material adverse impact on Ashland's business and financial operations; however, there are a number of contingencies in the future that could possibly have a material impact including adverse rulings or verdicts, allocation proceedings and related orders.

For additional information regarding environmental matters and reserves, see Note K of Notes to Condensed Consolidated Financial Statements in this quarterly report on Form 10-Q.

***Other Pending Legal Proceedings***

In addition to the matters described above, there are other various claims, lawsuits and administrative proceedings pending or threatened against Ashland and its current and former subsidiaries. Such actions are with respect to commercial matters, product liability, toxic tort liability and other environmental matters which seek remedies or damages, some of which are for substantial amounts. While Ashland cannot predict with certainty the outcome of such actions, it believes that adequate reserves have been recorded and losses already recognized with respect to such actions were immaterial as of March 31, 2018. There is a reasonable possibility that a loss exceeding amounts already recognized may be incurred related to these actions; however, Ashland believes that such potential losses were immaterial as of March 31, 2018.

**ITEM 1A. RISK FACTORS**

During the period covered by this report, there were no material changes from the risk factors previously disclosed in Ashland's Annual Report on Form 10-K for the fiscal year ended September 30, 2017.

## ITEM 2. UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS

Share repurchase activity during the three months ended March 31, 2018 was as follows:

| Q2 Fiscal Periods                      | Issuer Purchases of Equity Securities |  |  |   |
|--|---------------------------------------|--|--|---|
|  | Total Number of Shares Purchased      | Average Price Paid Per Share, including commission | Total Number of Shares Purchased as Part of Publicly Announced Plans or Programs | Dollar Value of Shares that May Yet Be Purchased Under the Plans or Programs (in millions)(a) |
| January 1, 2018 to January 31, 2018:   |                                       |  |  |   |
| Employee Tax Withholdings              | 3,105 (b)                             | \$ 72.39   | —  | \$ 500  |
| February 1, 2018 to February 28, 2018: |                                       |  |  |   |
| Employee Tax Withholdings              | 1,224 (b)                             | 70.24  | —  | 500   |
| March 1, 2018 to March 31, 2018:       |                                       |  |  |   |
| Employee Tax Withholdings              | 5 (b)                                 | 67.10  | —  | 1,000   |
| Total                                  | <u>4,334</u>                          |  | <u>—</u>   | <u>\$ 1,000</u>   |

(a) In April 2015, the Company's Board of Directors authorized a program to repurchase up to \$1 billion of the Company's stock, with the authorization expiring December 31, 2017. In September 2017, the Company's Board of Directors renewed the program for the remaining \$500 million. During March 2018, Ashland's Board of Directors approved a new \$1 billion stock repurchase program, which replaced the previous stock repurchase program. The Company's stock repurchase program does not obligate it to acquire any specific number of shares. Under the program, shares may be repurchased in privately negotiated and/or open market transactions, including under plans complying with Rule 10b5-1 of the Exchange Act. As of March 31, 2018, \$1 billion remains available for repurchase under this authorization.

(b) Shares withheld from employees to cover their withholding requirements for personal income taxes related to the vesting of restricted stock.

## ITEM 6. EXHIBITS

### (a) Exhibits

- 12\* [Computation of Ratio of Earnings to Fixed Charges.](#)
- 31.1\* [Certificate of William A. Wulfsohn, Chief Executive Officer of Ashland pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.](#)
- 31.2\* [Certificate of J. Kevin Willis, Chief Financial Officer of Ashland pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.](#)
- 32\* [Certificate of William A. Wulfsohn, Chief Executive Officer of Ashland, and J. Kevin Willis, Chief Financial Officer of Ashland pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.](#)
- 101.INS\*\* XBRL Instance Document.
- 101.SCH\*\* XBRL Taxonomy Extension Schema Document.
- 101.CAL\*\* XBRL Taxonomy Extension Calculation Linkbase Document.
- 101.DEF\*\* XBRL Taxonomy Extension Definition Linkbase Document.
- 101.LAB\*\* XBRL Taxonomy Extension Label Linkbase Document.
- 101.PRE\*\* XBRL Taxonomy Extension Presentation Linkbase Document.

\*Filed herewith.

\*\*Attached as Exhibit 101 to this report are the following documents formatted in XBRL (Extensible Business Reporting Language): (i) Statements of Consolidated Comprehensive Income (Loss) for the three and six months ended March 31, 2018 and March 31, 2017; (ii) Condensed Consolidated Balance Sheets at March 31, 2018 and September 30, 2017; (iii) Statements of Consolidated Equity at March 31, 2018; (iv) Statements of Condensed Consolidated Cash Flows for the six months ended March 31, 2018 and March 31, 2017; and (v) Notes to Condensed Consolidated Financial Statements.

<sup>SM</sup> Service mark, Ashland or its subsidiaries, registered in various countries.

<sup>TM</sup> Trademark, Ashland or its subsidiaries, registered in various countries.

**SIGNATURE**

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

May 2, 2018

Ashland Global Holdings Inc.

\_\_\_\_\_  
(Registrant)

/s/ J. Kevin Willis

\_\_\_\_\_  
J. Kevin Willis

Senior Vice President and Chief Financial Officer

(on behalf of the Registrant and as principal  
financial officer)

ASHLAND GLOBAL HOLDINGS INC.  
COMPUTATION OF RATIO OF EARNINGS TO FIXED CHARGES  
(In millions)

|  | Years ended September 30 |                 |               |                 |               | Six months ended<br>March 31 |               |
|--|--------------------------|-----------------|---------------|-----------------|---------------|------------------------------|---------------|
|  | 2017                     | 2016            | 2015          | 2014            | 2013          | 2018                         | 2017          |
| <b>EARNINGS</b>  |                          |                 |               |                 |               |                              |               |
| Income (loss) from continuing operations                                     | \$ (105)                 | \$ (283)        | \$ (12)       | \$ (121)        | \$ 301        | \$ 59                        | \$ (37)       |
| Income tax expense (benefit)   | 7                        | (25)            | (139)         | (290)           | 48            | 15                           | (45)          |
| Interest expense   | 123                      | 162             | 148           | 149             | 208           | 64                           | 60            |
| Interest portion of rental expense   | 16                       | 17              | 15            | 20              | 15            | 8                            | 8             |
| Amortization of deferred debt expense  | 109                      | 18              | 18            | 14              | 65            | 4                            | 97            |
| Distributions in excess of (less than) earnings of unconsolidated affiliates | 1                        | 1               | 1             | (9)             | (10)          | —                            | —             |
|  | <u>\$ 151</u>            | <u>\$ (110)</u> | <u>\$ 31</u>  | <u>\$ (237)</u> | <u>\$ 627</u> | <u>\$ 150</u>                | <u>\$ 83</u>  |
| <b>FIXED CHARGES</b>   |                          |                 |               |                 |               |                              |               |
| Interest expense   | \$ 123                   | \$ 162          | \$ 148        | \$ 149          | \$ 208        | \$ 64                        | \$ 60         |
| Interest portion of rental expense   | 16                       | 17              | 15            | 20              | 15            | 8                            | 8             |
| Amortization of deferred debt expense  | 109                      | 18              | 18            | 14              | 65            | 4                            | 97            |
| Capitalized interest   | 1                        | 1               | 2             | 1               | 1             | —                            | 1             |
|  | <u>\$ 249</u>            | <u>\$ 198</u>   | <u>\$ 183</u> | <u>\$ 184</u>   | <u>\$ 289</u> | <u>\$ 76</u>                 | <u>\$ 166</u> |
| <b>RATIO OF EARNINGS TO FIXED CHARGES</b>                                    | <b>(A)</b>               | <b>(B)</b>      | <b>(C)</b>    | <b>(D)</b>      | 2.17          | 1.97                         | <b>(E)</b>    |

(A) Deficiency Ratio - The Ratio of Earnings to Fixed Charges was less than 1x. To achieve a ratio of 1x, additional total earnings of \$98 million would have been required for the year ended September 30, 2017.

(B) Deficiency Ratio - The Ratio of Earnings to Fixed Charges was less than 1x. To achieve a ratio of 1x, additional total earnings of \$308 million would have been required for the year ended September 30, 2016.

(C) Deficiency Ratio - The Ratio of Earnings to Fixed Charges was less than 1x. To achieve a ratio of 1x, additional total earnings of \$152 million would have been required for the year ended September 30, 2015.

(D) Deficiency Ratio - The Ratio of Earnings to Fixed Charges was less than 1x. To achieve a ratio of 1x, additional total earnings of \$421 million would have been required for the year ended September 30, 2014.

(E) Deficiency Ratio - The Ratio of Earnings to Fixed Charges was less than 1x. To achieve a ratio of 1x, additional total earnings of \$83 million would have been required for the six months ended March 31, 2017.

**CERTIFICATIONS**

I, William A. Wulfsohn, certify that:

1. I have reviewed this quarterly report on Form 10-Q of Ashland Global Holdings Inc.;
2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
4. The registrant's other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:
  - a. Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
  - b. Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
  - c. Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
  - d. Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and
5. The registrant's other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the Audit Committee of the registrant's Board of Directors (or persons performing the equivalent functions):
  - a. All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and
  - b. Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.

Date: May 2, 2018

/s/ William A. Wulfsohn

William A. Wulfsohn  
Chairman and Chief Executive Officer  
(Principal Executive Officer)

**CERTIFICATIONS**

I, J. Kevin Willis, certify that:

1. I have reviewed this quarterly report on Form 10-Q of Ashland Global Holdings Inc.;
2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
4. The registrant's other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:
  - a. Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
  - b. Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
  - c. Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
  - d. Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and
5. The registrant's other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the Audit Committee of the registrant's Board of Directors (or persons performing the equivalent functions):
  - a. All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and
  - b. Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.

Date: May 2, 2018

/s/ J. Kevin Willis

J. Kevin Willis  
Chief Financial Officer  
(Principal Financial Officer)



ASHLAND GLOBAL HOLDINGS INC.

CERTIFICATION PURSUANT TO  
18 U.S.C. SECTION 1350,  
AS ADOPTED PURSUANT TO  
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Quarterly Report of Ashland Global Holdings Inc. (the "Company") on Form 10-Q for the period ended March 31, 2018, as filed with the Securities and Exchange Commission on the date hereof (the "Report"), each of the undersigned, William A. Wulfsohn, Chief Executive Officer of the Company, and J. Kevin Willis, Chief Financial Officer of the Company, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that:

- (1) The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and
- (2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

/s/ William A. Wulfsohn

William A. Wulfsohn  
Chief Executive Officer  
May 2, 2018

/s/ J. Kevin Willis

J. Kevin Willis  
Chief Financial Officer  
May 2, 2018

